<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiamoebic drugs for treating amoebic colitis - Gonzales, MLM - 2019 | Cochrane Library</title> <meta content="Antiamoebic drugs for treating amoebic colitis - Gonzales, MLM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006085.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiamoebic drugs for treating amoebic colitis - Gonzales, MLM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006085.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006085.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antiamoebic drugs for treating amoebic colitis" name="citation_title"/> <meta content="Maria Liza M Gonzales" name="citation_author"/> <meta content="University of the Philippines Manila College of Medicine‐Philippine General Hospital" name="citation_author_institution"/> <meta content="lizmgonzales@yahoo.com" name="citation_author_email"/> <meta content="Leonila F Dans" name="citation_author"/> <meta content="University of the Philippines Manila College of Medicine‐Philippine General Hospital" name="citation_author_institution"/> <meta content="Juliet Sio‐Aguilar" name="citation_author"/> <meta content="University of the Philippines Manila College of Medicine‐Philippine General Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006085.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006085.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006085.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006085.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Entamoeba histolytica; Amebicides [adverse effects, *therapeutic use]; Drug Therapy, Combination; Dysentery, Amebic [*drug therapy, parasitology]; Metronidazole [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Tinidazole [adverse effects, therapeutic use]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006085.pub3&amp;doi=10.1002/14651858.CD006085.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006085\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006085\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","pl","fr","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD006085.pub3",title:"Antiamoebic drugs for treating amoebic colitis",firstPublishedDate:"Jan 9, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006085.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006085.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006085.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006085.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006085.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006085.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006085.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006085.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006085.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006085.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>18533 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006085.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/appendices#CD006085-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/table_n/CD006085StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/table_n/CD006085StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiamoebic drugs for treating amoebic colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#CD006085-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Maria Liza M Gonzales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#CD006085-cr-0003">Leonila F Dans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information#CD006085-cr-0004">Juliet Sio‐Aguilar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information/en#CD006085-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006085.pub3">https://doi.org/10.1002/14651858.CD006085.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006085-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006085-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006085-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006085-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006085-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006085-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006085-abs-0001" lang="en"> <section id="CD006085-sec-0001"> <h3 class="title" id="CD006085-sec-0001">Background</h3> <p>Infection with the protozoan <i>Entamoeba histolytica</i> is common in low‐ and middle‐income countries, and up to 100,000 people with severe disease die every year. Adequate therapy for amoebic colitis is necessary to reduce illness, prevent development of complicated disease and extraintestinal spread, and decrease transmission. </p> </section> <section id="CD006085-sec-0002"> <h3 class="title" id="CD006085-sec-0002">Objectives</h3> <p>To evaluate antiamoebic drugs for treating amoebic colitis.</p> </section> <section id="CD006085-sec-0003"> <h3 class="title" id="CD006085-sec-0003">Search methods</h3> <p>We searched the available literature up to 22 March 2018. We searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, <i>m</i>RCT, and conference proceedings. We contacted individual researchers, organizations, and pharmaceutical companies, and we checked reference lists. </p> </section> <section id="CD006085-sec-0004"> <h3 class="title" id="CD006085-sec-0004">Selection criteria</h3> <p>Randomized controlled trials of antiamoebic drugs given alone or in combination, compared with placebo or another antiamoebic drug, for treating adults and children with a diagnosis of amoebic colitis. </p> </section> <section id="CD006085-sec-0005"> <h3 class="title" id="CD006085-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the eligibility and methodological quality of trials and extracted and analysed the data. We calculated clinical and parasitological failure rates and rates of relapse and adverse events as risk ratios (RRs) with 95% confidence intervals (CIs), using a random‐effects model. We determined statistical heterogeneity and explored possible sources of heterogeneity using subgroup analyses. We carried out sensitivity analysis by using trial quality to assess the robustness of reported results. </p> </section> <section id="CD006085-sec-0006"> <h3 class="title" id="CD006085-sec-0006">Main results</h3> <p>In total, 41 trials (4999 participants) met the inclusion criteria of this review. In this update, we added four trials to the 37 trials included in the first published review version. Thirty trials were published over 20 years ago. Only one trial used adequate methods of randomization and allocation concealment, was blinded, and analysed all randomized participants. Only one trial used an <i>E histolytica</i> stool antigen test, and two trials used amoebic culture. </p> <p>Tinidazole may be more effective than metronidazole for reducing clinical failure (RR 0.28, 95% CI 0.15 to 0.51; 477 participants, eight trials; low‐certainty evidence) and is probably associated with fewer adverse events (RR 0.65, 95% CI 0.46 to 0.92; 477 participants, 8 trials; moderate‐certainty evidence). Compared with metronidazole, combination therapy may result in fewer parasitological failures (RR 0.36, 95% CI 0.15 to 0.86; 720 participants, 3 trials; low‐certainty evidence), but we are uncertain which combination is more effective than another. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. </p> </section> <section id="CD006085-sec-0007"> <h3 class="title" id="CD006085-sec-0007">Authors' conclusions</h3> <p>Compared with metronidazole, tinidazole may be more effective in reducing clinical failure and may be associated with fewer adverse events. Combination drug therapy may be more effective for reducing parasitological failure compared with metronidazole alone. However, these results are based mostly on small trials conducted over 20 years ago with a variety of poorly defined outcomes. Tests that detect <i>E histolytica</i> more accurately are needed, particularly in countries where concomitant infection with other bacteria and parasites is common. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006085-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006085-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006085-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006085-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006085-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006085-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006085-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006085-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006085-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006085-abs-0004" lang="en"> <h3>Antiamoebic drugs for treating amoebic colitis</h3> <p><b>What is the aim of this review?</b> </p> <p>This Cochrane Review aims to determine the effectiveness and safety of drugs used to treat people with amoebic colitis, which is an infection of the large intestines caused by the parasite, <i>Entamoeba histolytica</i>. Cochrane researchers searched for all relevant studies to answer this question and included 41 relevant studies in this review. </p> <p><b>Key messages</b> </p> <p>Tinidazole may be more effective than metronidazole for reducing clinical symptoms and may be associated with fewer adverse events. Combination therapy resulted in fewer parasitological failures than occurred with metronidazole alone. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. Better quality randomized trials using accurate diagnostic methods and standardized outcomes are needed to evaluate the efficacy of drugs for treating individuals with amoebic colitis. </p> <p><b>What was studied in the review?</b> </p> <p><i>Entamoeba histolytica</i> is distributed throughout the world and is commonly acquired by ingestion of contaminated food or water. An estimated 40 to 50 million people infected with <i>E histolytica</i> develop amoebic colitis or extraintestinal abscesses, resulting in up to 100,000 deaths per year. </p> <p>Metronidazole is currently the standard therapy for treating adults and children with invasive amoebiasis, but it may not be sufficient to eliminate amoebic cysts from the intestine. Some unpleasant adverse effects have been associated with metronidazole, and the possibility of parasite resistance to metronidazole has led to the development of alternative drugs. Combinations of metronidazole with other drugs that eradicate surviving cysts in the intestines have been recommended, so evidence to support this approach needs to be assessed. </p> <p>This review compares different drugs used against amoebic colitis, alone or in combination, and also assesses single‐dose regimens versus longer regimens. </p> <p><b>What are the main results of the review?</b> </p> <p>This review included 41 studies, most of which were conducted in countries considered to be highly endemic for amoebiasis. Most trials were old: 30 were conducted before 1998. Trials varied in the inclusion criteria used to enrol participants and in the definition and timing of measured outcomes. Stool microscopy with direct wet saline smear was the method used most often to detect the presence of <i>E histolytica</i> in stools. Study participants ranged in age from seven months to 80 years. Included trials reported a variety of comparisons and involved 25 individual drugs, two herbal products, and 15 different combinations. </p> <p>The review shows that in individuals with amoebic colitis, tinidazole may be better for reducing clinical symptoms (low‐certainty evidence) and probably results in fewer adverse events when compared with metronidazole (moderate‐certainty evidence). However, we do not know whether it is more effective for eradicating amoebae from the stools. Combination drug therapy may be more effective than metronidazole alone for eradicating amoebae (low‐certainty evidence), but we are uncertain which drug combination is most effective, and if combination treatment will lead to more rapid resolution of clinical symptoms or in more adverse events (very low‐certainty evidence). Evidence is insufficient to allow conclusions regarding efficacy of the other antiamoebic drugs. </p> <p><b>How up‐to‐date is this review?</b><br/> The review authors searched for studies that had been published up to 22 March 2018. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006085-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006085-sec-0104"></div> <h3 class="title" id="CD006085-sec-0105">Implications for practice</h3> <section id="CD006085-sec-0105"> <p>Antiamoebic drugs are indicated for treating individuals with amoebic colitis. Metronidazole has been the standard therapy for treating amoebic colitis owing to its history of long use and availability. Compared with metronidazole, tinidazole may be more effective in reducing clinical failure and probably has fewer adverse effects, but evidence is insufficient to show whether it is more effective in eradicating amoebic parasites from the stools. Combination drug therapy may be more effective than metronidazole alone in reducing parasitological failure, but data are insufficient for recommendation of a specific combination or to show whether this will lead to more rapid resolution of clinical symptoms or to increased adverse effects. Trials were generally inadequate or unclear in the key components measuring methodological quality, and most used stool microscopy alone for diagnosis and evaluation of parasitological outcomes. Thus, evidence is insufficient for review authors to be certain about study results. No definitive conclusions can be drawn regarding the efficacy of other antiamoebic drugs when compared with metronidazole or other drugs. Many antiamoebic drugs are not available in all countries; therefore, the choice of antiamoebic drugs for treatment would depend largely on availability of, and accessibility to, drugs for treatment. </p> </section> <h3 class="title" id="CD006085-sec-0106">Implications for research</h3> <section id="CD006085-sec-0106"> <p>More randomized controlled trials on the efficacy of drugs for treating amoebic colitis, reporting better methodological quality and using standardized definitions for evaluating outcomes, are needed. The diagnosis of amoebic colitis should not rely solely on stool microscopy but should be confirmed by a reliable test that differentiates <i>E histolytica</i> from non‐pathogenic amoebae. The most cost‐effective and accurate diagnostic test that can be used in LMICs must be identified. Investigations on possible interactions of other intestinal pathogens affecting treatment response for <i>E histolytica</i> are needed, especially in areas where mixed infections along with other intestinal pathogens and helminths are common. Randomized controlled trials are also needed to determine which luminal agent would be most effective when used in conjunction with metronidazole, or another nitroimidazole, for eradicating <i>E histolytica</i> from the intestine and for decreasing relapse. Finally, additional trials are needed to compare single‐dose or shorter regimens versus multiple‐dose or longer duration of therapy. A network meta‐analysis to compare multiple treatments may reveal the best treatment for all or for a subgroup of patients with amoebic colitis. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006085-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006085-sec-0023"></div> <div class="table" id="CD006085-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Tinidazole compared with metronidazole as treatment for amoebic colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with amoebic colitis </p> <p><b>Settings:</b> low‐ and middle‐income countries </p> <p><b>Intervention:</b> tinidazole </p> <p><b>Comparison:</b> metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Tinidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> <p>(&lt; 1 to 7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.17</b> </p> <p>(0.02 to 1.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a‐d</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole may be more effective than metronidazole for reducing clinical failure</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 to 60 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> <p>(3 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> </p> <p>(0.15 to 0.51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (8 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e‐h</sup> </p> <p>due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole may be more effective than metronidazole for reducing clinical failure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Parasitological failure</b> </p> <p>Method: stool microscopy demonstrating <i>E histolytica</i> cysts or trophozoites </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> <p>(28 to 84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.58 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c,d,i</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparing tinidazole and metronidazole treatment, there may be little or no difference in number of parasitological failures </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 to 60 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> </p> <p>(4 to 23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> </p> <p>(0.25 to 1.64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (9 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,g,j</sup> </p> <p>due to imprecision, risk of bias, and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether the number of parasitological failures differs comparing tinidazole or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Until 30 days after start of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> <p>(21 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.46 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (8 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>g,k‐m</sup> </p> <p>due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole is probably associated with fewer adverse events than metronidazole</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; <i>E histolytica</i> :<i>Entamoeba histolytica</i>; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 for serious risk of bias: the two trials that assessed outcomes 1 to 14 days after end of treatment were unclear regarding randomization, allocation concealment, and blinding. Both trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>b</sup>Heterogeneity could not be assessed because only one trial contributed data.<br/> <sup>c</sup>No serious indirectness: studies were conducted in countries endemic for amoebiasis: India (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>) and Kenya (<a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>). Trials included participants with unspecified intestinal amoebiasis or amoebic colitis, and results could be applied to other populations for whom amoebic colitis is endemic and who have similar clinical presentation.<br/> <sup>d</sup>Downgraded by 1 for imprecision: total sample size and number of events are small. The 95% confidence interval around pooled estimates includes both no effect and appreciable benefit or appreciable harm for tinidazole.<br/> <sup>e</sup>Downgraded by 2 for very serious risk of bias: trials were at high risk of selection bias because of unclear randomization and allocation concealment and inadequate blinding of outcome assessors. In four trials (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>), treatment was extended to 10 days if there was persistence of clinical symptoms or presence of <i>E histolytica</i> in stools at the end of the planned treatment duration, but outcomes were analysed regardless of duration of treatment. It is also possible that <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a> is a duplicate of the study <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>. All trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>f</sup>No serious inconsistency: there was no statistical heterogeneity (I<sup>2</sup> is 0% and the P value for heterogeneity is greater than 0.10). Effect sizes in these trials all seem to favour tinidazole.<br/> <sup>g</sup>No serious indirectness: eight trials were conducted in endemic areas (seven trials in India and one trial in Bangladesh), and one trial was conducted in an industrialized country (Sweden). All trials included patients with unspecified intestinal amoebiasis or amoebic colitis, and study results could be applied to other populations for whom amoebic colitis is endemic and who have similar clinical presentation.<br/> <sup>h</sup>No serious imprecision: these studies are adequately powered to detect 50% reductions in clinical and parasitological failure. The result is statistically significant.<br/> <sup>i</sup>No serious inconsistency: there was no statistical heterogeneity (I<sup>2</sup> is 10% and the P value for heterogeneity is greater than 0.10). Confidence intervals in trials overlap, and the point estimate indicates both benefit and harm for tinidazole.<br/> <sup>j</sup>Downgraded by 1 for inconsistency: statistical heterogeneity was high (I<sup>2</sup> is 64% and the P value for heterogeneity is less than 0.10), which could be explained by differences in populations. All studies indicate that tinidazole is comparable with metronidazole, except <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>, which favours metronidazole.<br/> <sup>k</sup>Downgraded by 1 for serious risk of bias: trials had inadequate or unclear blinding of outcome assessors for adverse events. Procedures for reporting adverse events and for monitoring laboratory test results were not standardized and were inadequately reported.<br/> <sup>l</sup>No serious inconsistency: statistical heterogeneity was not significant (I<sup>2</sup> is 48% and the P value for heterogeneity is 0.10), except for one trial (<a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>); all trials consistently show lower risk of adverse events among those given tinidazole compared with those given metronidazole. Adverse effects reported were predominantly gastrointestinal, such as nausea, vomiting, anorexia, bitter or metallic taste, and abdominal discomfort.<br/> <sup>m</sup>No serious imprecision: studies are adequately powered to detect 50% difference in adverse events between the two groups. The result is statistically significant. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006085-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combination therapy compared with metronidazole alone as treatment for amoebic colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with amoebic colitis </p> <p><b>Settings:</b> low‐ and middle‐income countries </p> <p><b>Intervention:</b> combination therapy </p> <p><b>Comparison:</b> metronidazole alone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combination therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure 1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> <p>(8 to 70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> </p> <p>(0.11 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a‐d</sup> </p> <p>due to risk of bias, inconsistency, and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether clinical failure differs between combination therapy or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure 1 to 14 days after end of treatment</b> </p> <p>Method: stool microscopy demonstrating <i>E histolytica</i> cysts or trophozoites </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> <p>(2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> </p> <p>(0.15 to 0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>720 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c‐e</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy may result in fewer parasitological failures compared with metronidazole</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Adverse events were incompletely reported and could not be combined in a meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,f</sup> </p> <p>due to indirectness and risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether the number of adverse events differs with combination therapy or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; <i>E histolytica</i> :<i>Entamoeba histolytica</i>; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 for serious risk of bias: all three trials included for this outcome had unclear randomization and allocation concealment, and two trials had inadequate blinding. <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> was at high risk of selective reporting bias because of inadequate reporting of the method used for outcome evaluation and variable treatment duration ranging from 5 to 10 days. All trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>b</sup>Downgraded by 1 for inconsistency: heterogeneity was statistically significant (I<sup>2</sup> is 71% and the P value for heterogeneity is less than 0.05). Heterogeneity could be explained by differences in severity of illness and variable drug combinations used.<br/> <sup>c</sup>Downgraded by 1 for indirectness: trials were conducted in countries that are endemic for amoebiasis (India ‐ <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a> and <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> ‐ and South Africa ‐ <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>) but used various drug combinations. Studies using different combination of drugs would need to be studied. Some of these drugs are no longer marketed, and it is not known whether the results could be applied to other combinations.<br/> <sup>d</sup>No serious imprecision: these studies are adequately powered to detect 50% reductions in clinical and parasitological failure 15 to 60 days after end of treatment. The result is statistically significant.<br/> <sup>e</sup>No serious inconsistency: statistical heterogeneity was moderate with I<sup>2</sup> of 42% and P value for heterogeneity of 0.18). The CIs overlap, and the pooled estimate shows significant benefit favouring combination therapy.<br/> <sup>f</sup>Downgraded by 2 for very serious risk of bias: blinding was inadequate, and reporting of the frequency and type of adverse events in trials was incomplete. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006085-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006085-sec-0024"></div> <section id="CD006085-sec-0025"> <h3 class="title" id="CD006085-sec-0025">Description of the condition</h3> <p>Amoebiasis is a parasitic disease caused by <i>Entamoeba histolytica</i> , a protozoan parasite that is found worldwide. An estimated 40 to 50 million people infected with <i>E histolytica</i> develop amoebic colitis or extraintestinal abscess, which results in up to 100,000 deaths annually (<a href="./references#CD006085-bbs2-0225" title="BercuTE , PetriWA , BehmJW . Amebic colitis: new insights into pathogenesis and treatment. Current Gastroenterology Reports2007;9(5):429‐33. ">Bercu 2007</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>). Amoebic colitis is a leading cause of severe diarrhoea worldwide, particularly in children below five years of age living in low‐ and middle‐income countries (LMICs) (<a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). The greatest burden of amoebiasis occurs in LMICs in Asia, the sub‐Saharan and tropical regions of Africa, and in Central and South America (<a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). In these areas, prevalence rates vary with the population studied and differ between countries and areas with different socioeconomic and sanitary conditions and with the diagnostic test used. </p> <p>Seroprevalence studies have detected antibodies ranging from 12% to 65% among those living in highly endemic areas in Asia and Latin America, including asymptomatic individuals (<a href="./references#CD006085-bbs2-0227" title="BragaLL , LimaAAM , SearsCL , NewmanRD , WuhibT , PaivaCA , et al. Seroepidemiology of Entamoeba histolytica in a slum in Northeastern Brazil. American Journal of Tropical Medicine and Hygiene1996;55(6):693‐7. ">Braga 1996</a>; <a href="./references#CD006085-bbs2-0245" title="HaqueR , AliIM , PetriWAJr . Prevalence and immune response to Entamoeba histolytica infection in preschool children in Bangladesh. American Journal of Tropical Medicine and Hygiene1999;60(6):1031‐4. ">Haque 1999</a>; <a href="./references#CD006085-bbs2-0246" title="HaqueR , AliIM , SackRB , FarrBM , RamakrishnanG , PetriWAJr . Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. Journal of Infectious Diseases2001;183(12):1787‐93. ">Haque 2001</a>; <a href="./references#CD006085-bbs2-0224" title="BarwickRS , UzicaninA , LareauS , MalakmadzeN , ImnadzeP , IosavaM , et al. Outbreak of amebiasis in Tbilisi, Republic of Georgia, 1998. American Journal of Tropical Medicine and Hygiene2002;67(6):623‐31. ">Barwick 2002</a>; <a href="./references#CD006085-bbs2-0239" title="GattiS , SwierczynskiG , RobinsonF , AnselmiM , CorralesJ , MoreiraJ , et al. Amebic infections due to the Entamoeba histolytica‐Entamoeba dispar complex: a study of the incidence in a remote rural area of Ecuador. American Journal of Tropical Medicine and Hygiene2002;67(1):123‐7. ">Gatti 2002</a>). Antibodies that develop after invasive infection can be measured by several immunological tests, but these tests will differentiate past infection from current or active amoebiasis. Studies using more sensitive tests that can differentiate pathogenic <i>E histolytica</i> from non‐pathogenic species, such as enzyme‐linked immunosorbent assay (ELISA) stool antigen detection or polymerase chain reaction (PCR), reported that the incidence of intestinal amoebiasis in highly endemic areas ranged from 13% to 67% among individuals with diarrhoea (<a href="./references#CD006085-bbs2-0243" title="HaqueR , FaruqueASG , HahnP , LyerlyDM , PetriWAJr . Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. Journal of Infectious Diseases1997;175(3):734‐6. ">Haque 1997</a>; <a href="./references#CD006085-bbs2-0220" title="Abd‐AllaMD , RavdinJI . Diagnosis of amoebic colitis by antigen capture ELISA in patients presenting with acute diarrhoea in Cairo, Egypt. Tropical Medicine and International Health2002;7(4):365‐70. ">Abd‐Alla 2002</a>; <a href="./references#CD006085-bbs2-0291" title="TanyukselM , YilmazH , UlukanligilM , ArazE , CicekM , KoruO , et al. Comparison of two methods (microscopy and enzyme‐linked immunosorbent assay) for the diagnosis of amebiasis. Experimental Parasitology2005;110(3):322‐6. ">Tanyuksel 2005</a>; <a href="./references#CD006085-bbs2-0281" title="RiveraWL , SantosSR , KanbaraH . Prevalence and genetic diversity of Entamoeba histolytica in an institution for the mentally retarded in the Philippines. Parasitology Research2006;98:106‐10. ">Rivera 2006</a>; <a href="./references#CD006085-bbs2-0284" title="SamieA , ObiLC , BessongPO , StroupS , HouptE , GuerrantRL . Prevalence and species distribution of E. histolytica and E. dispar in the Venda Region, Limpopo, South Africa. American Journal of Tropical Medicine and Hygiene2006;75(3):565‐71. ">Samie 2006</a>), and from 1.0% to 13.8% among asymptomatic individuals (<a href="./references#CD006085-bbs2-0243" title="HaqueR , FaruqueASG , HahnP , LyerlyDM , PetriWAJr . Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. Journal of Infectious Diseases1997;175(3):734‐6. ">Haque 1997</a>; <a href="./references#CD006085-bbs2-0228" title="BragaLL , MendoncaY , PaivaCA , SalesA , CavalcanteALM , MannBJ . Seropositivity for and intestinal colonization with Entamoeba histolytica and Entamoeba dispar in individuals in Northeastern Brazil. Journal of Clinical Microbiology1998;36(10):3044‐5. ">Braga 1998</a>; <a href="./references#CD006085-bbs2-0280" title="RiveraWL , TachibanaH , KanbaraH . Field study on the distribution of Entamoeba histolytica and Entamoeba dispar in the Northern Philippines as detected by the polymerase chain reaction. American Journal of Tropical Medicine and Hygiene1998;59(6):916‐21. ">Rivera 1998</a>; <a href="./references#CD006085-bbs2-0277" title="RamosF , MoranP , GonzalezE , GarciaG , RamiroM , GomezA , et al. High prevalence rate of Entamoeba histolytica asymptomatic infection in a rural Mexican community. American Journal of Tropical Medicine and Hygiene2005;73(1):87‐91. ">Ramos 2005</a>). A prospective study conducted in asymptomatic schoolchildren two to five years of age living in an urban slum in Bangladesh showed that 90% were infected with <i>E histolytica</i> at least once, as determined by stool antigen detection, and that repeat infection occurred in 68% of 162 children who completed 8.2 years of observation (<a href="./references#CD006085-bbs2-0274" title="PetriWAJr , MondalD , PetersonKM , DuggalP , HaqueR . Association of malnutrition with amebiasis. Nutrition Reviews2009;67(Suppl 2):S207‐15. ">Petri 2009</a>). </p> <p>Infection is commonly acquired by ingestion of food or water contaminated with cysts of <i>E histolytica</i>, but transmission also occurs through oral and anal sex and via contaminated enema apparatuses (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). In high‐income countries, infection occurs primarily among returning travellers or recent immigrants from endemic regions, homosexuals engaging in oral‐anal sexual practices, immunosuppressed people, and institutionalized individuals (<a href="./references#CD006085-bbs2-0282" title="SalitIE , KhairnarK , GoughK , PillaiDR . A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain. Clinical Infectious Diseases2009;49:346–53. ">Salit 2009</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0250" title="HerbingerKH , FleischmannE , WeberC , PeronaP , LöscherT , BretzelG . Epidemiological, clinical, and diagnostic data on intestinal infections with Entamoeba histolytica and Entamoeba dispar among returning travelers. Infection2011;39(6):527‐35. ">Herbinger 2011</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). HIV infection was shown to be a common coexisting condition with amoebiasis among USA residents who died (<a href="./references#CD006085-bbs2-0242" title="GuntherJ , ShafirS , BristowB , SorvilloF . Short report: amebiasis‐related mortality among United States residents, 1990–2007. American Journal of Tropical Medicine and Hygiene2011;85(6):1038–40. ">Gunther 2011</a>), and <i>E histolytica</i> remains an important diagnostic consideration for those presenting with bloody diarrhoea (<a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>). Studies have documented increased prevalence of amoebiasis among HIV‐positive men who have sex with men in several Asia Pacific countries (<a href="./references#CD006085-bbs2-0295" title="TsaiJJ , SunHY , KeLY , TsaiKS , ChangSY , HsiehSM , et al. Higher seroprevalence of Entamoeba histolytica infection is associated with human immunodeficiency virus Type 1 infection in Taiwan. American Journal of Tropical Medicine and Hygiene2006;74:1016–9. ">Tsai 2006</a>; <a href="./references#CD006085-bbs2-0233" title="ChenY , ZhangY , YangB , QiT , LuH , ChengX , TachibanaH . Seroprevalence of Entamoeba histolytica infection in HIV infected patients in China. American Journal of Tropical Medicine and Hygiene2007;77:825–8. ">Chen 2007</a>; <a href="./references#CD006085-bbs2-0272" title="ParkWB , ChoePG , JoJH , KimSH , BangJH , KimHB , et al. Amebic liver abscess in HIV‐infected patients, Republic of Korea. Emerging Infectious Diseases2007;13:516–7. ">Park 2007</a>; <a href="./references#CD006085-bbs2-0253" title="HungCC , JiDD , SunHY , LeeYT , HsuSY , ChangSY , et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Neglected Tropical Diseases2008;2(2):e175.doi:10.1371/journal.pntd.0000175. ">Hung 2008</a>; <a href="./references#CD006085-bbs2-0254" title="JamesR , BarrattJ , MarriottD , HarknessJ , StarkD . Short report: seroprevalence of Entamoeba histolytica infection among men who have sex with men in Sydney, Australia. American Journal of Tropical Medicine and Hygiene2010;83(4):914–6. ">James 2010</a>; <a href="./references#CD006085-bbs2-0266" title="NagataN , ShimboT , AkiyamaJ , NakashimaR , NishimuraS , YadaT , et al. Risk factors for intestinal invasive amebiasis in Japan, 2003–2009. Emerging Infectious Diseases2012;18(5):717‐24. ">Nagata 2012</a>; <a href="./references#CD006085-bbs2-0308" title="ZhouF , LiM , LiX , YangY , GaoC , JinQ , GaoL . Seroprevalence of Entamoeba histolytica infection among Chinese men who have sex with men. PLoS Neglected Tropical Diseases2013;7(5):1‐7. ">Zhou 2013</a>), with higher risk of developing invasive disease reported in this population (<a href="./references#CD006085-bbs2-0253" title="HungCC , JiDD , SunHY , LeeYT , HsuSY , ChangSY , et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Neglected Tropical Diseases2008;2(2):e175.doi:10.1371/journal.pntd.0000175. ">Hung 2008</a>; <a href="./references#CD006085-bbs2-0288" title="StarkD , vanHalSJ , MatthewsG , HarknessJ , MarriottD . Invasive amebiasis in men who have sex with men, Australia. Emerging Infectious Diseases2008;14:1141–3. ">Stark 2008</a>; <a href="./references#CD006085-bbs2-0299" title="WatanabeK , GatanagaH , deCadizAE , TanumaJ , NozakiT , OkaS . Amebiasis in HIV‐1‐infected Japanese men: clinical features and response to therapy. PLoS Neglected Tropical Diseases2011;5(9):1‐5. ">Watanabe 2011</a>). </p> <p>About 90% of people infected with <i>E histolytica</i> have no symptoms of disease and spontaneously clear their infection, while the remaining 10% develop invasive disease (<a href="./references#CD006085-bbs2-0247" title="HaqueR , DuggalP , AliIM , HossainMB , MondalD , SackRB , et al. Innate and acquired resistance to amebiasis in Bangladeshi children. Journal of Infectious Diseases2002;186(4):547‐52. ">Haque 2002</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>). The underlying factors responsible for variable clinical outcomes of infection by <i>E histolytica</i> remain largely unknown and may be determined by a complex interaction between host factors, parasite genotype, and environmental factors (<a href="./references#CD006085-bbs2-0276" title="RalstonKS , PetriWAJr . Tissue destruction and invasion by Entamoeba histolytica. Trends in Parasitology2011;27(6):254–63. ">Ralston 2011</a>; <a href="./references#CD006085-bbs2-0306" title="WilsonIW , WeedallGD , HallN . Host–parasite interactions in Entamoeba histolytica and Entamoeba dispar: what have we learned from their genomes?. Parasite Immunology2012;34:90‐9. ">Wilson 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). </p> <p>Amoebic colitis is a manifestation of intestinal amoebiasis that commonly presents as ulcers and inflammation of the colon. This results in a complete spectrum of colonic signs and symptoms ranging from non‐bloody diarrhoea to dysentery (acute diarrhoea with bloody stools), and to necrotizing colitis (severe inflammation of the colon) with intestinal perforation and peritonitis (infection of abdominal cavity membranes) (<a href="./references#CD006085-bbs2-0278" title="RavdinJI . Entamoeba histolytica (Amebiasis). In: MandellGL , BennettJE , DolinR editor(s). Principles and Practice of Infectious Diseases. 6th Edition. Philadelphia: Churchill Livingstone, 2005:3097‐3111. ">Ravdin 2005</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). </p> <p>Based on clinical manifestation, amoebic colitis may be classified as amoebic dysentery or non‐dysenteric amoebic colitis (<a href="./references#CD006085-bbs2-0225" title="BercuTE , PetriWA , BehmJW . Amebic colitis: new insights into pathogenesis and treatment. Current Gastroenterology Reports2007;9(5):429‐33. ">Bercu 2007</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0307" title="XiménezC , MoránP , RojasL , ValadezA , GómezA , RamiroM , et al. Novelties on amoebiasis: a neglected tropical disease. Journal of Global Infectious Diseases2011;3(2):166–74. ">Ximenez 2011</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>). Amoebic dysentery is acute diarrhoea with visible blood and mucus in stools and the presence of haematophagous trophozoites (trophozoites with ingested red blood cells) in stools or tissues. Non‐dysenteric amoebic colitis presents as recurrent bouts of diarrhoea with or without mucus but with no visible blood and the presence of <i>E histolytica</i> cysts or non‐haematophagous trophozoites (trophozoites with no ingested red blood cells) in the stools. The sigmoidoscopic examination of the colon originally described in the Report of the WHO Expert Committee on Amoebiasis showed inflamed mucosa with discrete ulcers in amoebic dysentery but usually normal results in the nondysenteric type (<a href="./references#CD006085-bbs2-0300" title="WHO Expert Committee on Amoebiasis. Amoebiasis. Report of a WHO Expert Committee. World Health Organization Technical Report Series1969;421:1‐52. ">WHO 1969</a>). However, recent studies have documented mucosal inflammation with small colonic ulcers or erosions on colonoscopy even in those with mild or nonspecific symptoms of non‐dysenteric colitis (<a href="./references#CD006085-bbs2-0270" title="OkamotoM , KawabeT , OhataK , TogoG , HadaT , KatamotoT , et al. Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases. American Journal of Tropical Medicine and Hygiene2005;73(5):934‐5. ">Okamoto 2005</a>; <a href="./references#CD006085-bbs2-0257" title="LeeKC , LuCC , HuWS , LinSE , ChenHH . Colonoscopic diagnosis of amebiasis: a case series and systematic review. International Journal of Colorectal Disease2015;30(1):31–41. ">Lee 2015</a>). </p> <p>The most severe complication of amoebic colitis is fulminant or necrotizing colitis, occurring in 0.5% of cases (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). Necrotizing colitis occurs with profuse bloody diarrhoea, fever, and widespread abdominal pain, frequently progressing to severe injury of the bowel wall, intestinal haemorrhage, or perforation with peritonitis (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). Among people with this condition, the case‐fatality rate ranges from 40% to 89% (<a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). Young children, malnourished individuals, pregnant women, immunocompromised individuals, and those receiving corticosteroids are at higher risk for invasive disease (<a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0285" title="ShirleyD‐A , MoonahS . Fulminant amebic colitis after corticosteroid therapy: a systematic review. PLoS Neglected Tropical Diseases2016;10(7):e0004879. [DOI: 10.1371/journal.pntd.0004879] ">Shirley 2016</a>). Extraintestinal complications of amoebic infection include abscess in various organs, empyema (accumulation of pus around the lungs), and pericarditis (inflammation of membranes surrounding the heart) (<a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>). For treatment of necrotizing colitis and extraintestinal amoebiasis, surgery and additional antibiotics may be required, aside from specific antiamoebic drugs (<a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). </p> <p>In many countries where amoebiasis is endemic, amoebic colitis is commonly diagnosed by identifying cysts or motile trophozoites in a saline wet mount of a stool specimen. Finding in the stool trophozoites that contain ingested red blood cells is considered by many to be diagnostic of invasive intestinal amoebiasis (<a href="./references#CD006085-bbs2-0290" title="TanyukselM , PetriWAJr . Laboratory diagnosis of amebiasis. Clinical Microbiology Reviews2003;16(4):713‐29. ">Tanyuksel 2003</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0289" title="Talamás‐LaraD , Chávez‐MunguíaB , González‐RoblesA , Talamás‐RohanaP , Salazar‐VillatoroL , Durán‐DíazÁ , et al. Erythrophagocytosis in Entamoeba histolytica and Entamoeba dispar: a comparative study. BioMed Research International2014;2014:626259. ">Talamas‐Lara 2014</a>). Stool microscopy is incapable of differentiating <i>E histolytica</i> from non‐pathogenic species such as <i>Entamoeba dispar</i> or <i>Entamoeba moshkovskii</i>, and the accuracy of microscopic methods is highly dependent on the competence of the diagnostic laboratory (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>). When a definitive diagnosis by microscopy is not possible, the presence of the <i>E histolytica</i> /<i>E dispar</i> complex should be reported (<a href="./references#CD006085-bbs2-0304" title="World Health Organization/Pan American Health Organization/UNESCO. Amoebiasis. Weekly Epidemiological Record1997;72:97‐9. ">WHO 1997</a>; <a href="./references#CD006085-bbs2-0244" title="HaqueR , AliIKM , AktherS , PetriWAJr . Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. Journal of Clinical Microbiology1998;36(2):449‐52. ">Haque 1998</a>; <a href="./references#CD006085-bbs2-0231" title="CDC . Laboratory diagnosis of amebiasis: Entamoeba histolytica and Entamoeba dispar. CDC, Atlanta, GA, 2010. http://www.cdc.gov/dpdx/resources/pdf/benchAids/entamoeba_benchaid.pdf (accessed 12 April 2015). ">CDC 2010</a>). Culture followed by isoenzyme analysis will differentiate <i>E histolytica</i> from <i>E dispar</i> but is technically difficult and is associated with significant false‐negative rates (<a href="./references#CD006085-bbs2-0236" title="FotedarR , StarkD , BeebeN , MarriottD , EllisJ , HarknessJ . Laboratory diagnostic techniques for Entamoeba species. Clinical Microbiology Reviews2007;20:511‐32. ">Fotedar 2007</a>). Currently, specific and sensitive means to detect <i>E histolytica</i> in stools include stool antigen detection testing and PCR techniques based on amplification of the target parasite RNA and DNA (<a href="./references#CD006085-bbs2-0244" title="HaqueR , AliIKM , AktherS , PetriWAJr . Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. Journal of Clinical Microbiology1998;36(2):449‐52. ">Haque 1998</a>; <a href="./references#CD006085-bbs2-0268" title="NesbittRA , MoshaFW , KatkiHA , AshrafM , AssengaC , LeeCM . Amebiasis and comparison of microscopy to ELISA technique in detection of Entamoeba histolytica and Entamoeba dispar. Journal of the National Medical Association2004;96(5):671‐7. ">Nesbitt 2004</a>; <a href="./references#CD006085-bbs2-0236" title="FotedarR , StarkD , BeebeN , MarriottD , EllisJ , HarknessJ . Laboratory diagnostic techniques for Entamoeba species. Clinical Microbiology Reviews2007;20:511‐32. ">Fotedar 2007</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). Ideally, stool samples positive for<i>E histolytica</i> on microscopy should be confirmed with stool antigen or PCR before treatment starts. Unfortunately, in resource‐limited countries, where the incidence of amoebiasis is highest, these tests are not routinely used and are not widely available for the diagnosis of amoebic colitis. </p> </section> <section id="CD006085-sec-0026"> <h3 class="title" id="CD006085-sec-0026">Description of the intervention</h3> <p>The goals of treatment for individuals with amoebic colitis are to treat invasive disease and to eradicate intestinal carriage of the organism (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0255" title="KappagodaS , SinghU , BlackburnBG . Antiparasitic therapy. Mayo Clinic Proceedings2011;86(6):561‐83. ">Kappagoda 2011</a>). <i>E histolytica</i> may be found in the bowel lumen, in the bowel wall, and in tissues, including the liver (<a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>). Antiamoebic drugs vary in efficacy at the three sites where parasites commonly exist and generally are divided into two classes based on their main site of activity. Luminal amoebicides act principally in the bowel lumen, and tissue amoebicides act principally in the bowel wall and in the liver. See <a href="#CD006085-tbl-0003">Table 1</a> for examples. </p> <div class="table" id="CD006085-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Amoebicide classes and examples</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amoebicide</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Class</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Examples</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Luminal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arsenical compounds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbarsone, acetarsone or acetarsol, treparsol, diphetarsone, glycobiarsol or bismuth glycolylarsanilate, stovarsol, thioarsenite, thiocarbarsone, and arsthinol </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyquinoline derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiniofon or quinoxyl, clioquinol or iodochlorhydroxyquin, and iodoquinol or diiodohydroxyquin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dichloroacetamide derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate or entamide furoate, clefamide, eticlordifene or ethylchlordiphene, etofamide or etophamide, and quinfamide </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzylamine derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teclozan, chlorbetamide or mantomide, and chlorphenoxamide or mebinol</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic amoebicides</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline, oxytetracycline, chlortetracycline, erythromycin, paromomycin, and fumagillin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Tissue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emetine and its derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emetine hydrochloride, emetine bismuth iodide, dehydroemetine dihydrochloride, and dehydroemetine resinate </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminoquinoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloroquine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiazole derivative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niridazole</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitroimidazoles</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, tinidazole, ornidazole, secnidazole, and nimorazole</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nithrothiazole salicylamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitazoxanide</p> </td> </tr> </tbody> </table> </div> <p>Among the antiamoebic drugs listed in the table, nitazoxanide is the most recent addition. Nitazoxanide is a nitrothiazole derivative whose structure is similar to metronidazole; however, it has greater antiparasitic activity against various intestinal protozoal and parasitic infections when compared with metronidazole (<a href="./references#CD006085-bbs2-0237" title="FoxLM , SaravolatzLD . Nitazoxanide: a new thiazolide antiparasitic agent. Clinical Infectious Diseases2005;40:1173–80. ">Fox 2005</a>; <a href="./references#CD006085-bbs2-0269" title="OchoaTJ , WhiteACJr . Nitazoxanide for treatment of intestinal parasites in children. Pediatric Infectious Disease Journal2005;24(7):641‐2. ">Ochoa 2005</a>; <a href="./references#CD006085-bbs2-0271" title="ParasharA , AryaR . Nitazoxanide. Indian Pediatrics2005;42:1161‐5. ">Parashar 2005</a>). Effectiveness of nitazoxanide and its major metabolite, tizoxanide against both luminal and invasive forms have been demonstrated (<a href="./references#CD006085-bbs2-0221" title="AdaguIS , NolderD , WarhurstDC , RossignolJF . In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. Journal of Antimicrobial Chemotherapy2002;49:103‐11. ">Adagu 2002</a>; <a href="./references#CD006085-bbs2-0232" title="Cedillo‐RiveraR , ChavezB , Gonzales‐RoblesA , TapiaA , Yepez‐MuliaL . In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis, and Trichomonas vaginalis trophozoites. Journal of Eukaryotic Microbiology2002;49(3):201‐8. ">Cedillo‐Rivera 2002</a>; <a href="./references#CD006085-bbs2-0273" title="PetriWA . Therapy of intestinal protozoa. Trends in Parasitology2003;19(11):523‐6. ">Petri 2003</a>; <a href="./references#CD006085-bbs2-0286" title="ShirleyDT , FarrL , WatanabeK , MoonahS . A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infectious Diseases2018;5(7):ofy161. [DOI: 10.1093/ofid/ofy161] ">Shirley 2018</a>), but further studies are needed to determine if this can be recommended as treatment for amoebic colitis. </p> <p>Metronidazole is considered standard therapy for treating people with invasive amoebiasis (<a href="./references#CD006085-bbs2-0305" title="World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers [WHO/FCH/CAH/05.1]. 4th Edition. Geneva: World Health Organization, 2005. ">WHO 2005</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). The recommended regimen of metronidazole for treatment of amoebic colitis is 500 to 750 mg given three times daily in adults, and 30 to 50 mg/kg/day given for five to 10 days in children (<a href="./references#CD006085-bbs2-0305" title="World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers [WHO/FCH/CAH/05.1]. 4th Edition. Geneva: World Health Organization, 2005. ">WHO 2005</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). Although this dose may have sufficient activity against both trophozoites and cysts (<a href="./references#CD006085-bbs2-0302" title="World Health Organization. Diarrhoeal Disease Control Programme. The Management of Bloody Diarrhoea in Young Children [WHO/CDD/94.49]. Geneva: World Health Organization, 1994. ">WHO 1994</a>; <a href="./references#CD006085-bbs2-0259" title="LiE , StanleySLJr . Parasitic diseases of the liver and intestines. Gastroenterology Clinics1996;25(3):471‐92. ">Li 1996</a>), the predominant belief is that metronidazole alone is not reliably effective for eliminating cysts in the colonic lumen due to its failure to reach adequate therapeutic concentrations in the large intestines (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>). This results in persistence of the parasites in the intestine in as many as 40% to 60% of patients (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>). Thus, the general recommendation is that patients with invasive amoebiasis should receive a luminal amoebicide after treatment with a tissue amoebicide, to eliminate any surviving organisms in the colon (<a href="./references#CD006085-bbs2-0255" title="KappagodaS , SinghU , BlackburnBG . Antiparasitic therapy. Mayo Clinic Proceedings2011;86(6):561‐83. ">Kappagoda 2011</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). This recommendation is based on the assumption that drugs acting on different protozoal processes may enhance the effects of other drugs. However, evidence to support combination therapy has not been reviewed, and it is not known whether drug combinations reduce clinical symptoms or eradicate parasites more effectively than tissue amoebicides given alone. Controversy surrounds the need for cyst eradication following metronidazole or tinidazole treatment, especially in endemic areas, where re‐infection is frequent. Furthermore, the increased complexity of combination regimens, additional drug costs, and potentially increased adverse events, combined with the unavailability of luminal agents on the market, act as major deterrents to compliance with combination therapy. </p> <p>Adverse effects may occur even with conventional doses of metronidazole and include headache, loss of appetite, metallic taste, nausea, and vomiting (<a href="./references#CD006085-bbs2-0273" title="PetriWA . Therapy of intestinal protozoa. Trends in Parasitology2003;19(11):523‐6. ">Petri 2003</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>), the last two of which may be exacerbated by drinking alcohol. Dizziness, convulsions, poor co‐ordination, and numbness of the extremities are less common but more serious adverse effects that warrant discontinuation of metronidazole (<a href="./references#CD006085-bbs2-0273" title="PetriWA . Therapy of intestinal protozoa. Trends in Parasitology2003;19(11):523‐6. ">Petri 2003</a>). Other nitroimidazole drugs with longer half‐lives, such as tinidazole, ornidazole, and secnidazole, allow shorter periods of treatment and appear to be better tolerated than metronidazole. These drugs have been used successfully when administered in shorter courses and have been recommended as alternative antiamoebic drugs to metronidazole (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0305" title="World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers [WHO/FCH/CAH/05.1]. 4th Edition. Geneva: World Health Organization, 2005. ">WHO 2005</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). </p> <p>Treatment failure has been reported with metronidazole, and most of these cases have been attributed to incorrect diagnosis, selection of an unsuitable drug, or failure to observe certain principles of treatment, rather than to drug resistance (<a href="./references#CD006085-bbs2-0298" title="WassmanC , HellbergA , TannichE , BruchhausI . Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron‐containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. Journal of Biological Chemistry1999;274(37):26051‐6. ">Wassman 1999</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>). However, induction of metronidazole‐resistant <i>E histolytica</i> strains in the laboratory suggests that indiscriminate use of antiamoebic drugs can result in an increased minimum inhibitory concentration against <i>E histolytica</i> (<a href="./references#CD006085-bbs2-0283" title="SamarawickremaNA , BrownDM , UpcroftJA , ThammapalerdN , UpcroftP . Involvement of superoxide dismutase and pyruvate: ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. Journal of Antimicrobial Chemotherapy1997;40(6):833‐40. ">Samarawickrema 1997</a>; <a href="./references#CD006085-bbs2-0298" title="WassmanC , HellbergA , TannichE , BruchhausI . Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron‐containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. Journal of Biological Chemistry1999;274(37):26051‐6. ">Wassman 1999</a>; <a href="./references#CD006085-bbs2-0223" title="BansalD , SehgalR , ChawlaY , MallaN , MahajanRC . Multidrug resistance in amoebiasis patients. Indian Journal of Medical Research2006;124(2):189‐94. ">Bansal 2006</a>; <a href="./references#CD006085-bbs2-0267" title="NagpalI , RajI , SubbaraoN , GourinathS . Virtual screening, identification and in vitro testing of novel inhibitors of O‐acetyl‐L‐serine sulfhydrylase of Entamoeba histolytica. PLoS One2012;7(2):e30305. [DOI: 10.1371/journal.pone.0030305] ">Nagpal 2012</a>). Furthermore, continued morbidity and higher mortality seen among those who develop complicated severe disease, despite the availability of antiamoebic drugs such as metronidazole, not only imply delayed diagnosis and inappropriate treatment but also suggest that current therapeutic options may be insufficient (<a href="./references#CD006085-bbs2-0248" title="HaqueR , HustonCD , HughesM , HouptE , PetriWAJr . Amebiasis. New England Journal of Medicine2003;348(16):1565‐73. ">Haque 2003</a>; <a href="./references#CD006085-bbs2-0276" title="RalstonKS , PetriWAJr . Tissue destruction and invasion by Entamoeba histolytica. Trends in Parasitology2011;27(6):254–63. ">Ralston 2011</a>; <a href="./references#CD006085-bbs2-0249" title="HayatF , AzamA , ShinD . Recent progress on the discovery of antiamoebic agents. Bioorganic &amp; Medicinal Chemistry Letters2016;26(21):5149–59. ">Hayat 2016</a>). </p> </section> <section id="CD006085-sec-0027"> <h3 class="title" id="CD006085-sec-0027">Why it is important to do this review</h3> <p>In addition to being a potentially fatal disease, invasive amoebiasis has important social and economic consequences. Amoebic colitis is a temporarily incapacitating disease that may require hospitalization for some individuals presenting with severe diarrhoea or dysentery. Amoebic colitis affecting adults in the wage‐earning group may require several weeks of hospitalization and up to two to three months for full recovery (<a href="./references#CD006085-bbs2-0301" title="World Health Organization. Amoebiasis and its control. A WHO Meeting. Bulletin of the World Health Organization1985;63(3):417‐26. ">WHO 1985</a>; <a href="./references#CD006085-bbs2-0297" title="WalshJA . Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Reviews of Infectious Disease1986;8(2):228‐38. ">Walsh 1986</a>). Pregnant and postpartum women appear to have increased risk of severe disease and death (<a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0275" title="PetriWAJr , HaqueR . Entamoeba species, including amoebiasis. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2010:3411‐25. ">Petri 2010</a>). Persistent infection can impair physical and mental growth and can affect the nutrition and general development of children. Children with <i>E histolytica</i>‐associated diarrhoea during the first two years of life were three times more likely to be malnourished and were five times more prone to be stunted (<a href="./references#CD006085-bbs2-0263" title="MondalD , PetriWA , SackRB , KirkpatrickBD , HaqueR . Entamoeba histolytica‐associated diarrheal illness is negatively associated with the growth of preschool children: evidence from a prospective study. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(11):1032‐8. ">Mondal 2006</a>; <a href="./references#CD006085-bbs2-0296" title="VerkerkeHP , PetriWA , MarieCS . The dynamic interdependence of amebiasis, innate immunity, and undernutrition. Seminars in Immunopathology2012;34(6):771–85. ">Verkere 2012</a>). Other studies have demonstrated that malnutrition and amoebic dysentery were associated with cognitive deficiencies, particularly in preschool children (<a href="./references#CD006085-bbs2-0292" title="TarletonJL , HaqueR , MondalD , ShuJ , FarrBM , PetriWAJr . Cognitive effects of diarrhea, malnutrition, and Entamoeba histolytica infection on school age children in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene2006;74(3):475‐81. ">Tarleton 2006</a>; <a href="./references#CD006085-bbs2-0274" title="PetriWAJr , MondalD , PetersonKM , DuggalP , HaqueR . Association of malnutrition with amebiasis. Nutrition Reviews2009;67(Suppl 2):S207‐15. ">Petri 2009</a>). </p> <p>Adequate therapy for amoebic colitis is necessary to reduce severity of illness, prevent development of complicated disease and extraintestinal spread, and decrease infectiousness and transmission to others. In LMICs where amoebiasis is common and most patients are treated in private practice or as hospital outpatients, the aim of treatment should be to provide an effective, safe, and simple regimen that can be given on an outpatient basis. </p> <p>A reliable summary of the evidence is needed to determine the best treatment for people with amoebic colitis. Rapid relief of diarrhoea and other gastrointestinal symptoms associated with intestinal amoebiasis is an important concern of the individual with the disease, and eradication of the parasite is important to prevent further invasion with damage to the intestinal mucosa and possible extraintestinal spread. Treatment failure and unpleasant adverse effects associated with metronidazole in some patients and the possibility of overt clinical resistance of <i>E histolytica</i> to metronidazole make it imperative that alternative treatments are investigated. The benefits of using combination regimens over monotherapy and single‐dose regimens over longer regimens remain to be determined. Furthermore, the effectiveness of newly discovered antiamoebic drugs must be ascertained. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006085-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006085-sec-0028"></div> <p>To evaluate antiamoebic drugs for treating amoebic colitis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006085-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006085-sec-0029"></div> <section id="CD006085-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006085-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs). We excluded quasi‐RCTs.</p> </section> <section id="CD006085-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included trials with adults and children with clinical symptoms of amoebic colitis (as previously described) and demonstration of <i>E histolytica</i> cysts or trophozoites in a stool sample, or <i>E histolytica</i> trophozoites in a tissue biopsy or ulcer scraping by histopathology. We included individuals with positive <i>E histolytica</i> /<i>E dispar</i> on stool examination confirmed by <i>E histolytica</i> antigen detection testing or PCR. </p> <p>We excluded trials including only individuals with asymptomatic infection and those requiring surgery or additional antibiotic therapy, such as those with fulminant or necrotizing colitis; peritonitis, intestinal perforation, or haemorrhage; or with evidence of extraintestinal amoebiasis including hepatic amoebiasis. </p> </section> <section id="CD006085-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD006085-sec-0034"> <h5 class="title">Interventions</h5> <p>Antiamoebic drugs, administered alone or in combination.</p> </section> <section id="CD006085-sec-0035"> <h5 class="title">Controls</h5> <p>Placebo or another antiamoebic drug.</p> </section> </section> <section id="CD006085-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD006085-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006085-list-0001"> <li> <p>Clinical failure, defined as absence of <i>E histolytica</i> in stools or scrapings but with little or no relief of signs or symptoms, or with persistent rectal ulcerations on sigmoidoscopy </p> </li> <li> <p>Parasitological failure, defined as persistence of <i>E histolytica</i> cysts or trophozoites in stools or colonic ulcer scrapings, with or without the presence of symptoms or rectal ulcers </p> </li> <li> <p>Relapse, defined as reappearance of cysts or trophozoites of <i>E histolytica</i> after their initial disappearance, with or without recurrence of clinical signs or symptoms of amoebic colitis after completion of treatment </p> </li> <li> <p>Serious adverse events (death, life‐threatening events, hospitalization required or duration of hospitalization prolonged, development of a persistent or significant disability or incapacity, having offspring with a congenital anomaly or birth defect, or development of cancer) </p> </li> </ul> </p> </section> <section id="CD006085-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006085-list-0002"> <li> <p>Adverse events resulting in discontinuation of treatment</p> </li> <li> <p>Other adverse events including gastrointestinal adverse events, systemic symptoms such as weakness or fatigue, central nervous system effects such as headache or dizziness, and dermatological effects such as skin rashes </p> </li> </ul> </p> </section> </section> </section> <section id="CD006085-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all publications that described RCTs on antiamoebic drugs for treating amoebic colitis, regardless of language or publication status. </p> <section id="CD006085-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD006085-sec-0110">Appendix 1</a>: the Cochrane Infectious Diseases Group Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2018, Issue 1); MEDLINE (1966 to March 2018); Embase (1974 to March 2018); and Latin American Caribbean Health Sciences Literature (LILACS) (1982 to March 2018). Using ‘amoebic,' ‘amoeba', and ‘amoebiasis' as search terms, we also searched the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT; latest search February 2018), the WHO International Clinical Trials Registry Platform (ICTRP search portal; latest search February 2018), and the United Kingdom Clinical Trials Gateway (UKCTG; last searched February 2018). </p> </section> <section id="CD006085-sec-0041"> <h4 class="title">Searching other resources</h4> <section id="CD006085-sec-0042"> <h5 class="title">Conference proceedings</h5> <p>We searched electronic databases of the conference proceedings listed in <a href="./appendices#CD006085-sec-0111">Appendix 2</a> for relevant abstracts. </p> </section> <section id="CD006085-sec-0043"> <h5 class="title">Organizations and pharmaceutical companies</h5> <p>To help identify unpublished and ongoing trials, we contacted researchers working for the organizations listed in <a href="./appendices#CD006085-sec-0112">Appendix 3</a>, as well as the pharmaceutical companies and associated databases listed in <a href="./appendices#CD006085-sec-0113">Appendix 4</a>. </p> </section> <section id="CD006085-sec-0044"> <h5 class="title">Reference lists</h5> <p>We checked the reference lists and bibliographies of all studies identified by the above methods. </p> </section> </section> </section> <section id="CD006085-sec-0045"> <h3 class="title" id="CD006085-sec-0045">Data collection and analysis</h3> <section id="CD006085-sec-0046"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MLMG, LFD) independently assessed results of the literature search to determine whether the title or abstract of each trial described an RCT. We retrieved full reports for all trials considered by one or both review authors to be potentially relevant, as well as for those whose relevance was unclear. We used a standard eligibility form based on the inclusion criteria to assess trials independently. We contacted trial authors for clarification if necessary and resolved disagreements through discussion or by consultation with the third review author (JSA in this update). </p> <p>We included RCTs assessing the effectiveness of antiamoebic drugs given alone or in combination for treatment of amoebic colitis, and for which outcomes were measured in both experimental and control populations. We excluded quasi‐randomized trials (e.g. those utilizing alternate allocation), animal studies, duplicate publications, reviews, abstracts with no full report, and studies describing only results without providing detailed background and methods. </p> </section> <section id="CD006085-sec-0047"> <h4 class="title">Data extraction and management</h4> <p>For this update, two review authors (MLMG, JSA) independently extracted data from study reports using pre‐tested data extraction forms. We collected details regarding inclusion and exclusion criteria for participants, treatment interventions given, total numbers randomized, number of participants in each group for all outcomes, dropouts and withdrawals, and numbers experiencing each outcome. For dichotomous data, we extracted the number of participants who experienced the event of interest and the number of participants randomized and analysed in each treatment group. We resolved disagreements by referring to the trial report and holding discussions. When data were insufficient or missing, we made attempts to contact the trial authors. Review author MLM Gonzales entered data for analysis. </p> <p>For each study, we collected the following data: study methods (study design, sequence generation. allocation sequence concealment, blinding), participants (total number, age, sex, type of amoebic colitis, diagnostic method used, presence of concomitant infection with other intestinal parasites, duration of follow‐up), interventions (total number of intervention groups and specific interventions including dosage, route, and duration), setting, and funding source. For each outcome, we recorded the number of participants allocated to each intervention group<i>,</i> the proportion of participants with the outcome, methods or tests used to measure the outcome, and timing of outcome measurement. </p> </section> <section id="CD006085-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MLMG, LFD) independently assessed risk of bias in each trial using a prepared form. We resolved disagreements through discussion between review authors and with the third review author (JSA) if needed. </p> <p>We assessed risk of bias for each of the included trials and evaluated sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and ‘other sources of bias', using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006085-bbs2-0252" title="HigginsJPT , AltmanDG , SterneJAC , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For each item, we provided a description of what was reported to have happened in the study along with a subjective judgement regarding protection from bias (‘Yes’ for low risk of bias, ‘No’ for high risk of bias, ‘Unclear’ otherwise). For sequence generation and allocation concealment, we described for each included study the method used, and we made subjective judgements on the adequacy of the procedure to protect against possible bias. For blinding, we assessed who was blinded, such as trial participants, care providers, or outcome assessors, for both clinical and parasitological outcomes and for adverse events. We prepared separate reports for outcomes evaluated 1 to 14 days after end of treatment and those evaluated 15 to 60 days after end of treatment. We stated numbers included in the analysis compared with the total number of randomized participants, whether attrition and exclusions were reported, reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or were related to outcomes. For selective reporting bias, we described for each included trial whether it was clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review were reported. For ‘other sources of bias', we described for each included study any important concerns identified that could be possible sources of bias, such as study design, method of diagnosing amoebic infection, and presence of concomitant parasitic or protozoal infection. </p> <p>We recorded all assessments in risk of bias tables and produced an overall pictorial summary of the risk of bias assessment. </p> <p>For trials that were at high risk of bias according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006085-bbs2-0252" title="HigginsJPT , AltmanDG , SterneJAC , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact the findings. We explored the impact of the level of bias by performing sensitivity analyses. </p> </section> <section id="CD006085-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios (RRs) with 95% confidence intervals (CIs) to compare dichotomous data. When available, we recorded continuous data, such as time until resolution of clinical symptoms and disappearance of amoeba parasites in the stools, as mean value and standard deviation or as median with range of outcome measurements. </p> </section> <section id="CD006085-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>For trials with more than two intervention groups (e.g. two or more experimental interventions, different doses or preparations of the same drug), we combined multiple treatment arms as appropriate into one group and compared them collectively with the standard or control group to avoid counting placebo or control participants more than once in the same meta‐analysis. </p> </section> <section id="CD006085-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>If we noted a discrepancy between the number randomized and the number analysed, we calculated the percentage lost to follow‐up for each treatment group and reported this information. We performed an available‐case analysis, wherein only available data were analysed and no assumptions were made regarding missing data. </p> </section> <section id="CD006085-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We calculated summary RRs from meta‐analysis using both a fixed‐effect model (Mantel‐Haenszel method), which assumes trial homogeneity, and a random‐effects model (DerSimonian and Laird method), which accounts for trial heterogeneity. </p> <p>We reported results using the random‐effects model when we noted differences between trials that may potentially influence the size of the treatment effect, or when we detected significant statistical heterogeneity. We determined the presence of statistical heterogeneity among the same interventions by inspecting forest plots for overlapping confidence intervals and by applying the Chi<sup>2</sup> test for heterogeneity (P &lt; 0.10 considered statistically significant) and the I<sup>2</sup> statistic to quantify inconsistency across trials (I<sup>2</sup> &gt; 50% used to denote substantial heterogeneity). If we detected heterogeneity but still considered it clinically meaningful to combine trial data, we explored potential sources of heterogeneity by conducting subgroup analysis. We presented subtotals for each subgroup only if pooled results showed significant heterogeneity. </p> </section> <section id="CD006085-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>When at least 10 trials were included in the meta‐analysis, we determined publication bias by looking for asymmetry in a funnel plot. The presence of asymmetry in the funnel plot suggests possible publication bias but may also indicate heterogeneity or poor methodological quality of trials. </p> </section> <section id="CD006085-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We analysed data collected using Review Manager 5 (RevMan 5) (<a href="./references#CD006085-bbs2-0279" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For dichotomous outcomes, we calculated risk ratios (RRs) with 95% confidence intervals (CIs). We did not perform meta‐analysis of continuous data because of inconsistency of trial reporting, but we described and summarized outcomes in a table. </p> <p>The main comparisons were between any single antiamoebic drug and metronidazole (current standard therapy), any antiamoebic drug and placebo, combination regimens and monotherapy, and any single‐dose regimen and longer regimens. We included but did not pool data from other trials that compared any antiamoebic drug with another antiamoebic drug, and we did not address any particular pharmacological or clinical questions relevant to this review. </p> <p>For trials reporting results at multiple or varying time points, we performed separate analyses for outcomes measured from end of treatment to 14 days and 15 to 60 days after end of treatment. For trials comparing drugs with different treatment durations, we measured the time point in relation to the last day of the longest treatment period. We did not consider outcomes that were measured during treatment or before completion of treatment. Likewise, we did not include outcomes measured beyond two months because this could indicate re‐infection rather than true failure or relapse. </p> <section id="CD006085-sec-0055"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the evidence for important outcomes using the GRADE approach (<a href="./references#CD006085-bbs2-0241" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal2004;328(1490):1‐8. ">GRADE 2004</a>), and we presented this information in ‘Summary of fIndings' tables. </p> </section> </section> <section id="CD006085-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis for the time of outcome measurements (from end of treatment to 14 days and 15 to 60 days after end of treatment) and for subgroups that may influence treatment response, such as clinical categories (amoebic dysentery, non‐dysenteric amoebic colitis, or unspecified amoebic colitis) and participant age (adults 15 years of age or older, and children younger than 15 years). We could not undertake subgroup analysis based on diagnostic tests as planned because only one trial used a stool <i>E histolytica</i> ELISA test. </p> <p>Potential sources of heterogeneity explored for the primary outcome measures involved the methodological quality of studies. Other sources of heterogeneity included in the post hoc subgroup analysis were type of intestinal infection (<i>E histolytica</i> infection alone or mixed intestinal infection) and criteria for determining outcomes (based on <a href="./references#CD006085-bbs2-0300" title="WHO Expert Committee on Amoebiasis. Amoebiasis. Report of a WHO Expert Committee. World Health Organization Technical Report Series1969;421:1‐52. ">WHO 1969</a> criteria or other criteria). </p> </section> <section id="CD006085-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis to assess the robustness of overall estimates by calculating the results using all trials and then excluding trials of lower methodological quality (i.e. trials with inadequate generation of allocation sequence, allocation concealment, or blinding, or trials that analysed &lt; 90% of randomized participants), and by excluding trials that were sponsored by pharmaceutical companies. Although pharmaceutical industry‐sponsored trials may publish only when demonstrating positive treatment effects, it is possible that pharmaceutical industry‐sponsored trials were conducted with better methodological quality because they received adequate funds. We determined the effect of the date of publication on the overall pooled effect in a sensitivity analysis when we noted large differences in the publication dates. It is unclear whether two trials reported the same results, and our attempts to contact trial authors for clarification were not successful (<a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>). We entered these two trials as separate trials and carried out sensitivity analysis to determine whether exclusion of the latter trial would have an effect on the overall estimate. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006085-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006085-sec-0058"></div> <section id="CD006085-sec-0059"> <h3 class="title">Description of studies</h3> <p>We have presented a summary of included studies in <a href="#CD006085-tbl-0004">Table 2</a>, and we have listed further study details in the ‘<a href="./references#CD006085-sec-0131" title="">Characteristics of included studies</a>' table. </p> <div class="table" id="CD006085-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year completed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test used to measure parasitological outcome</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Various antiamoebic drugs versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the University of Chile in Santiago, Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346 adults and children with clinical symptoms of intestinal amoebiasis and stool specimens positive for cysts and/or trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0003"> <li> <p>Dimethychlortetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 15 mg/kg and adults 900 mg </p> </li> <li> <p>Oxytetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 25 mg/kg and adults 1500 mg </p> </li> <li> <p>Tetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 25 mg/kg and adults 1500 mg </p> </li> <li> <p>Chlorphenoxamide: once daily after meals for 10 days at the following oral daily doses – children 125 mg for every 2 years of age and adults 1500 mg </p> </li> <li> <p>Chlorbetamide: once daily after meals for 10 days at the following oral daily doses – children 100 mg/kg and adults 4000 mg </p> </li> <li> <p>Racemic dehydroemetine: once daily after meals for 10 days at the following oral daily doses – children 5 mg for every 2 years of age and adults 40 mg </p> </li> <li> <p>Diiodohydroxyquinoline: once daily after meals for 21 days at the following oral daily doses – children 200 mg for every 2 years of age and adults 1800 mg </p> </li> <li> <p>Phenanthridinone: once daily after meals for 10 days at the following oral daily doses – children 25 mg for every 2 years of age and adults 300 mg </p> </li> <li> <p>Bismuth glycoarsanilate: once daily after meals for 10 days at the following oral daily doses – children 250 mg for every 2 years of age and adults 2000 mg </p> </li> <li> <p>Iodochlorhydroxyquinoline: once daily after meals for 21 days at the following oral daily doses – children 125 mg for every 2 years of age and adults 1000 mg </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (starch): once daily after meals for 10 days at the following oral daily doses – children 250 mg for every 2 years of age and adults 1500 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0004"> <li> <p>Parasitological failure: presence of cysts and/or trophozoites in stool examinations done 10 and 40 days after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants every 3 days during treatment and every 10 to 15 days after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using modified Telemann concentration technique (centrifugation with saline formol and ether) for cysts; polyvinyl alcohol with fixative of Schaudinn for the trophozoites </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Hospital of the Federal University of Pernambuco, Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 adults with chronic intestinal amoebiasis and stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0005"> <li> <p>Win 40.014 (quinfamide): 100 mg single oral dose</p> </li> <li> <p>Win 40.014 (quinfamide): 100 mg twice a day orally at 12‐hourly intervals for 1 day</p> </li> <li> <p>Win 40.014 (quinfamide): 100 mg thrice a day orally at 8‐hourly intervals for 1 day</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo: 300 mg daily dose orally, no information given on the frequency of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0006"> <li> <p>Parasitological cure: clearance of amoebae from stools on days 2 and 7 after treatment</p> </li> <li> <p>Clinical cure: disappearance of the 4 symptoms recorded at baseline (pain, colic, diarrhoea, and constipation) evaluated on days 2 and 7 after treatment </p> </li> <li> <p>Adverse events: only 2 symptoms (nausea and headache) solicited from participants; laboratory tests done before and after treatment but results not presented </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using Lugol's stain (Telemann‐Richter or Hoffman, Pons, and Janer methods) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Department of Hepatology, Gastroenterology, and Infectious Diseases of the Benha University Hospital, Governorate of Kalubia, Nile Delta, Egypt </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 adults and children with diarrhoea and stool specimens positive for cysts or trophozoites of <i>E histolytica</i> and/or <i>E dispar</i> alone or with concomitant <i>G intestinalis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: 500 mg twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo tablet (identical): twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0007"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from 2 stool specimens collected between days 7 and 10 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms, resolution of diarrhoea and haematochezia on day 7 after start of treatment </p> </li> <li> <p>Median duration of diarrhoea (days)</p> </li> <li> <p>Adverse events: clinical adverse events monitored by study personnel</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear, concentration technique, Ziehl‐Neelsen stain, and immunofluorescent assay (MeriFluor Meridian Diagnostics) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Benha University Hospital, Benha, Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 adults and children with diarrhoea; ≥ 1 enteric symptoms; <i>E histolytica</i> /<i>E dispar</i> trophozoites identified in stool and stool‐positive for <i>E histolytica</i> by antigen‐based ELISA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: for 3 days; adults aged ≥ 12 years, 500‐mg tablet twice daily; children 100 mg/5 mL suspension – 1 to 3 years received 5 mL twice daily, 4 to 11 years received 10 mL twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo: matching placebo tablet or suspension twice daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0008"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from 2 stool specimens collected between days 7 and 10 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms, resolution of diarrhoea and haematochezia on day 7 after start of treatment </p> </li> <li> <p>Adverse events: monitored by patient diary</p> </li> </ul> </p> <p><i>Not included in this review:</i> time from first dose to passage of last unformed stool (survival graph) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and concentration technique; <i>E histolytica</i> by antigen‐based ELISA </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tinidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bangladesh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 adults and children with clinical signs and symptoms of intestinal amoebiasis and motile haematophagous trophozoites of <i>E histolytica</i> in fresh stool specimens and on sigmoidoscopy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0009"> <li> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </li> <li> <p>Tinidazole: 2 g single oral dose daily for 2 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single dose for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0010"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 from start of therapy </p> </li> <li> <p>Clinical cure: resolution of baseline symptoms of intestinal amoebiasis on day 30 from start of therapy </p> </li> <li> <p>Adverse events: voluntary reporting of side effects by participants; laboratory tests monitored before and after treatment including complete blood count, serum bilirubin, alkaline phosphatase, and liver transaminase (SGOT) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient departments of 3 district hospitals in Kiambo, Kilifi, and Machakos in Kenya </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 adults and children presenting with at least any 4 of the following symptoms of intestinal amoebiasis: abdominal pain, diarrhoea, constipation, mucoid stools, malaise, flatulence, nausea, fever, tenesmus, and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0011"> <li> <p>Tinidazole (Fasigyn): 2 g single oral dose daily for 3 days</p> </li> <li> <p>Tinidazole (Tynazole): 2 g single oral dose daily for 3 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0012"> <li> <p>Metronidazole (Flagyl): 400 mg thrice daily orally for 5 days</p> </li> <li> <p>Metronidazole (Metrozol): 400 mg thrice daily orally for 5 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0013"> <li> <p>Parasitological cure: absence of trophozoites or cysts from stool specimens on day 6 after start of treatment </p> </li> <li> <p>Clinical cure: absence of any 4 of the symptoms initially present at day 6 after start of treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahmedabad, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 or 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0014"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical response: complete or partial relief of symptoms and healing of ulcers on sigmoidoscopy, when carried out </p> </li> <li> <p>Adverse events: voluntary reporting by participants; laboratory tests monitored before and after treatment including haemogram, urinalysis, serum bilirubin, serum transaminases (SGOT, SGPT), alkaline phosphatase, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults and adolescents with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days (for acute amoebic dysentery) or 800 mg thrice daily for 5 days (for other cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0015"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: relief of presenting clinical signs and symptoms and healing of ulcers on sigmoidoscopy, when carried out </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including haemogram, urinalysis, serum bilirubin, transaminases (SGOT, SGPT), alkaline phosphatase, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical College Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults and children with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E. histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days (for acute amoebic dysentery) or 800 mg thrice daily orally for 5 days (for chronic intestinal amoebiases if symptoms were of more than 15 days' duration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0016"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> on follow‐up stool examinations or ulcer scrapings on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before and after treatment including complete blood count and platelet count, urinalysis, electrocardiogram, blood urea, serum bilirubin, alkaline phosphatase, and liver transaminases (SGOT, SGPT) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or concentration method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0017"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools or ulcer scrapings on day 30 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including urinalysis, complete blood count, serum bilirubin, alkaline phosphatase, liver transaminases (SGOT, SGPT), blood urea, and electrocardiogram </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0018"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory monitoring done before and after treatment including complete blood count, urinalysis, and blood chemistry </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique, sigmoidoscopy for colonic pathology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic in Stockholm, Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 adults with clinical symptoms of intestinal amoebiasis but no signs of invasion (e.g. no fever or acute dysentery) and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0019"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> trophozoites or cysts in any of the 3 stool specimens taken 1 month after end of treatment </p> </li> <li> <p>Adverse events: only adverse events severe enough to result in cessation of therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical outpatient department of the Government Medical College and Hospital, Patiala, India </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 500 mg tablets × 4 (2 g) single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400‐mg tablets × 5 (2 g) single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0020"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on follow‐up stool examinations on day 30 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of presenting clinical signs and symptoms on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including complete blood count, urinalysis, serum bilirubin, alkaline phosphatase, transaminases, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visakhapatnam, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single dose daily for 3 days</p> <p>Treatment was extended if <i>E histolytica</i> persisted in the stool on the day following the last treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0021"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on follow‐up stool examinations on day 30 after start of treatment </p> </li> <li> <p>Clinical response: relief of presenting clinical signs and symptoms on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of adverse events by participants; laboratory tests monitored before and after treatment including blood counts, urinalysis, serum bilirubin, alkaline phosphatase, transaminases (SGOT, SGPT), and blood urea </p> </li> </ul> </p> <p><i>Not included in this review:</i> number of participants who required extension of treatment beyond 3 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ornidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Medellin, Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 adult males with clinical symptoms of intestinal amoebiasis confirmed by the presence of <i>E histolytica</i> in the stools </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole): 2 × 250‐mg capsules twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 × 250‐mg capsules twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0022"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools at end of treatment and at weekly intervals on follow‐up for at least 1 month </p> </li> <li> <p>Relapse: reappearance of <i>E histolytica</i> in the stools within 1 month after becoming negative at end of treatment </p> </li> <li> <p>Clinical response: disappearance of or improvement in clinical signs and symptoms on day 5, at end of treatment, and at weekly intervals during follow‐up for at least 1 month </p> </li> <li> <p>Adverse events: clinical adverse events monitored for all participants, but cardiovascular, neurological, and laboratory monitoring only for the first 20 participants (laboratory tests not specified) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and Ritchie formalin‐ether concentration methods </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinics in Jakarta, Indonesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 adults and children with bloody diarrhoea and stools positive for motile haematophagous trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole) given as follows: 2 to 6 years of age – 125 mg daily in 3 divided doses for 7 days; 7 to 12 years of age – 250 mg daily in 3 divided doses for 7 days; adults – 1500 mg daily in 3 divided doses for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole given as follows: 2 to 6 years of age – 125 mg daily in 3 divided doses for 7 days; 7 to 12 years of age – 250 mg daily in 3 divided doses for 7 days; adults – 1500 mg daily in 3 divided doses for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0023"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools at end of treatment and 1 month after end of treatment </p> </li> <li> <p>Clinical cure: disappearance of symptoms at end of treatment and at 1 month after end of treatment </p> </li> <li> <p>Relapse: reappearance of <i>E histolytica</i> in stools 1 month after end of treatment </p> </li> <li> <p>Time (range in days) from start of treatment to clearance of <i>E histolytica</i> in stool specimens </p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of bloody diarrhoea</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before and after end of treatment including complete blood counts, liver transaminase (SGPT), alkaline phosphatase, urinalysis, blood urea, and electrocardiogram </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and stained smears using eosin and iodine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Department of Child Health, Medical School University of Indonesia, Jakarta, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 children with bloody diarrhoea and stools positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole): 125‐mg capsule given as follows: up to 2 years of age – 62.5 mg, 2 to 6 years of age – 125 mg, and 6 to 12 years of age 250 mg daily, divided into 3 daily doses for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 125‐mg capsule given as follows: up to 2 years of age – 62.5 mg, 2 to 6 years of age – 125 mg, and 6 to 12 years of age 250 mg daily, divided into 3 daily doses for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0024"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools after 7 days of treatment </p> </li> <li> <p>Clinical response: disappearance of clinical symptoms after 7 days of treatment</p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of <i>E histolytica</i> from the stools </p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of bloody diarrhoea</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before, during, and after treatment including complete blood count, urinalysis, electrocardiogram, liver transaminases (SGPT), and alkaline phosphatase </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and eosin and Lugol's solution</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Military hospital in Erzurum, Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 adults with acute amoebic dysentery and stool specimens positive for <i>E histolytica</i> cysts and/or trophozoites </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 2 g single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 750 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0025"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools on days 14 and 21 </p> </li> <li> <p>Time (mean number of days) from start of treatment to resolution of clinical symptoms (abdominal pain, diarrhoea, bloody diarrhoea, abdominal distension, tenesmus, fever) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using 0.85% saline water, Lugol's solution, and trichrome stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Panidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 adult males with clinical symptoms of intestinal amoebiasis and stools positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panidazole: 2 × 250‐mg tablets (500 mg), 4 times daily for 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 × 250‐mg tablets (500 mg), 4 times daily for 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0026"> <li> <p>Parasitological cure: eradication of parasites in any of the post‐treatment laboratory examinations </p> </li> <li> <p>Clinical response: improvement in or disappearance of symptoms during weekly follow‐up until 4 weeks after treatment </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment and on follow‐up; laboratory tests monitored before and after treatment including complete blood count, erythrocyte sedimentation rate, blood urea nitrogen, liver transaminases, urinalysis, and electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> number of stools passed in 24 hours on day 3 and day 6 of treatment, and on days 7 and 21 after treatment; clearance of <i>E histolytica</i> in 14 asymptomatic carriers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and Ritchie formalin‐ether concentration methods </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Satranidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults with symptoms of intestinal amoebiasis and stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GO 10213 (satranidazole): 150 mg thrice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0027"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on stool examinations on follow‐up 28 days after start of treatment </p> </li> <li> <p>Clinical response: relief of presenting clinical signs and symptoms and healing of ulcers on sigmoidoscopy on follow‐up 28 days after start of treatment </p> </li> <li> <p>Adverse events: volunteered by participants; laboratory tests monitored before and after treatment including complete blood count, liver transaminases (SGOT, SGPT), serum bilirubin, blood urea, urinalysis, and electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> frequency of loose stools/d from start of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using formol‐ether concentration methods, sigmoidoscopy, colonic ulcer scrapings, and positive stool culture on NIH media </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Praziquantel versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients in Iraq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for vegetative trophozoite forms (acute amoebic dysentery) or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Praziquantel: 40 mg/kg body weight divided into 2 doses orally and taken 4 to 6 hours apart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0028"> <li> <p>Parasitological response: disappearance of <i>E histolytica</i> from stools 1 week after treatment </p> </li> <li> <p>Clinical response: disappearance of baseline clinical signs and symptoms at end of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants only for praziquantel </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Durban, South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 children with amoebic dysentery presenting with acute onset of diarrhoea with blood, mucus, and actively motile haematophagous trophozoites of <i>E histolytica</i> in stool specimens </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydroemetine, tetracycline, and diloxanide furoate: dehydroemetine (2 mg/kg body weight daily by subcutaneous injection for 10 days), tetracycline (50 mg/kg body weight daily orally for 7 days), and diloxanide furoate (25 mg/kg body weight daily orally for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 50 mg per kg body weight orally for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0029"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> at end of treatment and on subsequent stool specimens during follow‐up until 28 days after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms at end of treatment and during follow‐up until 28 days after start of treatment </p> </li> <li> <p>Adverse events: only tolerance to drugs reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and zinc sulphate flotation technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various cities in India (not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961 male and non‐pregnant female patients &gt; 12 years of age with clinical symptoms of intestinal amoebiasis and/or presence of trophozoites or cysts of<i>E histolytica</i> in stool specimens </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole and diiodohydroxyquinoline: fixed‐drug combination of metronidazole (200 mg) plus diiodohydroxyquinoline (325 mg) (Qugyl by Sil Pharma, Bombay, India) given as 2 tablets thrice daily for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0030"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> from stool specimens at end of treatment </p> </li> <li> <p>Clinical cure: remission of clinical symptoms on days 5 and 10 after start of treatment</p> </li> <li> <p>Adverse events: clinical adverse events monitored by study personnel during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> average daily frequency of stools on admission and on day 5 and day 10 of treatment; overall clinical response (rated as "poor" if &lt; 25% relief and not tolerated, "fair" if 25% to 49% relief and not well tolerated, "poor" if 50% to 74% relief and well tolerated, or "excellent" if 75% to 100% relief and well tolerated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paediatric outpatient department of S.N. Medical College, Agra, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 children with clinical symptoms of intestinal amoebiasis or giardiasis (diarrhoea, abdominal pain, dysentery, gastrocolic urgency, etc.) and whose stools were positive for amoebae or <i>Giardia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole plus furazolidone: fixed‐drug combination suspension of (per 5 mL) metronidazole 75 mg plus furazolidone 25 mg, given as 5 mL thrice daily for those 1 to 5 years of age and as 10 mL thrice daily for those 6 to 15 years of age for 5 or 10 days depending on severity of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 100 mg/5 mL suspension, given as 5 mL thrice daily for those 1 to 5 years of age and as 10 mL thrice daily for those 6 to 15 years of age for 5 or 10 days depending on severity of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0031"> <li> <p>Parasitological and clinical response: evaluated jointly on day 7 after start of therapy; overall outcome was reported as complete cure, partial cure, and no cure, but these terms were not defined </p> </li> <li> <p>Adverse events: clinical adverse events reported by participants during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> clinical and parasitological response in those with mixed amoebiasis and giardiasis infection; 12/63 from the metronidazole group and 15/101 from the fixed‐drug combination metronidazole plus furazolidone had mixed amoebiasis and giardiasis and were not included in this review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination versus aminosidine or etophamide or nimorazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 district hospitals of Kiambo, Machakos, and Kilifi in Kenya, Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 adults and children with clinical symptoms of intestinal amoebiasis with stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0032"> <li> <p>Combination of nimorazole and aminosidine (NA): same doses as above for 5 days</p> </li> <li> <p>Combination of nimorazole and etophamide (NE): same doses as above for 5 days</p> </li> <li> <p>Combination of etophamide and aminosidine (EA): same doses as above for 5 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0033"> <li> <p>Aminosidine (A): 500 mg twice daily orally for adults, 15 mg/kg body weight twice daily orally for children for 5 days </p> </li> <li> <p>Etophamide (E): 600 mg twice daily orally for adults, 15 mg/kg body weight twice daily orally for children for 5 days </p> </li> <li> <p>Nimorazole (N): 1 g twice daily orally for adults, 20 mg/kg body weight twice daily orally for children for 5 days </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0034"> <li> <p>Parasitological cure: disappearance of any form of <i>E histolytica</i> from stools or ulcer scrapings at end of treatment </p> </li> <li> <p>Recurrence (relapse): reappearance of <i>E histolytica</i> during follow‐up on days 15, 30, and 60 after initial disappearance; owing to incomplete data on follow‐up, results could not be included in the meta‐analysis </p> </li> <li> <p>Clinical cure: disappearance of all baseline symptoms at end of treatment</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> cumulative daily clearance of <i>E histolytica</i> from stools during treatment, at end of treatment, and on days 15, 30, and 60 after start of treatment; evolution of mild and severe amoebic ulcers seen on rectosigmoidoscopy; and anatomical cure (healing of previous ulceration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and a concentration method (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Quinfamide and mebendazole versus nitazoxanide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 communities in Colima, Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 children enrolled with various helminthic and protozoal intestinal infections; 105/275 (38%) had <i>E histolytica</i> or <i>E dispar</i> infection (25 single infection and 80 mixed infection with other intestinal parasites) and were included in the review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide: 100 mg/5 mL single oral dose; mebendazole 100 mg/5 mL twice daily orally for 3 days was added to quinfamide when another parasite other than <i>E histolytica</i> /<i>E dispar</i> was observed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: 100 mg/5 mL twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0035"> <li> <p>Parasitological cure: eradication of <i>E histolytica/E dispar</i> in stool examination 14 days after treatment </p> </li> <li> <p>Adverse events: only tolerance to drugs reported</p> </li> </ul> </p> <p>Data for parasitological cure were presented separately for nitazoxanide versus quinfamide for single infections and for nitazoxanide versus quinfamide plus mebendazole for mixed infections, and were included in a separate meta‐analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy with direct smear or Kato‐Katz technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination tetracycline and clioquinol versus secnidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient in the Padang Bulan Health Centre, Medan, Indonesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 children with clinical symptoms of acute intestinal amoebiasis with stool specimens positive for trophozoites or haematophagous forms of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline and clioquinol: tetracycline (750 mg) and clioquinol (1 g for 5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 2 g orally in a single dose</p> <p><i>Co‐intervention:</i> 2 patients in secnidazole group were given spasmolytics (unspecified) for stomach cramps </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0036"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools examined on days 1 to 7, and on days 7, 14, and 21 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of clinical symptoms on days 1 to 7, and on days 14, 21, and 28 after start of treatment </p> </li> <li> <p>Adverse events: clinical adverse events during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination tinidazole and diloxanide versus tinidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Stockholm, Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 adults and children with clinical symptoms of intestinal amoebiasis but no signs of invasion (e.g. no fever or acute dysentery) and stool specimens positive for trophozoites or cysts of <i>E histolytic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole plus diloxanide furoate: tinidazole 40 mg/kg body weight in a single oral dose daily for 5 days plus diloxanide furoate 20 mg/kg body weight divided into 3 daily doses for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 40 mg/kg body weight in a single oral dose daily for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0037"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from any of the 3 stool specimens evaluated 1 month after end of treatment </p> </li> <li> <p>Adverse events: only adverse events severe enough to result in cessation of therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique by Ridley and Hawgood </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole single dose versus tinidazole for 2 days</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 different centres in Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 children with clinical symptoms of intestinal amoebiasis with stool specimens positive for <i>E histolytica</i> enrolled; 275/303 (90.7%) included in evaluation for clinical efficacy; 300/303 (99%) included in evaluation for parasitological efficacy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 1 mL/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 0.5 mL/kg body weight once daily orally for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0038"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stool specimens collected on days 7, 14, and 21 following treatment </p> </li> <li> <p>Clinical response: disappearance of all symptoms at end of the study (day 21)</p> </li> <li> <p>Adverse events: solicited from participants or their guardians during follow‐up visits</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and the Faust and Katz method and no history of intolerance to imidazole drugs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Ornidazole versus tinidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the sub‐department of Gastroenterology, Department of Child Health Medical School, General Hospital, Medan, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 children with amoebic dysentery presenting with bloody stools and motile haematophagous trophozoites of <i>E histolytica</i> in stools: 25/40 (62.5%) analysed 1 week after treatment, 17/40 (42.5%) analysed 2 weeks after treatment, 11/40 (27.5%) analysed 3 weeks after treatment, and 6/40 (15%) analysed 4 weeks after treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole: 50 mg/kg body weight in a single oral dose daily for 3 days</p> <p><i>Other interventions:</i> Children with concomitant intestinal helminthic infection were given single‐dose pyrantel pamoate 10 mg/kg; those with trichuriasis were given mebendazole 1 tablet twice daily for 3 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 50 mg/kg body weight in a single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0039"> <li> <p>Parasitological cure: disappearance of all forms of <i>E histolytica</i> on stool examinations done weekly until 4 weeks after completion of treatment </p> </li> <li> <p>Re‐infection: reappearance of <i>E histolytica</i> after the second month </p> </li> <li> <p>Clinical cure: disappearance of blood and mucus from stools at follow‐up examinations done weekly until 4 weeks after completion of treatment </p> </li> <li> <p>Adverse events: clinical adverse effects reported by participants during treatment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and eosin 2% stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Pediatric Gastroenterology Subdivision, Department of Child Health, School of Medicine, University of North Sumatra/Dr Pirngadi Hospital, Medan, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 children with amoebic dysentery presenting with bloody diarrhoea and motile haematophagous trophozoites of <i>E histolytica</i> in stools: 41/50 (82%) analysed on the third day or 2 days after treatment, 18/50 (36%) were analysed 1 week after treatment </p> <p><i>Losses to follow‐up:</i> 9/51 (18%) were lost to follow‐up by the third day or 2 days after treatment ‐ 7 participants in the tinidazole group and 2 in the ornidazole group; 32/50 (64%) were lost to follow‐up 1 week after treatment ‐ 18 in the tinidazole group and 14 in the ornidazole group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole: 50 mg/kg body weight in a single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 50 mg/kg body weight in a single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0040"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools on subsequent follow‐up visits on days 2 to 4 and 1 week after treatment </p> </li> <li> <p>Clinical response: disappearance of diarrhoea, and faeces no longer contained mucus or red blood cells on days 2 to 4 and 1 week after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and eosin 1% stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole versus quinfamide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 urban federal elementary schools in Celaya, Guanajuato, Mexico (Urban Federal Elementary schools ‘Carmen Serdan' and ‘Juan Jesus de los Reyes') </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239 children with clinical symptoms of non‐dysenteric amoebic colitis with at least 1 of 3 stool specimens positive for <i>E histolytica</i> cysts </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 30 mg/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide: 4.3 mg/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0041"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> cysts on days 5, 6, and 7 after administration of drugs </p> </li> <li> <p>Adverse events: Clinical adverse events were solicited by investigators through direct questioning for the presence of abdominal pain, nausea, vomiting, headache, diarrhoea, and unpleasant taste in the mouth </p> </li> </ul> </p> <p><i>Not included in this review:</i> acceptability of the test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and the Faust concentration method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ornidazole versus secnidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical Center Hospital, Ankara, Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 children with gastrointestinal symptoms and stool specimens positive for haematophagous trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole 15 mg/kg body weight given twice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 30 mg/kg body weight given as a single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0042"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> cysts or trophozoites from stools 10 days after completion of treatment </p> </li> <li> <p>Clinical response: resolution of diarrhoea and abdominal discomfort</p> </li> <li> <p>Time (median and range in days) from start of treatment to resolution of clinical symptoms </p> </li> <li> <p>Adverse events: side effects; method for obtaining information and specific adverse events not reported </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Quinfamide versus teclozan</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients were hospitalized for 1 day, then were followed up as outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults with non‐dysenteric amoebiasis with trophozoites of <i>E histolytica</i> in recently emitted faecal material and/or in recto‐colonic mucosal exudate; recto‐colonic lesions suggestive of amoebiasis present or not; and not presenting clinical manifestations of acute amoebic recto‐colitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide given at 3 doses in 1 day: 100 mg for 3 doses (300 mg), 200 mg for 3 doses (600 mg), 400 mg for 3 doses (1200 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teclozan at 3 doses in 1 day: 500 mg for 3 doses (1500 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0043"> <li> <p>Parasitological failure: persistence of trophozoites in rectal exudates by rectosigmoidoscopy 15 and 30 days after end of treatment and in fresh faecal material 8, 15, and 30 days after treatment </p> </li> <li> <p>Adverse events: Clinical and laboratory tests were monitored on the day after drug administration, then 8, 15, and 30 days after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Chlorhexidine versus diiodohydroxyquinoline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bombay, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 patients with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites and/or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorhydroxquinoline: 500 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Di‐diiodohydroxyquinoline: 500 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0044"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools at the end of the 10‐day treatment period </p> </li> <li> <p>Clinical cure: improvement in or disappearance of symptoms at the end of the 10‐day treatment period </p> </li> <li> <p>Adverse events: clinical adverse events and liver function test monitored before and after treatment including total bilirubin, serum albumin and globulin, and zinc sulphate </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>MK‐910 low dose versus high dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in New Delhi, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 patients (age unspecified) with acute amoebic dysentery and stool specimens positive for trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Methyl‐2‐(4'fluorophenyl)‐5‐nitroimidazole (MK‐910) at low doses: 0.5 mg/kg body weight or 1.0 mg/kg body weight, given in 3 divided doses orally for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Methyl‐2‐(4'fluorophenyl)‐5‐nitroimidazole (MK‐910) at high doses: 2.0 mg/kg body weight or 3.0 mg/kg body weight, given in 3 divided doses orally for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0045"> <li> <p>Parasitological response: disappearance of <i>E histolytica</i> from stools on day 5 and day 10 of treatment, on both saline and iodine smear examination and on stool culture using NIH medium </p> </li> <li> <p>Clinical response: reduction in clinical signs and symptoms (tenesmus, diarrhoea, bloody stools) </p> </li> <li> <p>Time (range in hours) until disappearance of <i>E histolytica</i> cysts and trophozoites in stools </p> </li> <li> <p>Adverse events: monitored by study personnel during treatment; laboratory tests monitored before and on day 5 and day 11 of treatment including complete blood count, platelet count, urinalysis, blood urea, blood sugar, serum bilirubin, alkaline phosphatase, liver transaminases (SGOT, SGPT), thymol turbidity tests, and 12‐lead electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> disappearance of colonic ulcers on sigmoidoscopic examination on day 5 and at end of treatment on day 10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and iodine smears</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Fixed drug combination diloxanide‐tetracycline‐chloroquine versus fixed‐drug combination diloxanide‐tetracycline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yaba Military Hospital in Lagos, Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 military personnel and their families given diagnosis of acute amoebic dysentery and stool specimens positive for <i>E histolytica:</i> 60 analysed at end of treatment, and 58 (96.8%) analysed 7 weeks after end of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate, tetracycline hydrochloride, and chloroquine phosphate (per capsule): diloxanide furoate (187.5 mg), tetracycline hydrochloride (125 mg), and chloroquine phosphate (50 mg) given in 3 dosage regimens of 2 capsules 4 times a day for 5 days, 2 capsules 4 times a day for 7 days, or 2 capsules 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate and tetracycline hydrochloride (per capsule): diloxanide furoate (187.5 mg) and tetracycline hydrochloride (125 mg) given in 3 dosage regimens of 2 capsules 4 times a day for 5 days, 2 capsules 4 times a day for 7 days, or 2 capsules 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0046"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> cysts and trophozoites at end of treatment, then on follow‐up 7 weeks from completion of treatment; patients whose stools remained negative 7 weeks after treatment were followed up 3 and 6 months from completion of treatment </p> </li> <li> <p>Clinical response: recurrence of symptoms (reported only for those given 10 days' treatment: 16/34 in the diloxanide furoate‐tetracycline hydrochloride‐chloroquine phosphate group and 10/26 in the diloxanide furoate‐tetracycline hydrochloride group) </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment and on follow‐up; laboratory tests monitored before and after treatment including urine cytology and presence of protein, blood examination for haemoglobin, total erythrocyte and leucocyte counts, and differential count </p> </li> </ul> </p> <p><i>Not included in this review:</i> results of stool examination 3, 6, and 12 months after treatment; clearance of <i>E histolytica</i> from stools of 36 asymptomatic cyst carriers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and iodine‐stained smears</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 children from 1 to 15 years of age who presented with <i>E histolytica</i> ‐<br/> associated diarrhoea defined as presence of compatible clinical presentations (acute diarrhoea, fever, and abdominal pain) and presence of <i>E histolytica</i> trophozoite engulfing red blood cells in diarrhoeal stool </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 30 to 50 mg/kg/d orally for 10 days (maximum: 500 to 750 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole plus <i>S boulardii</i> (Reflor, Sanofi‐Synthelabo, France): metronidazole 30 to 50 mg/kg/d orally (maximum: 500 to 750 mg) plus lyophilized <i>S boulardii</i> 250 mg (includes 5,000,000 living microorganisms) orally once a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0047"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stool specimens collected 14 days after end of treatment </p> </li> <li> <p>Clinical response: disappearance of all symptoms (diarrhoea, bloody diarrhoea, vomiting, fever, abdominal pain) at the end of the study (day 10) </p> </li> <li> <p>Time (median and range in days) to resolution of diarrhoea, bloody diarrhoea, vomiting, fever, abdominal pain </p> </li> <li> <p>Adverse events: recorded during the active treatment period</p> </li> </ul> </p> <p><i>Not included in this review:</i> survival analysis graph of the number of stools per day during the 10‐day treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and trichrome stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Metro‐iodoquinol versus metro‐iodoquinol + <i>Saccharomyces</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shahid Beheshti Educational and Therapeutic Center in Shiraz, Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 adults with amoebic dysentery presenting with mucous bloody diarrhoea, fever, and abdominal pain; stool specimens positive for haematophagous trophozoites of <i>E histolytica</i> in the laboratory </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, iodoquinol, and placebo: metronidazole 750 mg and iodoquinol 650 mg given thrice daily orally with placebo tablets for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, iodoquinol, and <i>S boulardii</i> : 750 mg and iodoquinol 650 mg thrice daily given orally for 10 days plus lyophilized <i>S boulardii</i> 250 mg orally thrice daily given for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0048"> <li> <p>Parasitological failure: persistence of amoebic cysts at stool examination at 4 weeks after treatment </p> </li> <li> <p>Mean duration of diarrhoea, abdominal pain, fever, and headache from start of treatment to resolution of symptoms </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct faecal smear and flotation technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Herbal versus fixed‐drug combination metronidazole‐diloxanide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient department of 2 centres in Pakistan (Shifa‐Ul‐Maluk Hospital, Gadap and Zahida Medical Centre, North Karachi) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 patients between the ages of 5 and 60 years with symptoms of amoebiasis (abdominal pain, blood in stool, or diarrhoea) and positive for <i>E histolytica</i> cyst or trophozoite: 153 analysed; 18/171 were not included in the analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal product (Endemali, Pakistan) available in 4‐g sachet containing <i>Boswellia glabra</i> 270.9 mg, <i>Kaolinum ponderosum</i> 255 mg, <i>Ocimum pilosum</i> 580 mg, <i>Pistacia terebinthus</i> 116.1 mg, <i>Plantago ispagula</i> 812.7 mg, and <i>Vateria indica</i> 232.2 mg sweetening agent q.s. Endemali was given 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of metronidazole 400 mg + diloxanide furoate 500 mg (Entamizole DS, Pakistan) in tablet form given 3 times a day for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0049"> <li> <p>Parasitological response: no <i>E histolytica</i> cyst found in the stool 5 days after treatment was stopped </p> </li> <li> <p>Clinical response: absence (partial or complete) of symptoms after treatment was stopped</p> </li> <li> <p>Adverse events: Clinical adverse events were reported by participants after they received study drugs, but the method of reporting was not specified; no biochemical tests were monitored </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear, Lugol's iodine smear, zinc sulphate flotation preparation, or formalin‐ether sedimentation method </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Herbal product versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital, multi‐centre (Shifa‐ul‐mulk Memorial Hospital, Hamdard University Karachi, Hakeem, Pakistan) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 adult patients suffering from amoebiasis infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal drug Amoebex 400‐mg tablet 2 tablets after meal thrice daily, duration not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole 400 mg 2 tablets thrice daily for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0050"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stool specimens at end of treatment </p> </li> <li> <p>Clinical response: disappearance of signs and symptoms of amoebiasis at the end of the study </p> </li> </ul> </p> <p><i>Not included in this review:</i> improvement in intensity of symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><i>E dispar</i> : <i>Entamoeba dispar</i> ; <i>E histolytica</i> :<i>Entamoeba histolytica</i> ; ELISA: enzyme‐linked immunosorbent assay; <i>G intestinalis</i> : <i>Giardia intestinalis</i>; SGOT: aspartate aminotransferase; SGPT: alanine aminotransferase. </p> </div> </div> <section id="CD006085-sec-0060"> <h4 class="title">Results of the search</h4> <p>Thirty‐seven trials met the inclusion criteria of the first published version of this review (<a href="./references#CD006085-bbs2-0310" title="GonzalesMLM , DansLF , MartinezEG . Antiamoebic drugs for treating amoebic colitis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006085.pub2] ">Gonzales 2009</a>). We retrieved one trial previously classified under ‘Studies awaiting classification' following the initial search (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>), and we assessed 14 additional studies identified in updated searches conducted from the time of publication of the review in 2009 until 22 March 2018. Of these, we retrieved the full‐text articles of six studies, of which we excluded three for the following reasons: one was quasi‐randomized with alternate treatment assignment (<a href="./references#CD006085-bbs2-0082" title="DinleyiciEC , ErenM , YargicZA , DoganN , VandenplasY . Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. American Journal of Tropical Medicine and Hygiene2009;80(6):953‐5. ">Dinleyici 2009</a>), and two included an ineligible population: one enrolled patients with bacillary dysentery with no mention of amoebic colitis (<a href="./references#CD006085-bbs2-0182" title="SharifA , KashaniHH , NasriE , SoleimaniZ , SharifMR . The role of probiotics in the treatment of dysentery: a randomized double‐blind clinical trial. Probiotics and Antimicrobial Proteins2017;21:1‐6 [Epub ahead of print]. [DOI: 10.1007/s12602‐017‐9271‐0] ">Sharif 2017</a>); one with asymptomatic schoolchildren (<a href="./references#CD006085-bbs2-0190" title="SpeichB , MartiH , AmeSM , AliSM , BogochII , UtzingerJ , AlbonicoM , et al. Prevalence of intestinal protozoa infection among school‐aged children on Pemba Island, Tanzania, and effect of single‐dose albendazole, nitazoxanide and albendazole‐nitazoxanide. Parasites &amp; Vectors2013;6(3):1‐8. ">Speich 2013</a>)). See <a href="#CD006085-fig-0001">Figure 1</a> and the ‘<a href="./references#CD006085-sec-0132" title="">Characteristics of excluded studies</a>' table for studies detected by the search specifications but excluded from this review. </p> <div class="figure" id="CD006085-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006085-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We included four new RCTs in this review update. <a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a> was previously classified as awaiting classification and compared quinfamide with teclozan for treatment of adults with non‐dysenteric amoebiasis. One trial compared a probiotic, <i>Saccharomyces boulardii</i>, in addition to metronidazole versus metronidazole alone (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). Two trials compared various herbal products versus a combination of metronidazole and diloxanide furoate ‐ as in <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a> ‐ or metronidazole alone ‐ as in <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>. We identified two ongoing RCTs: one trial will determine the efficacy of auranofin, a gold‐containing chemical salt oral drug, for treating adults with amoebiasis or giardiasis (<a href="./references#CD006085-bbs2-0217" title="National Institute of Allergy and Infectious Diseases (NIAID). Phase IIa Randomized, Single‐blinded, Placebo‐controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa. clinicaltrials.gov Last Update Posted: September 15, 2017. [ClinicalTrials.gov identifier: NCT02736968] ">NIAID 2016</a>), and the other is a non‐randomized trial that will determine the safety and efficacy of paromomycin for treating individuals with intestinal amoebiasis (<a href="./references#CD006085-bbs2-0218" title="Drug Use Investigation of Paromomycin. clinicaltrials.gov Last update posted: March 6, 2018. [ClinicalTrials.gov identifier NCT02680665 ] ">Pfizer 2016</a>). See <a href="./references#CD006085-sec-0133" title="">Characteristics of ongoing studies</a>. </p> <p>Thus, we included 41 trials in total in this review update. All trial reports were published in English, except <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a> (Portuguese), <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> (Turkish), and <a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a> and <a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a> (Spanish). Trials included in this review were published between 1964 and 2016; 27 were conducted between 1964 and 1989, three between 1990 and 1997, and eleven between 1998 and 2016 (see the ‘<a href="./references#CD006085-sec-0131" title="">Characteristics of included studies</a>' table and <a href="#CD006085-tbl-0004">Table 2</a>). </p> </section> <section id="CD006085-sec-0061"> <h4 class="title">Included studies</h4> <section id="CD006085-sec-0062"> <h5 class="title">Locations</h5> <p>A total of 39 trials were conducted in 16 different countries (see details in <a href="./appendices#CD006085-sec-0114">Appendix 5</a>), 15 of which are considered to be highly endemic for amoebiasis: India (12), Indonesia (5), Mexico (3), Turkey (3), Colombia (2), Brazil (2), Pakistan (2), Kenya (2), Egypt (2), Bangladesh (1), Nigeria (1), South Africa (1), Chile (1), Iran (1), and Iraq (1). The remaining two trials were conducted in Sweden. </p> <p>Trials were conducted in a variety of settings (see details in <a href="./appendices#CD006085-sec-0115">Appendix 6</a>): hospital (14), outpatient clinic (15), community (1), and school (1). Eight trials did not state the study setting. One trial treated most participants as outpatients but treated a few with severe symptoms in the hospital (<a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>). In another trial, patients were initially hospitalized for one day, then were followed up as outpatients (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>). </p> </section> <section id="CD006085-sec-0063"> <h5 class="title">Source of funding</h5> <p>Twenty‐one trials did not state the source of funding. Seventeen trials reported that a pharmaceutical company provided funding (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>), or supplied study drugs (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). Two trials reported that at least one trial author was connected with the pharmaceutical company manufacturing the study drug (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>), although study authors did not describe the level of involvement of the company. One trial was funded by the university at which study authors were affiliated (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). </p> </section> <section id="CD006085-sec-0064"> <h5 class="title">Participants</h5> <p>A total of 4999 participants were enrolled in the trials; 17 trials included 1200 adults, 11 trials included 1185 children, 11 trials included 2474 children and adults, and two trials did not mention the age of participants. Included trials used different inclusion criteria for study participants. </p> <p> <ul id="CD006085-list-0051"> <li> <p>Acute amoebic dysentery in 12 trials (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). </p> </li> <li> <p>Chronic or vague abdominal symptoms compatible with non‐dysenteric amoebic colitis, without bloody diarrhoea or other signs of intestinal invasion, in five trials (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>; <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>). </p> </li> <li> <p>Acute amoebic dysentery and non‐dysenteric amoebic colitis among enrolled participants and analysed separately in five trials. </p> <ul id="CD006085-list-0052"> <li> <p>Three trials stratified participants during the analysis of outcomes into those with acute amoebic dysentery and those with non‐dysenteric amoebic colitis (<a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>; <a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>). </p> </li> <li> <p>Two trials classified participants as having invasive trophozoite forms and non‐invasive cyst forms based on stool microscopy findings and analysed the two groups separately (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). </p> </li> </ul> </li> <li> <p>Clinical symptoms of intestinal amoebiasis, with no differentiation between amoebic dysentery and non‐dysenteric amoebic colitis in 19 trials. </p> <ul id="CD006085-list-0053"> <li> <p>Two trials categorized participants as having acute amoebic dysentery, subacute amoebiasis, or chronic amoebiasis based on severity of symptoms and whether trophozoites or cysts of <i>E histolytica</i> were present but analysed participants as one group (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>). </p> </li> <li> <p>Two trials classified participants as having acute or chronic amoebiasis based on duration of symptoms but analysed study participants as one group (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>). </p> </li> <li> <p>Fifteen trials recruited and analysed participants with symptoms of intestinal amoebiasis or amoebic colitis, regardless of whether or not they presented with dysentery. </p> </li> </ul> </li> </ul> </p> <p>Participant age ranged from seven months to 80 years; see <a href="./appendices#CD006085-sec-0116">Appendix 7</a> for details. Seventeen trials enrolled only adults, and 11 trials recruited only children. The remaining 11 trials recruited both adults and children. Two trials did not state participant age (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>). </p> </section> <section id="CD006085-sec-0065"> <h5 class="title">Methods used to diagnose amoebic colitis</h5> <p>Trials used stool microscopy with direct wet saline smear as the predominant method for determining the presence of <i>E histolytica</i> cysts or trophozoites in stools (details in <a href="./appendices#CD006085-sec-0117">Appendix 8</a>). In addition to direct smears, researchers used other methods ‐ various staining methods (10 trials), concentration methods such as formalin or formol‐ether (12 trials), zinc sulphate centrifugal flotation technique (four trials), or an unspecified concentration method (four trials) ‐ for better detection of cysts; one trial used polyvinyl alcohol fixative for detection of trophozoites. Two trials used National Institute of Health (NIH) media to culture stools for <i>E histolytica,</i> in addition to stool microscopy to evaluate parasitological response (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>), but one trial did not use this as an inclusion criterion (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>). In addition to stool examination, 11 trials performed rectosigmoidoscopy whenever possible to determine the appearance of the bowel mucosa and the presence of ulcers but did not use this as the sole criterion for enrolling participants or evaluating outcomes. Only one trial used stool antigen‐based ELISA testing (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). One trial used antibody detection testing in addition to stool microscopy to confirm amoebiasis infection (<a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). </p> </section> <section id="CD006085-sec-0066"> <h5 class="title">Concomitant infection with other intestinal parasites</h5> <p>Aside from <i>E histolytica,</i> 10 trials identified concomitant infection with other intestinal parasites: giardiasis (<a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>); intestinal helminth infection (<a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>); and other intestinal protozoal and helminth infections (<a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). Six trials explicitly stated that stool bacterial culture was done before enrolment; five trials included only those found to be negative for pathogenic bacteria (<a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>), and one trial analysed those found to be positive for <i>Shigella</i> separately from those positive for <i>E histolytica</i> (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>). The remaining trials did not examine or mention concomitant infection with other intestinal pathogens or bacteria. Because clinical symptoms may not have been exclusively caused by amoebiasis in those with concomitant intestinal parasites, and given that the effect of concomitant infection on eradication of <i>E histolytica</i> by antiamoebic drugs is not known, we used data for <i>E histolytica</i> infection alone in assessing outcomes, except for trials that did not separate the data for those with single infection from those with mixed infection. Three trials performed separate analyses for clinical outcomes among those with <i>E histolytica</i> alone and those with concomitant infection with <i>Giardia</i> and <i>E histolytica</i> (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). </p> </section> <section id="CD006085-sec-0067"> <h5 class="title">Drug comparisons</h5> <p>Included trials reported a variety of comparisons that involved over 30 individual drugs and combinations. As shown in <a href="./appendices#CD006085-sec-0118">Appendix 9</a>, we grouped trials into the following categories (some trials are included in more than one category). </p> <p> <ul id="CD006085-list-0054"> <li> <p><b>Single‐agent alternative versus metronidazole (17 trials):</b> 10 trials on tinidazole versus metronidazole; three on ornidazole versus metronidazole; and one each on secnidazole versus metronidazole, panidazole versus metronidazole, satranidazole versus metronidazole, and praziquantel versus metronidazole. </p> </li> <li> <p><b>Any antiamoebic drug versus placebo (four trials):</b> two trials on nitazoxanide versus placebo; one on quinfamide versus placebo; and one on 10 different drugs belonging to six drug classes versus placebo. </p> </li> <li> <p><b>Combination regimen versus monotherapy (seven trials):</b> three trials on various combinations (dehydroemetine plus oral tetracycline and diloxanide furoate, metronidazole and diiodohydroxyquinolone, metronidazole and furazolidone) versus metronidazole alone; one on nimorazole and aminosidine or nimorazole and etofamide or etofamide and aminosidine versus nimorazole or aminosidine or etofamide monotherapy; and one each on tetracycline and clioquinol versus secnidazole, quinfamide and mebendazole versus nitazoxanide, and tinidazole and diloxanide furoate versus tinidazole. </p> </li> <li> <p><b>Single‐dose regimens versus longer regimens (five trials):</b> one trial each on quinfamide (one dose) versus quinfamide (two or three doses); secnidazole (one dose) versus tetracycline and clioquinol (five days); secnidazole (one dose) versus tinidazole (two days); quinfamide (one dose) versus nitazoxanide (three days); and secnidazole (one dose) versus metronidazole (10 days). </p> </li> <li> <p><b>Other amoebic drug comparisons (13 trials):</b> two trials on ornidazole versus tinidazole; 11 trials using different drug comparisons, with one trial reporting on each of the following: ornidazole versus secnidazole, chlorhydroxyquinoline versus diiodohydroxyquinoline, MK‐910 low dose (0.5 mg/kg and 1 mg/kg) versus MK‐910 high dose (2 mg/kg and 3 mg/kg), quinfamide versus secnidazole, quinfamide versus teclozan, quinfamide versus nitazoxanide, metronidazole and iodoquinol with <i>Saccharomyces boulardii</i> versus metronidazole and iodoquinol, metronidazole and iodoquinol with <i>Saccharomyces boulardii</i> versus metronidazole alone, herbal drug versus metronidazole, fixed‐drug combination of metronidazole and diloxanide furoate versus herbal product, and fixed‐drug combination of diloxanide furoate and tetracycline with chloroquine versus fixed‐drug combination of diloxanide furoate and tetracycline without chloroquine. </p> </li> </ul> </p> <p>Six trials compared more than two interventions. Four trials compared different doses of the same drug using standard or control groups: three dosages of quinfamide with teclozan (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>); three dosages of quinfamide with placebo (<a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>); two treatment durations of tinidazole with metronidazole (<a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>); and four dosages of MK‐910 (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>). <a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a> compared 10 different treatment groups with placebo, and <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a> compared three drugs used alone or in three different combinations. One trial compared two brands of tinidazole and two brands of metronidazole (<a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>). For trials with more than two intervention groups, we combined multiple treatment arms as appropriate into one group and compared them collectively with the standard or control group. This is the recommended approach to avoid a unit of analysis error by not counting placebo or control participants more than once in the same meta‐analysis (<a href="./references#CD006085-bbs2-0251" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2008</a>). For the trial comparing two brands of tinidazole and two brands of metronidazole (<a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>), the two brands of tinidazole were combined as one group and were compared with the two brands of metronidazole used in the other group. </p> </section> <section id="CD006085-sec-0068"> <h5 class="title">Duration of follow‐up</h5> <p>The follow‐up period varied considerably between trials. Seven trials followed participants only until the end of the treatment period (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). Duration of follow‐up was less than 15 days and ranged from 7 to 14 days in 10 trials (<a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>; <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). Seventeen trials had a duration of follow‐up of about four weeks, and two of about three weeks. Five trials had a follow‐up period longer than four weeks and ranging from 40 days to 12 months after treatment (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). </p> </section> <section id="CD006085-sec-0069"> <h5 class="title">Outcome measures</h5> <p>The primary outcomes in this review were clinical failure, parasitological failure, and relapse. Thirty‐three trials evaluated both clinical and parasitological outcomes, and six evaluated parasitological outcomes only (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). One trial based the final evaluation on parasitological outcomes (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>), and it is unclear whether clinical outcomes were evaluated after treatment. The definition of clinical and parasitological cure or failure varied between trials. Nine trials ‐ <a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a> ‐ used the definitions set by the WHO Expert Committee on Amoebiasis (<a href="./references#CD006085-bbs2-0300" title="WHO Expert Committee on Amoebiasis. Amoebiasis. Report of a WHO Expert Committee. World Health Organization Technical Report Series1969;421:1‐52. ">WHO 1969</a>), which defined ‘cure' as symptom‐free, ulcers healed, stools negative for <i>E histolytica;</i> ‘probable failure' as persistent symptoms and rectal ulcerations despite disappearance of <i>E histolytica</i> from stools or ulcer scrapings; and ‘failure' as positive <i>E histolytica</i> with or without symptoms and rectal ulcers. For this review, review authors interpreted ‘probable failure' as clinical failure, and ‘failure' as parasitological failure, based on the definitions given. Most trials presented data for clinical and parasitological outcomes as dichotomous data. </p> <p>Nine trials presented the duration of time from start of treatment until resolution of diarrhoea and other clinical symptoms but measured this in a variety of ways: range in hours (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>), number of days (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>), mean duration in days and standard deviation (<a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>), median and range in days (<a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>), median time in days (<a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>), and survival analysis of time from first dose to passage of last unformed stools (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). Two trials reported the duration of time from start of treatment to disappearance of <i>E histolytica</i> from stools (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>). Four trials reported on the number of stools passed at different periods: during treatment (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>); after treatment (<a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>); and during treatment and on follow‐up after treatment (<a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>), while another reported average daily frequency of stools on admission and at the end of days 5 and 10 of treatment (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>). One trial assessed clinical and parasitological outcomes jointly as ‘cure' (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>); only dichotomous outcomes were included in the analysis because of inconsistency in reporting continuous data (see <a href="#CD006085-tbl-0005">Table 3</a>). </p> <div class="table" id="CD006085-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time‐to‐event in trials using various antiamoebic drugs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Time to resolution of diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 low dose (≤ 1 mg/kg/d</b> ) </p> <p>Range (h) = 24 to 72, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 high dose (≥ 2 mg/kg/d)</b> </p> <p>Range (h) = 24 to 48, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 1; n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 2, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol and</b> </p> <p><i><b>S boulardii</b> </i> </p> <p>Mean (h) = 12 ± 3.7 (SD), n = 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol and placeb</b>o </p> <p>Mean (h) = 48 ± 18.5 (SD), n = 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitazoxanide</b> </p> <p>Median (d) = 3,</p> <p>n = 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>No median presented because 60% still had diarrhoea at end of follow‐up period, n = 31 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and range not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitazoxanide</b> </p> <p>Mean or median and range not presented, n = 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>Mean or median and range not presented, n = 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented as survival analysis graph of time from first dose to passage of last unformed stools </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 4.5 (1 to 10), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 5 (1 to 10), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Mean (d) = 2 to 3, range (d) = 1 to 5, n = 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 5, range (d) = 1 to 29, n = 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD of mean and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Time to resolution of bloody stools</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 low dose, ≤ 1 mg/kg/d</b> </p> <p>Range = 48 to 72 hours, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 high dose, ≥ 2 mg/kg/d</b> </p> <p>Range = 48 to 72, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 1, n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 1, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (h) = 48 to 72, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (h) = 48 to 72, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 3 to 7, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 3 to 7, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 2 (1 to 5), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 2 (1 to 3), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Time to resolution of abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 2, n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 3, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol, and</b> </p> <p><i><b>S boulardii</b> </i> </p> <p>Mean (h) = 12 ± 3.2 (SD), n = 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol, and placebo</b> </p> <p>Mean (h) = 24 ± 7.3 (SD), n = 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 3 (1 to 10), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 2 (1 to 10), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to disappearance of <i>E. histolytica</i> in stools </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 2 to 3, n = 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 2 to 3, n = 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 2 to 4, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 2 to 4, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><i>E histolytica</i> : <i>Entamoeba histolytica</i> ; <i>S boulardii</i> :<i>Saccharomyces boulardii</i>; SD: standard deviation. </p> </div> </div> <p>Two trials reported relapse or recurrence; both compared ornidazole with metronidazole (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>). Another trial reported the proportion of participants who developed recurrence, but we could not include the data because researchers did not report the actual number of participants followed up (<a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). </p> <p>Measurements of clinical and parasitological outcomes were made at different time points. Fifteen trials reported outcomes between end of treatment and 14 days, and 16 trials reported outcomes from 18 to 30 days after end of treatment. Nine trials measured outcomes repeatedly, and six trials reported outcomes measured at two time points (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>). Three trials reported results at only one time point because of high dropout rates during the other follow‐up periods (<a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). </p> <p>A total of 37 trials reported adverse events, and four trials did not ascertain adverse events (<a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>). Seventeen trials provided incomplete data: Five reported specific adverse events but not the number of participants who developed any adverse event (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>); two reported only the number of participants with adverse events severe enough to cause discontinuation of drug treatment (<a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>); five did not report the actual number of participants who developed any adverse event (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>); two mentioned that one or more adverse events were reported but did not specify the treatment groups affected (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>); two reported adverse events only for the experimental group (<a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>); and one reported serious adverse events and allergic reactions severe enough to result in discontinuation of treatment but did not specify the treatment groups affected (<a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). </p> </section> </section> <section id="CD006085-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We have described in the ‘<a href="./references#CD006085-sec-0132" title="">Characteristics of excluded studies</a>' table trials identified by specifications from initial and updated searches but excluded from the review. </p> </section> </section> <section id="CD006085-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>Review authors prepared a risk of bias assessment for each trial with clinical and parasitological outcomes as outcome measures. Only one trial reported using appropriate procedures to minimize or eliminate bias in allocation concealment; generation of the allocation sequence; blinding of care providers, participants, and outcome assessors; and inclusion of all randomized participants (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). Many trials provided little information on which to make any assessment other than ‘unclear' for most criteria. </p> <p>We assessed eight trials as having low risk of bias for at least three criteria (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). Many trials had high risk for bias for one or more criteria, most commonly lack of blinding and selective outcome reporting. Most trials had unclear risk of bias for random sequence generation and allocation concealment. Many trials also had the potential risk of misclassification of amoebic colitis because the diagnosis of amoebiasis was based solely on stool microscopy in most trials, except in one that used <i>E histolytica</i> stool antigen testing to confirm the diagnosis (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>), and in two trials that used NIH stool culture for <i>E histolytica</i> to monitor response (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>).     </p> <p>We have provided an overall pictorial summary of the risk of bias assessment in <a href="#CD006085-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006085-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006085-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006085-sec-0072"> <h4 class="title">Allocation</h4> <section id="CD006085-sec-0073"> <h5 class="title">Generation of allocation sequence</h5> <p>Only seven trials reported adequate generation of the allocation sequence: Four trials used a random numbers table (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>), and one trial each used computer‐generated randomization (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>), coin toss (<a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>), and random selection of papers marked with the treatment assignment (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). Other trials did not describe the method used. </p> </section> <section id="CD006085-sec-0074"> <h5 class="title">Allocation concealment</h5> <p>Four trials reported adequate allocation concealment: Two trials used sequentially numbered coded drug containers prepared independently by a person or at a site remote from the study site (<a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>); one trial used sealed opaque envelopes prepared by another person (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>); and another trial used random selection of papers marked with the treatment assignment by another person independent of the study team (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). Two trials had inadequate allocation concealment as communicated by the primary author (<a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>). The remaining 35 trials did not report on this. </p> </section> </section> <section id="CD006085-sec-0075"> <h4 class="title">Blinding</h4> <p>Only eight trials reported blinding of participants, care providers, and outcome assessors (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). One trial reported blinding of participants and the microscopist assessing stool specimens but did not mention blinding of the outcome assessor for clinical outcomes (<a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>), and another reported blinding only of the microscopist assessing stool specimens but not of care providers or outcome assessors for clinical outcomes (<a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). Eleven trials were reported to be ‘double‐blind', but most of these (nine trials) did not describe the procedure for blinding, the person(s) blinded, similarity of the appearance of drugs, or the use of placebo (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>; <a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a>; <a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>; <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). One trial mentioned blinding only of participants and care providers but was unclear about blinding of outcome assessors for clinical and parasitological outcomes (<a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>), and one trial mentioned blinding only of laboratory personnel assessing the stool specimens (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). One trial was reported as ‘single‐blind', but it is unclear who was blinded (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>). Four trials were open trials (<a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>), and three were unclear regarding blinding (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>). We assessed the other 12 trials as being at high risk of performance and detection bias because researchers used different dosages and regimens of study drugs and did not mention blinding procedures. </p> </section> <section id="CD006085-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>The number of participants followed up was adequate (≥ 90%) for at least one outcome (clinical or parasitological failure) in 34 trials. Of these 34 trials with adequate follow‐up, three trials had missing data owing to incomplete follow‐up of participants and lack of reporting of the treatment group to which participants were randomized (<a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>), and another trial did not mention the reason for incomplete data (<a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>). Four trials reported loss of participants greater than 10% (<a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>; <a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>), and three trials reported only the number included in the final analysis and did not report the actual number initially randomized (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). </p> </section> <section id="CD006085-sec-0077"> <h4 class="title">Selective reporting</h4> <p>Fourteen trials reported all relevant outcomes, 17 were at high risk for selective outcome reporting, and 10 were at unclear risk for selective reporting bias. Selective outcome reporting was noted in the following 17 trials: Five trials assessed parasitological outcomes but not clinical outcomes (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>; <a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>; <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>); four trials provided incomplete clinical assessment for some patients (<a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>; <a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>); one trial reported only the "average days of clearance of symptoms" but did not report the number of participants analysed for clinical outcomes (<a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>); three trials did not pre‐specify the method or timing used for outcome assessment or criteria for clinical cure (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>); one trial did not mention the timing of assessment of clinical and parasitological outcomes (<a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>); one trial did not report the number of participants remaining in the study at specified time points and reported parasitological cure as cumulative clearance of amoebic forms from stools, which was not pre‐specified (<a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>); one trial included only specific adverse effects but did not mention the number of participants who showed clinical improvement (<a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>); and one trial incompletely reported on adverse events (<a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>)<i>.</i> Three trials did not report the number of participants who developed adverse events (<a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>), and five trials incompletely reported adverse events (<a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>; <a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). The presence of selective reporting bias was unclear in 10 trials owing to the following: Three trials did not report results of rectosigmoidoscopy, even if this was pre‐specified as a criterion for enrolment and/or clinical cure (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>); one trial reported outcomes only as duration from start of treatment until disappearance of blood or parasites from the stools (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>); and six trials provided incomplete reporting of adverse events (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>). In addition, two trials included an analysis that was not pre‐specified: frequency of loose stools per day and rate of disappearance of parasites in stools (<a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>); and time from first dose to passage of last unformed stools shown on a survival analysis graph (<a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>). </p> </section> <section id="CD006085-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>Duration of treatment was variable in six trials and could be extended up to 10 days if there was persistence of clinical symptoms or <i>E histolytica</i> in stools at the end of five‐day treatment (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>), or at the end of three‐day treatment (<a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>). In two trials, the number of participants for whom treatment was extended was greater among those given metronidazole than among those given tinidazole (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>). In both trials, clinical and parasitological cure was greater in the tinidazole group, despite the longer treatment duration reported in more patients given metronidazole. The effect could be greater if the outcome was assessed before treatment was extended. Two other trials did not report the number of participants in each group for which treatment was extended (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>), and bias could favour those given longer treatment. One trial studied 10 different antiamoebic drugs and one placebo and randomized participants to another treatment after poor response to the first treatment but did not mention who among the participants received additional drugs (<a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>). Another trial compared various treatment regimens (<a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>): For those randomized to the nitazoxanide group, nitazoxanide alone was given regardless of the type of parasitosis, while for those in the second group, participants could receive quinfamide alone, mebendazole alone, or both quinfamide and mebendazole depending on the types of parasites seen. Treatment types received by the two groups were very different, and this may represent a potential source of bias. One group stopped recruitment early owing to adverse events (<a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). Another trial administered different dosages and duration of treatment for adults (five days) and for children (seven days) but analysed these data together (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>). </p> <p>Exept for <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>, which used <i>E histolytica</i> stool antigen testing to confirm the diagnosis of intestinal amoebiasis, diagnosis of amoebiasis in the included trials was based on stool microscopy, and non‐pathogenic <i>Entamoeba</i> species were not differentiated by more sensitive tests such as PCR and stool antigen testing. Two trials used amoebic stool culture (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>), but one of these did not mention whether all patients had a positive stool culture on admission (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>). Most trials did not identify <i>E histolytica</i> as the true cause of colitis or diarrhoea; this could lead to overestimation of the treatment effect if infection is due to non‐pathogenic<i>Entamoeba</i> species and resolves spontaneously. In addition, many studies did not mention whether concomitant infection with other protozoa, such as giardiasis or other helminth parasites, was determined. Many of the symptoms of giardiasis and intestinal parasites may be seen in intestinal amoebiasis, and not all trials identified <i>E histolytica</i> as the single cause for the intestinal symptoms; therefore, assessment of clinical outcomes may be biased if persistent symptoms after treatment were caused by these other infections. </p> </section> </section> <section id="CD006085-sec-0079"> <h3 class="title" id="CD006085-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD006085-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings table 1</a>; <a href="./full#CD006085-tbl-0002"><b>Summary of findings 2</b> Summary of findings table 2</a> </p> <p>We have shown in <a href="./appendices#CD006085-sec-0118">Appendix 9</a> details of the comparisons and interventions included in this review. We have presented ‘Summary of findings' tables for two important outcomes: tinidazole compared with metronidazole as treatment for amoebic colitis (<a href="./full#CD006085-tbl-0001">summary of findings Table for the main comparison</a>); and combination therapy compared with metronidazole alone as treatment for amoebic colitis (<a href="./full#CD006085-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD006085-sec-0080"> <h4 class="title">1. Single alternative drug versus metronidazole</h4> <p>Sixteen trials compared alternative nitroimidazoles versus metronidazole, and one trial compared praziquantel versus metronidazole (<a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a>). </p> <section id="CD006085-sec-0081"> <h5 class="title">1.1.  Tinidazole versus metronidazole</h5> <p>Ten trials compared tinidazole versus metronidazole, with two trials evaluating clinical and parasitological failure 1 to 14 days after end of treatment (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>); eight trials evaluating clinical failure 15 to 60 days after end of treatment (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>); and nine trials evaluating parasitological failure 15 to 60 days after end of treatment (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>). We graded the overall certainty of evidence as low because of serious risk of bias (see <a href="./full#CD006085-tbl-0001">summary of findings Table for the main comparison</a>): All trials had unclear allocation concealment and randomization except <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; five trials were not blinded for clinical outcomes and were unclear on blinding for parasitological outcomes (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>; <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>); and four trials had variable duration of treatment with treatment extended to 10 days for persistence of clinical symptoms or <i>E histolytica</i> in the stools at the end of planned treatment (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>). In addition, all trials used only stool microscopy for diagnosis and assessment of parasitological outcomes, hence misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible. Nine trials were conducted in countries endemic for amoebiasis (eight in India, one in Bangladesh). For clinical failure 1 to 14 days after end of treatment, results showed imprecision probably due to small sample sizes and few events (RR 0.17, 95% CI 0.02 to 1.30; 285 participants, 2 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0007" title="">Analysis 1.1</a>). </p> <p>For clinical failure 15 to 60 days after end of treatment, tinidazole reduced clinical failure by 72% compared with metronidazole (RR 0.28, 95% CI 0.15 to 0.51; 477 participants, 8 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0008" title="">Analysis 1.2</a> and <a href="#CD006085-fig-0003">Figure 3</a>). A sensitivity analysis evaluating quality in relation to allocation concealment and blinding was not possible. We noted no significant change in the overall result when we excluded <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>, which may be a duplicate publication of an earlier trial ‐ <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a> (RR 0.31, 95% CI 0.16 to 0.61; 418 participants, 7 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0045" title="">Analysis 12.1</a>). Excluding four trials funded by pharmaceutical companies also did not affect the overall result (RR 0.24, 95% CI 0.11 to 0.50; 241 participants, 4 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0046" title="">Analysis 12.2</a>) (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>). </p> <div class="figure" id="CD006085-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Alternative drug versus metronidazole: clinical failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Alternative drug versus metronidazole: clinical failure 15 to 60 days after end of treatment. </p> </div> </div> </div> <p>Results for parasitological failure did not show that tinidazole was more effective than metronidazole in eradicating <i>E histolytica</i> 1 to 14 days after end of treatment (RR 1.01, 95% CI 0.58 to 1.74; 285 participants, 2 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0009" title="">Analysis 1.3</a>) or 15 to 60 days after end of treatment (RR 0.64, 95% CI 0.25 to 1.64; 507 participants, 9 trials; very low‐certainty evidence; <a href="./references#CD006085-fig-0010" title="">Analysis 1.4</a> and <a href="#CD006085-fig-0004">Figure 4</a>). Heterogeneity was significant in trials that evaluated parasitological failure 15 to 60 days after end of treatment. Subgroup analysis conducted to investigate possible sources of heterogeneity showed reduced heterogeneity in trials with non‐dysenteric amoebic colitis and unspecified amoebic colitis (<a href="./references#CD006085-fig-0029" title="">Analysis 6.1</a>), as well as in trials that used the WHO criteria (<a href="./references#CD006085-fig-0032" title="">Analysis 6.4</a>). Age and the presence or absence of other concomitant intestinal infection did not explain heterogeneity (<a href="./references#CD006085-fig-0030" title="">Analysis 6.2</a> and <a href="./references#CD006085-fig-0031" title="">Analysis 6.3</a>). Subgroup analysis showed greater treatment effects of tinidazole in those given the higher dose of 2 grams in a single dose for three days compared with lower doses of tinidazole at 600 mg twice daily for five days. although this was significant only for clinical improvement (RR 0.24, 95% CI 0.13 to 0.47; 297 participants, 5 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0043" title="">Analysis 11.1</a>) ‐ not for parasitological response (<a href="./references#CD006085-fig-0044" title="">Analysis 11.2</a>). </p> <div class="figure" id="CD006085-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment. </p> </div> </div> </div> <p>Researchers reported no data on relapse.</p> <p>Eight trials reported adverse events (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>). We graded the certainty of evidence for this outcome as moderate because of serious risk of bias due to lack of blinding or unclear blinding in all trials, and lack of standardization in reporting of both clinical and laboratory adverse events. Four trails reported no blinding of outcome assessors for adverse events (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a>; <a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a>), and in the other four trials, this was unclear (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>). Participants in seven trials voluntarily reported adverse events, but one trial did not specify the method used to solicit adverse events (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>). Five trials monitored adverse events for 30 days from start of treatment, but two trials did not mention the duration of monitoring (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a>). All eight trials reported no abnormalities seen on haematological, biochemical, and urine analyses, and two trials reported no abnormalities on electrocardiographic studies (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>). All trials conducted laboratory tests before treatment, but trials repeated testing at different time points during and after treatment. No trials reported that serious adverse events or adverse events necessitated drug withdrawal. Other non‐serious adverse events appeared to be less common among those given tinidazole than among those given metronidazole (RR 0.65, 95% CI 0.46 to 0.92; 477 participants, 8 trials; moderate‐certainty evidence; <a href="./references#CD006085-fig-0012" title="">Analysis 1.6</a>); nausea, vomiting, decreased appetite, and altered taste or metallic taste were the most common (see <a href="./appendices#CD006085-sec-0119">Appendix 10</a> for other details). </p> </section> <section id="CD006085-sec-0082"> <h5 class="title">1.2. Other nitroimidazole drugs versus metronidazole</h5> <p>Other alternative drugs tested were ornidazole (155 participants, 3 trials; <a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973;</a><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973;</a><a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>), secnidazole (44 participants, 1 trial; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>), panidazole (86 participants, 1 trial; <a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a>), and satranidazole (40 participants, 1 trial; <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>). The number of participants in these trials comparing other nitroimidazoles versus metronidazole was inadequate to allow detection of any significant difference in clinical failure or parasitological failure 1 to 14 days after end of treatment (<a href="./references#CD006085-fig-0007" title="">Analysis 1.1</a> and <a href="./references#CD006085-fig-0009" title="">Analysis 1.3</a>), or 15 to 60 days after end of treatment (<a href="./references#CD006085-fig-0008" title="">Analysis 1.2</a> and <a href="./references#CD006085-fig-0010" title="">Analysis 1.4</a>). Researchers reported no differences in time to resolution of clinical symptoms and eradication of <i>E histolytica</i> in stools between intervention and control groups (see <a href="#CD006085-tbl-0005">Table 3</a>). </p> <p>For relapse, the data reported in two small trials, both comparing ornidazole versus metronidazole (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>), were of very low certainty because of inadequate description of the randomization process and allocation concealment, and additionally in one trial for unclear blinding procedures (<a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>). In these trials, more relapses were evident among those given ornidazole than among those given metronidazole (RR 4.74, 95% CI 1.07 to 20.99; 135 participants, 2 trials; very low‐certainty evidence; <a href="./references#CD006085-fig-0011" title="">Analysis 1.5</a>), but data are insufficient to allow definitive conclusions because of the small numbers of events reported. </p> <p>Three trials comparing ornidazole versus metronidazole reported adverse events (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>; <a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a>; <a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a>), as did one trial comparing panidazole with metronidazole ‐ <a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a> ‐ and another trial comparing satranidazole with metronidazole ‐ <a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a>. No trials reported serious adverse events or withdrawals resulting from adverse events, except one ‐ <a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a> ‐ in which one participant given ornidazole developed temporary numbness of the hands and tongue with difficulty speaking that disappeared after treatment was stopped. In another trial (<a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a>), the dosage of two participants each in the ornidazole group and the metronidazole group had to be reduced because of dizziness or nausea. No abnormalities in laboratory tests were seen in trials that conducted these tests (see <a href="./appendices#CD006085-sec-0119">Appendix 10</a> for other details). There seems to be no difference in adverse events among those given ornidazole, panidazole, and satranidazole compared with metronidazole (<a href="./references#CD006085-fig-0012" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD006085-sec-0083"> <h4 class="title">2. Any antiamoebic drug versus placebo</h4> <p>Four studies involved comparison of any antiamoebic drug versus placebo: nitazoxanide (167 participants, 2 trials; <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a>; <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>) and quinfamide (96 participants, 1 trial; <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>); and versus 10 different drugs belonging to six drug classes (367 participants, 1 trial; <a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a>). </p> <p>Compared with placebo, both quinfamide and nitazoxanide reduced clinical and parasitological failure rates 1 to 14 days after end of treatment (<a href="./references#CD006085-fig-0013" title="">Analysis 2.1</a> and <a href="./references#CD006085-fig-0014" title="">Analysis 2.2</a>). However, heterogeneity among trials was significant, even in the two trials that evaluated nitazoxanide. Subgroup analysis using clinical categories did not explain heterogeneity (<a href="./references#CD006085-fig-0033" title="">Analysis 7.1</a>), but such heterogeneity was reduced in trials that included adult participants only (<a href="./references#CD006085-fig-0034" title="">Analysis 7.2</a> and <a href="./references#CD006085-fig-0035" title="">Analysis 7.3</a>). Excluding the single trial that used stool antigen‐based ELISA testing to confirm <i>E histolytica</i> ‐ <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> ‐ also reduced heterogeneity in the remaining trials (<a href="./references#CD006085-fig-0036" title="">Analysis 7.4</a> and <a href="./references#CD006085-fig-0037" title="">Analysis 7.5</a>). Sensitivity analysis using concealment and blinding was not possible because only one trial was concealed ‐ <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> ‐ and only two trials were blinded ‐ <a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a> and <a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a>. </p> <p>Researchers reported no data on relapse.</p> <p>No trial reported serious adverse events or withdrawals due to adverse events. Also no trials reported differences in adverse events among those given antiamoebic drugs compared with placebo (530 participants, 3 trials; <a href="./references#CD006085-fig-0015" title="">Analysis 2.3</a>), although the results could be biased because of a great imbalance in the numbers of those given active drugs versus placebo. The most common adverse events were mild gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and headache. One individual given diiodohydroxyquinoline presented with severe intestinal colic (see <a href="./appendices#CD006085-sec-0120">Appendix 11</a> for details). </p> </section> <section id="CD006085-sec-0084"> <h4 class="title">3. Combination regimen versus monotherapy</h4> <p>Three trials compared various combination regimens versus metronidazole alone (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>), and four trials compared other combination regimens versus alternative single drugs (<a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). </p> <section id="CD006085-sec-0085"> <h5 class="title">3.1. Combination regimen versus metronidazole alone</h5> <p>We graded the overall certainty of evidence as very low for the outcome of clinical failure 1 to 14 days after end of treatment (<a href="./full#CD006085-tbl-0002">summary of findings Table 2</a>). All three trials did not describe the randomization process and allocation concealment, and blinding was lacking in two trials (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>; <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>). <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> was at high risk of selective reporting bias because researchers did not adequately describe the method used for outcome evaluation and researchers analysed participants after different treatment durations ranging from 5 to 10 days, depending on severity of disease and response to therapy. All three trials were conducted in countries endemic for amoebiasis and used only stool microscopy to assess parasitological outcomes, hence misclassification of eradication of <i>E histolytica</i> from stools is possible. The pooled result shows that compared with metronidazole alone, combination therapy reduced clinical failure 1 to 14 days after end of treatment by 67% (RR 0.33, 95% CI 0.11 to 0.98; 1025 participants, 3 trials; very low‐certainty evidence; <a href="./references#CD006085-fig-0038" title="">Analysis 8.1</a>). However, significant heterogeneity seen in these trials could be due to the various combination regimens used: a combination of dehydroemetine, tetracycline, and diloxanide furoate (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>); a fixed‐drug combination suspension of metronidazole and furazolidone (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>); and a fixed‐drug combination tablet of metronidazole and diiodohydroxyquinoline (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>). Heterogeneity could also be explained by differences in clinical disease, because exclusion of the trial that included only children with amoebic dysentery resulted in greater effect favouring combination therapy in patients with unspecified intestinal amoebiasis (RR 0.17, 95% CI 0.12 to 0.25; 986 participants, 2 trials; very low‐certainty evidence; <a href="./references#CD006085-fig-0040" title="">Analysis 9.1</a>) (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>). This could be attributed to additional luminal drugs (diiodohydroxyquinoline in <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a> and furazolidone in <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>) that may be more effective against cyst forms in patients with unspecified intestinal amoebiasis. </p> <p>For parasitological failure 1 to 14 days after end of treatment, we graded the overall certainty of evidence as low because of lack of allocation concealment and blinding, selective reporting, and indirectness as described above. Results showed a 64% reduction in parasitological failure 1 to 14 days after end of treatment among those given the combination compared with those given metronidazole alone (RR 0.36, 95% CI 0.15 to 0.86; 720 participants, 3 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0039" title="">Analysis 8.2</a>). We noted no significant heterogeneity among trials (<a href="#CD006085-fig-0005">Figure 5</a>). Subgroup analysis showed that excluding the trial on children with amoebic dysentery showed greater benefit for those with unspecified intestinal amoebiasis (RR 0.25, 95% CI 0.13 to 0.46; 681 participants, 2 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0041" title="">Analysis 9.2)</a>. </p> <div class="figure" id="CD006085-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Combination regimen versus monotherapy: parasitological failure 1 to 14 days after end of treatment, subgrouped by intervention." data-id="CD006085-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Combination regimen versus monotherapy: parasitological failure 1 to 14 days after end of treatment, subgrouped by intervention. </p> </div> </div> </div> <p>For both clinical and parasitological failure, the overall results were driven by one trial, which analysed a large number of participants (896 participants analysed for clinical failure; 591 participants analysed for parasitological failure) compared with the other two trials (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>). This was an open‐label trial with unclear allocation concealment and method of randomization, hence the high possibility of bias. This trial also may have been funded by a pharmaceutical company because one of the study authors is connected with the company that provided the study drug ‐ a fixed‐drug combination of metronidazole and diiodohydroxyquinoline. A sensitivity analysis performed while excluding this trial reduced heterogeneity and significantly changed the overall results for both clinical and parasitological outcomes (i.e. no benefit in giving combination therapy compared with giving metronidazole alone) (RR 0.58, 95% CI 0.20 to 1.73; 129 participants, 2 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0047" title="">Analysis 13.1</a>; <a href="./references#CD006085-fig-0048" title="">Analysis 13.2</a>). </p> <p>Researchers reported no data on relapse.</p> <p>The three trials reported no serious adverse events but indicated that one participant given a fixed‐drug combination tablet of metronidazole and diiodohydroxyquinoline developed an unspecified allergic reaction on the first day, necessitating withdrawal from the trial. Two trials did not blind outcome assessors for adverse events (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>; <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>). One trial reported that tolerance of both regimens was excellent and noted no toxicity (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>); another trial reported no difference in the overall incidence of side effects between the two groups but did not report on the number who developed adverse events (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>). The most frequently reported adverse events in both groups were metallic taste, abdominal pain, and nausea. Only one trial reported a higher incidence of side effects with metronidazole compared with the fixed‐drug combination suspension of furazolidone and metronidazole but did not report the specific adverse events and the number who developed adverse events (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>). See <a href="./appendices#CD006085-sec-0121">Appendix 12</a> for details. </p> </section> <section id="CD006085-sec-0086"> <h5 class="title">3.2. Combination regimen versus other single‐drug regimens </h5> <p>Four trials studied the efficacy of combination regimens compared with other single‐drug regimens. Two trials compared combination regimens with other nitroimidazoles: a combination of tetracycline and clioquinol versus secnidazole alone (80 participants, 1 trial; <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>); and a combination of tinidazole and diloxanide furoate versus tinidazole alone (41 participants, 1 trial; <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>). The third trial compared three different combinations (nimorazole and aminosidine, nimorazole and etophamide, and etophamide and aminosidine) versus the same drugs given as monotherapy (400 participants, 1 trial; <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a>). The fourth trial compared quinfamide and mebendazole versus nitazoxanide (80 participants, 1 trial; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). </p> <p>Trials could not be pooled because they performed different drug comparisons, but we have presented the data for clinical failure (<a href="./references#CD006085-fig-0016" title="">Analysis 3.1</a>) and parasitological failure (<a href="./references#CD006085-fig-0017" title="">Analysis 3.2</a>). Trials did not show any difference in clinical or parasitological failure rates between combination regimens and single‐drug regimens, except in two comparisons. <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> showed that secnidazole alone resulted in greater resolution of clinical symptoms and greater eradication of <i>E histolytica</i> when compared with the combination of tetracycline and clioquinol on day 28 of treatment (80 participants, 1 trial; <a href="./references#CD006085-fig-0016" title="">Analysis 3.1</a>; <a href="./references#CD006085-fig-0017" title="">Analysis 3.2</a>). <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a>, another small trial, showed that the combination of tinidazole and diloxanide furoate resulted in greater eradication of <i>E histolytica</i> compared with tinidazole alone one month after end of treatment (41 participants, 1 trial). Both trials reported wide confidence intervals; thus no definitive conclusions regarding these regimens can be made. </p> <p>Researchers reported no data on relapse.</p> <p>Trials incompletely reported adverse events. <a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a> discontinued recruitment of participants in the combination etophamide‐aminosidine group because of the high incidence of severe diarrhoea. <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> and <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a> reported that both treatment regimens were well tolerated with only a few side effects but did not report the specific adverse events and the number of participants who developed any adverse events. <a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a> reported that no serious adverse events necessitated discontinuation of treatment but provided no details. See <a href="./appendices#CD006085-sec-0121">Appendix 12</a> for details. </p> </section> </section> <section id="CD006085-sec-0087"> <h4 class="title">4. Single‐dose regimen versus longer or multiple‐dose regimens</h4> <p>Five trials compared a single‐dose regimen versus longer duration of therapy or multiple‐dose regimens. Three trials compared longer duration of other drugs versus single‐dose secnidazole (<a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>; <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>), and two trials compared longer duration of other drugs versus single‐dose quinfamide (<a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). </p> <section id="CD006085-sec-0088"> <h5 class="title">4.1. Single‐dose secnidazole versus longer or multiple‐dose regimens</h5> <p><a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> compared single‐dose secnidazole versus tinidazole for two days (303 participants, 1 trial), <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> compared single‐dose secnidazole versus metronidazole for 10 days (44 participants, 1 trial), and <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> compared single‐dose secnidazole versus a combination of tetracycline and clioquinol for five days (80 participants, 1 trial). These trials were unclear on allocation concealment and were not blinded. </p> <p><a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> showed that single‐dose secnidazole resulted in greater resolution of clinical symptoms at end of treatment compared with five days of tetracycline and clioquinol (RR 0.12, 95% CI 0.03 to 0.48; 80 participants, 1 trial; low certainty evidence; <a href="./references#CD006085-fig-0020" title="">Analysis 4.1</a>). <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> did not show any difference in clinical failure 19 days after end of treatment between single‐dose secnidazole and two‐day tinidazole treatment (275 participants, 1 trial; <a href="./references#CD006085-fig-0021" title="">Analysis 4.2</a>). We could not pool results for clinical failure because of a difference between the two trials in the time of evaluation of clinical outcomes (<a href="./references#CD006085-fig-0020" title="">Analysis 4.1</a> and <a href="./references#CD006085-fig-0021" title="">Analysis 4.2</a>). </p> <p>Single‐dose secnidazole may result in lower parasitological failure 1 to 14 days after end of treatment compared with multi‐dose regimens (<a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>; <a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>) (RR 0.14, 95% CI 0.06 to 0.35; 124 participants, 2 trials; low‐certainty evidence; <a href="./references#CD006085-fig-0022" title="">Analysis 4.3</a> and <a href="./references#CD006085-fig-0042" title="">Analysis 10.1</a>). Although no heterogeneity was evident, the antiamoebic drugs compared with secnidazole were different; secnidazole was compared with metronidazole in one trial (<a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a>), and with a combination of tetracycline and clioquinol in another trial (<a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a>). Both trials were small with unclear allocation concealment and blinding of the microscopist examining the stools. Another trial compared single‐dose secnidazole versus tinidazole and suggested that secnidazole may be more effective than tinidazole for eradication of amoebae from the stools 19 days after end of treatment (RR 0.61, 95% CI 0.43 to 0.88; 300 participants, 1 trial; low‐certainty evidence; <a href="./references#CD006085-fig-0023" title="">Analysis 4.4</a>) (<a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a>). As this was an open trial, <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> appears to be at high risk of bias. </p> <p>Researchers reported no data on relapse.</p> <p>Only <a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> reported on adverse events. Researchers reported no serious adverse events or withdrawals for adverse events. Adverse events most commonly reported were bitter taste, nausea, vomiting, and abdominal pain, with no difference in frequency between those given single‐dose secnidazole compared with tinidazole for two days. <a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> did not report the proportion of participants who developed adverse events but mentioned that side effects were few and treatment was well tolerated regardless of the regimen received (see <a href="./appendices#CD006085-sec-0121">Appendix 12</a> for details). </p> </section> <section id="CD006085-sec-0089"> <h5 class="title">4.2. Single‐dose quinfamide versus multiple doses of quinfamide or longer duration of another drug </h5> <p>Investigators compared single‐dose quinfamide versus two or three doses of quinfamide (72 participants; <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>), and they compared single‐dose quinfamide versus nitazoxanide for three days (25 participants; <a href="./references#CD006085-fig-0020" title="">Analysis 4.1</a>; <a href="./references#CD006085-fig-0022" title="">Analysis 4.3</a>) (<a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>).  </p> <p><a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a> showed no difference in clinical failure between those given one dose compared with two or three doses of quinfamide (72 participants; <a href="./references#CD006085-fig-0020" title="">Analysis 4.1</a>). </p> <p>For parasitological failure 1 to 14 days after end of treatment, pooling of results from two trials revealed a trend favouring more doses compared with single‐dose quinfamide for eradicating <i>E histolytica</i> (RR 2.13, 95% CI 1.02 to 4.46; 97 participants; two trials; low‐certainty evidence; <a href="./references#CD006085-fig-0042" title="">Analysis 10.1</a>) (<a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>). Both trials were unclear regarding generation of the allocation sequence, concealment, and blinding. Results were not heterogeneous, but numbers of trials and participants were too small to permit any definitive conclusions.  </p> <p>Researchers reported no data on relapse.</p> <p>Only <a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a> reported on adverse events; these reports were based on only two symptoms ‐ nausea and headache. None of those given single‐dose quinfamide developed adverse effects, but 12 among those who received two or three doses of quinfamide developed nausea and headache. <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a> reported that both quinfamide and nitazoxanide were well‐tolerated but mentioned no specific adverse effects (see <a href="./appendices#CD006085-sec-0121">Appendix 12</a> for details). </p> </section> </section> <section id="CD006085-sec-0090"> <h4 class="title">5. Other antiamoebic drug comparisons</h4> <p>Thirteen trials studied different drug comparisons (see <a href="./appendices#CD006085-sec-0118">Appendix 9</a> for details). Only two trials were adequately concealed (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>; <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). Blinding was not done or was unclear in all except two trials (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>). Dropout rates were high in two trials, with one trial analysing only 62.5% of those initially randomized (<a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>), and the other trial analysing 82% (<a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>). </p> <p>Eight trials assessed clinical failure 1 to 14 days after end of treatment (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>; <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). <a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a> showed chlorhydroxyquinoline to be probably more effective than diiodohydroxyquinoline in reducing clinical failure (RR 0.24, 95% CI 0.11 to 0.53; 100 participants, 1 trial). Two trials reported no difference in clinical failure rates when comparing the other antiamoebic drugs: ornidazole versus tinidazole (66 participants, 2 trials; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>). Other trials reported no difference in clinical failure rates when comparing ornidazole versus secnidazole (102 participants, 1 trial; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>), a fixed combination of metronidazole and diloxanide furoate versus an herbal product composed of several different natural products (153 participants, 1 trial; <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>), and metronidazole versus an herbal product (184 participants, 1 trial; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). Two trials reported no clinical failures when comparing respectively four dosage regimens of MK‐910 (40 participants, 1 trial) and <i>Saccharomyces boulardii</i> probiotic added to metronidazole versus metronidazole alone (85 participants, 1 trial; <a href="./references#CD006085-fig-0025" title="">Analysis 5.1</a>) (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). Two trials evaluated the effect of added <i>S boulardii</i> on duration of clinical symptoms; one trial reported this outcome as the mean (<a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>), and the other trial as median and range (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). One trial evaluating resolution of diarrhoea and abdominal pain showed significantly shorter mean duration among those given <i>S boulardii</i> in addition to metronidazole and iodoquinol (<a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>), but another trial did not show a difference in median and range for this outcome when <i>S boulardii</i> was added to metronidazole (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). See <a href="#CD006085-tbl-0005">Table 3</a>. </p> <p>Ten trials assessed parasitological failure one to 14 days after end of treatment (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>; <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). Two trials assessed parasitological failure approximately one month after treatment (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>), and another trial assessed parasitological failure during two time periods ‐ 1 to 14 days and 15 to 60 days after treatment (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>). One trial showed that chlorhydroxyquinoline probably was more effective than diiodohydroxyquinoline in reducing parasitological failure 1 to 14 days after end of treatment (RR 0.53, 95% CI 0.35 to 0.80; 100 participants, 1 trial; low‐certainty evidence; <a href="./references#CD006085-fig-0027" title="">Analysis 5.3</a>) (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>). Researchers reported no difference in eradication of amoebae from the stools in trials comparing ornidazole versus other nitroimidazoles: ornidazole versus tinidazole (74 participants, 2 trials; <a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>); and ornidazole versus secnidazole (102 participants, 1 trial; <a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>). Single‐dose quinfamide appeared to result in better parasitological eradication when compared with single‐dose secnidazole in one trial (RR 0.57, 95% CI 0.34, 0.96; 239 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>; low‐certainty evidence; <a href="./references#CD006085-fig-0027" title="">Analysis 5.3)</a> but not when compared with nitazoxanide in another trial (25 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002;</a><a href="./references#CD006085-fig-0027" title="">Analysis 5.3</a>). Another trial comparing three doses of quinfamide versus teclozan reported no differences between the two groups (37 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>; <a href="./references#CD006085-fig-0028" title="">Analysis 5.4</a>). <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> noted no difference in parasitological failure when comparing low‐dosage regimens of MK‐910 versus higher dosages (≥ 2 mg/kg/d) of the same drug (40 participants, 1 trial). Two trials evaluated the efficacy of adding the probiotic <i>S boulardii</i> to metronidazole and found a trend toward increased parasitological eradication in the group given <i>S boulardii</i> in addition to metronidazole and iodoquinol (54 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003;</a><a href="./references#CD006085-fig-0027" title="">Analysis 5.3</a>), and in addition to metronidazole alone (85 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009;</a><a href="./references#CD006085-fig-0026" title="">Analysis 5.2</a>), but the results were not statistically significant. Another trial showed a non‐significant increase in both clinical and parasitological failure at end of treatment among those given an herbal product compared with those given a fixed‐drug combination of metronidazole and diloxanide furoate (154 participants, 1 trial ‐ <a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>; <a href="./references#CD006085-fig-0025" title="">Analysis 5.1</a> and <a href="./references#CD006085-fig-0026" title="">Analysis 5.2</a>). One trial showed no significant difference in parasitological failure at end of treatment between an herbal drug product and metronidazole (184 participants, 1 trial; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). A small trial that compared a fixed‐drug combination of diloxanide furoate, tetracycline, and chloroquine versus the fixed‐drug combination without chloroquine showed no difference in parasitological failure between the two groups at end of treatment (59 participants, 1 trial; <a href="./references#CD006085-fig-0026" title="">Analysis 5.2</a>) but showed a significant advantage for the combination containing chloroquine on follow‐up seven weeks after end of treatment (RR 0.29, 95% CI 0.09 to 0.92; 58 participants, 1 trial; low‐certainty evidence; <a href="./references#CD006085-fig-0027" title="">Analysis 5.3</a>) (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>). </p> <p>Researchers reported no data on relapse.</p> <p>One trial reported that the higher dosage regimen of MK‐910 resulted in nausea, vomiting, and abdominal pain severe enough to require withdrawal from treatment for two participants (<a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>). Gastrointestinal adverse effects occurred more frequently in the secnidazole group than in the quinfamide group (<a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a>). Mild vomiting occurred in one participant given ornidazole, but none occurred among those given tinidazole (<a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a>). Those given a fixed‐drug combination of metronidazole and diloxanide furoate had significantly greater gastrointestinal adverse effects compared with those given the herbal product (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>). One trial reported no difference in adverse effects between those given quinfamide or teclozan (<a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a>). Three trials mentioned that participants reported no side effects but provided no further details (<a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a>; <a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a>; <a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). One trial reported that 57.4% of those given metronidazole developed mild side effects, including nausea and vomiting, but did not report any adverse effects of the herbal drug (<a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). Two trials reported only on specific adverse events ‐ not on the number of participants with adverse events (<a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a>; <a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a>); and three trials did not report on clinical adverse effects (<a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a>; <a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a>; <a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>). See <a href="./appendices#CD006085-sec-0121">Appendix 12</a> for details. </p> </section> <section id="CD006085-sec-0091"> <h4 class="title">Funnel plot</h4> <p>We constructed a funnel plot with 10 trials for one outcome measure and examined it visually for possible bias or heterogeneity: any antiamoebic drug versus metronidazole and measuring parasitological failure 15 to 60 days after end of treatment (13 trials; <a href="#CD006085-fig-0006">Figure 6</a>). This included nine trials that compared tinidazole with metronidazole. Asymmetry in the funnel plot may indicate the presence of publication bias but may also indicate inadequate trial methodological quality or heterogeneity resulting from differences in study populations, interventions, outcome measurements, and trial design. </p> <div class="figure" id="CD006085-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot. Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot. Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006085-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006085-sec-0092"></div> <p>See <a href="./full#CD006085-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD006085-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD006085-sec-0093"> <h3 class="title" id="CD006085-sec-0093">Tinidazole versus metronidazole</h3> <p>In patients with amoebic colitis, treatment with tinidazole reduced clinical failure by 72% compared with treatment with metronidazole for outcomes evaluated 15 to 60 days after end of treatment and may be as effective as metronidazole in eradicating <i>Entamoeba histolytica</i> from stools. The incidence of mild to moderate gastrointestinal complaints also appeared to be lower among those given tinidazole. These results must be interpreted with caution because most trials are old (8 of the 10 trials were conducted between 1974 and 1978), the overall certainty of trial evidence is very low, and standardization in enrolment, diagnosis, treatment, and outcome assessment is lacking. None of the trials used <i>E histolytica</i> antigen detection or culture for diagnosis, and none determined the presence of infection with other pathogenic organisms, so uncertainty surrounds the diagnosis of amoebic colitis and the decision of whether clinical symptoms are due to amoebic colitis alone. Differences in clinical responses could also be due to lack of standardization of dosage, interval, and duration of drug treatments given. Other studies have shown that tinidazole is better when given as a single dose than in divided doses because of its longer half‐life of approximately 12 to 14 hours, resulting in longer concentrations in the body (<a href="./references#CD006085-bbs2-0264" title="MonroAM . Blood levels of chemotherapeutic drugs and the pharmacokinetics of tinidazole and metronidazole. Current Medical Research and Opinion1974;2(3):130‐6. ">Monro 1974</a>; <a href="./references#CD006085-bbs2-0260" title="LookeDFM . Metronidazole and tinidazole compared. Australian Prescriber1987;10(2):35‐7. ">Looke 1987</a>), whereas metronidazole has a shorter half‐life of about 6 to 10 hours and is better given in divided doses. Also, longer courses may lead to re‐excretion through the bile, resulting in higher concentrations within the bowel lumen (<a href="./references#CD006085-bbs2-0294" title="TracyJW , WebsterLTJr . Drugs used in the chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, leishmaniasis, and other protozoal infections. In: HardmanJG , LimbirdLE , Goodman GilmanA editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw Hill Medical Publishing Division, 2001:1097‐1120. ">Tracy 2001</a>). This is supported by the summary report of nine trials conducted in India, which reported that tinidazole given as a single dose daily was more effective than divided doses, and was more effective and was associated with fewer gastrointestinal adverse events when compared with metronidazole given once daily (<a href="./references#CD006085-bbs2-0052" title="BakshiJS , GhiaraJM , NanivadekarAS . How does tinidazole compare with metronidazole? A summary report of Indian trials in amoebiasis and giardiasis. Drugs1978;15 Suppl 1:133‐42. ">Bakshi 1978</a>). </p> <p>The risk difference for clinical failure among those given tinidazole and those given metronidazole is 0.16, yielding a number needed to treat for an additional beneficial outcome (NNTB) of 6.25. Thus, seven people will have to be treated with tinidazole for clinical failure to be reduced in one more individual. However, this finding cannot be applied to parasitological failure, as no significant difference in eradication of <i>E histolytica</i> is apparent between those given tinidazole and those given metronidazole. </p> </section> <section id="CD006085-sec-0094"> <h3 class="title" id="CD006085-sec-0094">Other nitroimidazole drugs versus metronidazole</h3> <p>Ornidazole and secnidazole are promising alternative antiamoebic drugs because they share the same mechanism of action as metronidazole against amoebae but remain longer in the blood. Compared with metronidazole, ornidazole remains in the blood around 1.7 times longer (with half‐life ranging from 11 to 14 hours), and secnidazole remains in the blood around three times longer (with half‐life ranging from 17 to 28 hours) (<a href="./references#CD006085-bbs2-0256" title="LampKC , FreemanCD , KlutmanNE , LacyMK . Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clinical Pharmacokinetics1999;36(5):353‐73. ">Lamp 1999</a>). This review shows that evidence is insufficient at the moment to demonstrate advantage of these drugs over metronidazole for treating individuals with amoebic colitis. More high‐quality trials in larger populations will be needed to determine whether or not these other nitroimidazole agents will be significantly more effective than metronidazole in reducing clinical signs of amoebiasis and in preventing persistence of amoebae in the stools. </p> </section> <section id="CD006085-sec-0095"> <h3 class="title" id="CD006085-sec-0095">Antiamoebic drugs versus placebo</h3> <p>The general recommendation is to give antiamoebic treatment to all individuals with definitive <i>E histolytica</i> infection, including those who have no symptoms of disease (<a href="./references#CD006085-bbs2-0304" title="World Health Organization/Pan American Health Organization/UNESCO. Amoebiasis. Weekly Epidemiological Record1997;72:97‐9. ">WHO 1997</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). Approximately 3% to 10% of infected individuals may develop symptoms of invasive amoebiasis if left untreated (<a href="./references#CD006085-bbs2-0246" title="HaqueR , AliIM , SackRB , FarrBM , RamakrishnanG , PetriWAJr . Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. Journal of Infectious Diseases2001;183(12):1787‐93. ">Haque 2001</a>; <a href="./references#CD006085-bbs2-0247" title="HaqueR , DuggalP , AliIM , HossainMB , MondalD , SackRB , et al. Innate and acquired resistance to amebiasis in Bangladeshi children. Journal of Infectious Diseases2002;186(4):547‐52. ">Haque 2002</a>; <a href="./references#CD006085-bbs2-0226" title="BlessmanJ , AliIKM , Ton NuPA , DinhBT , Ngo VietTQ , VanAL , et al. Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. Journal of Clinical Microbiology2003;41(10):4745‐50. ">Blessman 2003</a>). However, it is not known who among these asymptomatic individuals with <i>E histolytica</i> infection will develop symptomatic disease. Therefore, unless the diagnosis of <i>E histolytica</i> infection is uncertain for an asymptomatic individual, use of placebo as a comparison drug, particularly in patients with symptoms of invasive disease, is not appropriate. This review shows that antiamoebic drugs were more effective than placebo in reducing clinical symptoms of amoebic colitis and in eradicating <i>E histolytica</i> from the stools, although trials were of very low quality and heterogeneity was significant. Heterogeneity could be attributed to differences in participant characteristics or to the varied antiamoebic drugs used. The disappearance of parasites in 50 out of 133 (38%) individuals taking placebo may be explained by spontaneous eradication of <i>E histolytica</i> or infection with non‐pathogenic amoebae. Studies have shown that up to 90% of individuals with untreated <i>E histolytica</i> infection spontaneously clear their infection within one year (<a href="./references#CD006085-bbs2-0238" title="GathiramV , JacksonTFHG . A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. South African Medical Journal1987;72:669‐72. ">Gathiram 1987</a>; <a href="./references#CD006085-bbs2-0246" title="HaqueR , AliIM , SackRB , FarrBM , RamakrishnanG , PetriWAJr . Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. Journal of Infectious Diseases2001;183(12):1787‐93. ">Haque 2001</a>; <a href="./references#CD006085-bbs2-0247" title="HaqueR , DuggalP , AliIM , HossainMB , MondalD , SackRB , et al. Innate and acquired resistance to amebiasis in Bangladeshi children. Journal of Infectious Diseases2002;186(4):547‐52. ">Haque 2002</a>; <a href="./references#CD006085-bbs2-0226" title="BlessmanJ , AliIKM , Ton NuPA , DinhBT , Ngo VietTQ , VanAL , et al. Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. Journal of Clinical Microbiology2003;41(10):4745‐50. ">Blessman 2003</a>; <a href="./references#CD006085-bbs2-0287" title="StanleySLJr . Amoebiasis. Lancet2003;361(9362):1025‐34. ">Stanley 2003</a>; <a href="./references#CD006085-bbs2-0234" title="ChoudhuriG , RanganM . Amebic infection in humans. Indian Journal of Gastroenterology2012;31(4):153–62. ">Choudhuri 2012</a>). It may also be possible that patients were actually infected with non‐pathogenic amoebae because stool microscopy was the only diagnostic test utilized. </p> </section> <section id="CD006085-sec-0096"> <h3 class="title" id="CD006085-sec-0096">Combination regimen versus metronidazole alone</h3> <p>For all forms of invasive disease, including amoebic colitis, the standard recommendation is to give a tissue amoebicide followed by a luminal amoebicide to eliminate surviving cysts in the bowel lumen (<a href="./references#CD006085-bbs2-0303" title="World Health Organization. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases. 2nd Edition. Geneva: World Health Organization, 1995. ">WHO 1995</a>; <a href="./references#CD006085-bbs2-0304" title="World Health Organization/Pan American Health Organization/UNESCO. Amoebiasis. Weekly Epidemiological Record1997;72:97‐9. ">WHO 1997</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>; <a href="./references#CD006085-bbs2-0219" title="American Academy ofPediatrics . Amebiasis. In: KimberlinDW , BradyMT , JacksonMA , LongSS editor(s). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL: American Academy of Pediatrics, 2012:228‐30. ">AAP 2015</a>). Compared with metronidazole alone, combination therapy resulted in a reduction of about 60% for both clinical and parasitological failure. The advantage of combination therapy is attributed to the distinct activities of different drugs against cysts and trophozoites found at the different sites (<a href="./references#CD006085-bbs2-0303" title="World Health Organization. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases. 2nd Edition. Geneva: World Health Organization, 1995. ">WHO 1995</a>; <a href="./references#CD006085-bbs2-0294" title="TracyJW , WebsterLTJr . Drugs used in the chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, leishmaniasis, and other protozoal infections. In: HardmanJG , LimbirdLE , Goodman GilmanA editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw Hill Medical Publishing Division, 2001:1097‐1120. ">Tracy 2001</a>; <a href="./references#CD006085-bbs2-0293" title="The Medical Letter. Drugs for parasitic infections. 3rd edition. 2013. https://secure.medicalletter.org/article‐share?a=143a&amp;p=tg&amp;title=Drugs%20for%20Parasitic%20Infections&amp;cannotaccesstitle=1 (accessed 1 September 2017). ">The Medical Letter 2013</a>). This was consistent with the greater effect of combination therapy for those with unspecified intestinal amoebiasis when both invasive and cyst forms could be present compared with individuals with amoebic dysentery alone. However, interpretation of these results is complicated because trials used different combinations of drugs in comparison with metronidazole: fixed‐drug combination of diiodohydroxyquinoline and metronidazole (<a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a>); fixed‐drug combination suspension of furazolidone and metronidazole (<a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a>); and combination of subcutaneous dehydroemetine plus oral tetracycline and diloxanide furoate (<a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>). No conclusions can be drawn regarding the most effective combination antiamoebic drug regimen because none of the included trials were of sufficient size to reveal this. Some of these drugs are no longer marketed, and it is not known whether these results could be applied to other combinations. It is also not known whether combination therapy would lead to increased adverse events, because this information was incompletely reported. </p> </section> <section id="CD006085-sec-0097"> <h3 class="title" id="CD006085-sec-0097">Single‐dose regimen compared with longer‐duration or other single‐dose regimens</h3> <p>The advantages of single‐dose regimens are numerous, including ease of administration, convenience, better patient compliance, and reduced cost with no evidence of increased adverse effects. Two antiamoebic drugs ‐ secnidazole and quinfamide ‐ were evaluated as single‐dose therapy: Results were inconclusive owing to the small sample size and the low methodological quality of trials. More trials are needed to determine the clinical and parasitological efficacy of single‐dose regimens of secnidazole or quinfamide and of other antiamoebic drugs that can be given for a shorter duration than other drugs, including the current standard antiamoebic drug, metronidazole. </p> </section> <section id="CD006085-sec-0098"> <h3 class="title" id="CD006085-sec-0098">Other antiamoebic drug comparisons</h3> <p>Available data are insufficient to establish the efficacy and safety of the other antiamoebic drugs for treating amoebic colitis. More recently, interest in the effect of non‐traditional therapy against amoebiasis has been increasing. Two trials evaluated the effect of adding <i>Saccharomyces boulardii,</i> a probiotic fungal organism, to metronidazole therapy. Probiotics are live micro‐organisms that confer a health benefit on the host, including prevention and treatment of diarrhoea. Reviews on the efficacy of probiotics support clinical benefit in preventing <i>Clostridium difficile</i>‐associated diarrhoea (<a href="./references#CD006085-bbs2-0240" title="GoldenbergJZ , MaSSY , SaxtonJD , MartzenMR , VandvikPO , ThorlundK , et al. Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006095.pub3] ">Goldenberg 2013</a>), as well as in reducing the duration and severity of acute infectious diarrhoea in children (<a href="./references#CD006085-bbs2-0222" title="AllenSJ , MartinezEG , GregorioGV , DansLF . Probiotics for treating acute infectious diarrhoea. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD003048.pub3] ">Allen 2010</a>). In general, this beneficial effect has been shown to be dose‐dependent and strain‐dependent. Probiotics may have the potential to restore the normal gut flora, although the exact mechanism of the antiamoebic effect of <i>S boulardii</i> remains to be elucidated. Two studies included in this review reported conflicting results: In one study, the addition of <i>S boulardii</i> to the combination of metronidazole and iodoquinol reduced stool frequency and duration of illness in adults with acute amoebic colitis (<a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a>), whereas the second study, which enrolled children, did not show a significant decrease in symptoms nor in eradication of amoebae from stools when <i>S boulardii</i> was added to metronidazole (<a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a>). Two other studies evaluated the effects of herbal products and suggested that herbal products may be as effective as or superior to conventional antiamoebic therapy with fewer adverse effects (<a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a>; <a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a>). Potential use of probiotics or herbal products in combination with antiamoebic drugs includes situations in which single‐drug therapy does not result in satisfactory clinical and parasitological cure rates, additional antiamoebic drugs such as luminal antiamoebic drugs are warranted but are not available, and adverse reactions to additional or higher doses of antiamoebic drugs may arise. Further studies are needed to determine the role of these natural products in treating people with amoebic colitis. </p> </section> <section id="CD006085-sec-0099"> <h3 class="title" id="CD006085-sec-0099">Summary of main results</h3> <p>This review shows that for individuals with amoebic colitis, tinidazole may be better in reducing clinical symptoms and may result in fewer adverse events compared with metronidazole, but we do not know if it will be more effective in eradicating amoebae from the stools. Combination drug therapy may be more effective than metronidazole alone for eradicating amoebae, but we do not know which drug combination will be most effective, and if this will lead to more rapid resolution of clinical symptoms or to an increase in adverse events. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. Two trials comparing ornidazole versus metronidazole evaluated relapse and showed higher occurrence of relapse among those given ornidazole, but we are uncertain about this result. Randomized controlled trials of better quality and using standardized outcomes are needed to evaluate the efficacy of drugs for treating patients with amoebic colitis. </p> </section> <section id="CD006085-sec-0100"> <h3 class="title" id="CD006085-sec-0100">Overall completeness and applicability of evidence</h3> <p>This review was limited to symptomatic individuals with uncomplicated amoebic colitis. The effects of antiamoebic drugs on those with severe amoebic colitis, complicated disease, or extraintestinal amoebiasis were not studied. The potential effect of malnutrition, immune suppression, or AIDS on treatment is not known. Studies have demonstrated that severity of disease outcomes following <i>E histolytica</i> infection are determined by host susceptibility, which can be dependent on genetic factors or on environmental factors, such as malnutrition, and therefore may vary among different populations and geographical locations (<a href="./references#CD006085-bbs2-0265" title="MorflL , SinghU . Entamoeba histolytica: a snapshot of current research and methods for genetic analysis. Current Opinion in Microbiology2012;15(4):469–75. ">Morfl 2012</a>). Although asymptomatic infection with <i>E histolytica</i> is more common than symptomatic disease, treatment of these individuals remains controversial because most will clear their infection within one year, and only about 3% to 10% will manifest invasive disease (<a href="./references#CD006085-bbs2-0238" title="GathiramV , JacksonTFHG . A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. South African Medical Journal1987;72:669‐72. ">Gathiram 1987</a>; <a href="./references#CD006085-bbs2-0246" title="HaqueR , AliIM , SackRB , FarrBM , RamakrishnanG , PetriWAJr . Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. Journal of Infectious Diseases2001;183(12):1787‐93. ">Haque 2001</a>; <a href="./references#CD006085-bbs2-0247" title="HaqueR , DuggalP , AliIM , HossainMB , MondalD , SackRB , et al. Innate and acquired resistance to amebiasis in Bangladeshi children. Journal of Infectious Diseases2002;186(4):547‐52. ">Haque 2002</a>; <a href="./references#CD006085-bbs2-0226" title="BlessmanJ , AliIKM , Ton NuPA , DinhBT , Ngo VietTQ , VanAL , et al. Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. Journal of Clinical Microbiology2003;41(10):4745‐50. ">Blessman 2003</a>). </p> <p>The limited availability of many antiamoebic drugs must be addressed in the light of reports that newer nitroimidazole drugs may be as effective as, and better tolerated than, metronidazole, and that clinical and parasitological failures may be fewer when luminal agents are given in conjunction with tissue amoebicides. Metronidazole is widely used and may be the only available antiamoebic drug in many countries. Tinidazole and the other nitroimidazole drugs, such as ornidazole and secnidazole, and luminal agents, such as diloxanide furoate, iodoquinol, and paromomycin, are not widely available and may be purchased only from certain pharmaceutical companies or requested from government agencies. Although tinidazole was shown in this review as probably more effective and better tolerated than metronidazole, the limitations of currently available evidence and the limited availability of tinidazole in many regions would make a widespread recommendation for its use impractical. Similarly, evidence by which combination therapy can be recommended is inadequate, and the limited availability of luminal agents in the market poses a major deterrent to compliance with the recommendation for combination therapy. </p> <section id="CD006085-sec-0101"> <h4 class="title">Certainty of the evidence</h4> <p>We used the GRADE approach in assessing the certainty of trial evidence. Limitations in study quality, imprecise or sparse data for some outcomes, important inconsistencies across trials, and a high probability of reporting or publication bias decrease the certainty of evidence. Therefore the conclusions of this review should be interpreted with caution. More than half of the included studies were conducted before 1990, and the very low quality of trials included for primary outcomes implies uncertainty in the results. Inaccurate diagnosis of <i>E histolytica</i> infection by stool microscopy, absence of standardized classification of the various categories of amoebic colitis (particularly non‐dysenteric amoebic colitis), and variable timing and definitions of outcome measurements would lead to inaccuracy in assessing treatment effects. In areas highly endemic for amoebiasis, true treatment failure or relapse would be difficult to differentiate from re‐infection without the benefit of finger typing or genotyping. Incomplete reporting may lead to an inaccurate assessment of adverse events. </p> </section> </section> <section id="CD006085-sec-0102"> <h3 class="title" id="CD006085-sec-0102">Potential biases in the review process</h3> <p>This systematic review included data from a large number of small, randomized, low‐quality trials comparing all eligible treatments, making it difficult to draw an overall conclusion about the best treatment for amoebic colitis. Asymmetry in the funnel plot for an outcome with a sufficient number of studies indicates the presence of publication bias, as well as possible overestimation of intervention effects in smaller trials of poor methodological quality. </p> <p>An advanced approach to meta‐analysis of multiple treatments, such as a network meta‐analysis, may be conducted in the future to incorporate information from a combination of all relevant direct and indirect treatment comparisons and to generate a ranking scheme of different drugs according to best treatment outcomes (<a href="./references#CD006085-bbs2-0229" title="CaldwellDM , AdesAE , HigginsJPT . Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal2005;331(7521):897–900. ">Caldwell 2005</a>; <a href="./references#CD006085-bbs2-0230" title="Catala‑LepezF , TobiasA , CameronC , MoherD , HuttonB . Network meta‑analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatology International2014;34(11):1489‐96. ">Catalla‐Lopez 2014</a>). </p> </section> <section id="CD006085-sec-0103"> <h3 class="title" id="CD006085-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review published in <i>Clinical Evidence</i> summarized the effects of different drug treatments for amoebic dysentery in endemic areas (<a href="./references#CD006085-bbs2-0235" title="DansL , MartinezE . Amoebic dysentery. Clinical Evidence2006;15:1007‐13. ">Dans 2006</a>). This systematic review included 12 randomized controlled trials and concluded that ornidazole, secnidazole, and tinidazole were likely to be beneficial in treating amoebic dysentery, but that metronidazole was unlikely to be beneficial. Trial results were not combined, and no formal statistical methods were performed to determine summary measures of drug effectiveness. Updates to the <i>Clinical Evidence</i> review ‐ <a href="./references#CD006085-bbs2-0261" title="Mackey‐LawrenceN , Petri JrWA . Amoebic dysentery. BMJ Clinical Evidence2011;2011:0918. ">Mackey‐Lawrence 2011</a> and <a href="./references#CD006085-bbs2-0262" title="MarieC , PetriWAJr . Amoebic dysentery. BMJ Clinical Evidence2013;2013:0918. ">Marie 2013</a> ‐ mainly summarized findings from the previous version of this current Cochrane review on antiamoebic drugs and performed GRADE evaluation of the certainty of evidence for applied interventions (<a href="./references#CD006085-bbs2-0310" title="GonzalesMLM , DansLF , MartinezEG . Antiamoebic drugs for treating amoebic colitis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006085.pub2] ">Gonzales 2009</a>). Authors of the <i>Clinical Evidence</i> reviews recognized the generally poor quality of the included trials, largely due to methodological flaws and limitations of diagnostic tests for amoebic infection. </p> <p>An earlier systematic review on amoebic dysentery published in <i>Clinical Evidence</i> concluded that metronidazole was "unlikely to be beneficial" in that some trials demonstrated ineffectiveness or associated harm, and that ornidazole, secnidazole, and tinidazole were "likely to be beneficial" because other trials demonstrated effectiveness of these drugs with no increased harm (<a href="./references#CD006085-bbs2-0235" title="DansL , MartinezE . Amoebic dysentery. Clinical Evidence2006;15:1007‐13. ">Dans 2006</a>). This review used the <i>Clinical Evidence</i> search strategy and included 12 randomized controlled trials, defined therapeutic failure as persistence of symptoms or persistence of parasites or both, analysed outcomes reported together for different time points, and did not pool data to generate an overall summary measure. Subsequent updates of this <i>Clinical Evidence</i> review ‐ <a href="./references#CD006085-bbs2-0261" title="Mackey‐LawrenceN , Petri JrWA . Amoebic dysentery. BMJ Clinical Evidence2011;2011:0918. ">Mackey‐Lawrence 2011</a> and <a href="./references#CD006085-bbs2-0262" title="MarieC , PetriWAJr . Amoebic dysentery. BMJ Clinical Evidence2013;2013:0918. ">Marie 2013</a> ‐ mainly summarized findings of the previous version of the earlier published Cochrane review on antiamoebic drugs and included a GRADE evaluation of the certainty of evidence for interventions (<a href="./references#CD006085-bbs2-0310" title="GonzalesMLM , DansLF , MartinezEG . Antiamoebic drugs for treating amoebic colitis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006085.pub2] ">Gonzales 2009</a>). Review authors concluded that compared with placebo, ornidazole may be more effective in clearing parasites, and that secnidazole, tinidazole, and metronidazole may be as effective as ornidazole in curing amoebic dysentery. They also concluded that metronidazole may be less effective than tinidazole in reducing clinical symptoms but may be as effective in clearing parasites. For the other antiamoebic drugs, nitazoxanide was found more effective than placebo for reducing clinical failure but not for preventing parasitological failure. As described in this Cochrane review, the authors of the <i>Clinical Evidence</i> review recognized the generally poor quality of trials included in the systematic review, largely due to methodological flaws such as lack of blinding, sparse data, and lack of directness due to uncertainty of the diagnosis of amoebic dysentery. </p> <p>We have made no changes to the conclusions of this updated version of the earlier review (<a href="./references#CD006085-bbs2-0310" title="GonzalesMLM , DansLF , MartinezEG . Antiamoebic drugs for treating amoebic colitis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006085.pub2] ">Gonzales 2009</a>). We conclude that although tinidazole may be more effective than metronidazole in reducing clinical failure and was probably associated with fewer adverse effects, it did not show any significant advantage over metronidazole in reducing parasitological failure. Data were also insufficient to show the efficacy of other antiamoebic drugs compared with metronidazole or other drugs. Compared with metronidazole, combination therapy may result in fewer parasitological failures, although the optimal combination of antiamoebic drugs cannot be determined by this review. More high‐quality trials including sufficient numbers of participants and using more accurate diagnostic tests are needed to determine the most effective antiamoebic drug or combination of drugs for treating amoebic colitis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006085-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006085-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006085-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Alternative drug versus metronidazole: clinical failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Alternative drug versus metronidazole: clinical failure 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Combination regimen versus monotherapy: parasitological failure 1 to 14 days after end of treatment, subgrouped by intervention." data-id="CD006085-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Combination regimen versus monotherapy: parasitological failure 1 to 14 days after end of treatment, subgrouped by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot. Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment." data-id="CD006085-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot. Alternative drug versus metronidazole: parasitological failure 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 2 Clinical failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 2 Clinical failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 3 Parasitological failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 3 Parasitological failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 4 Parasitological failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 4 Parasitological failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 5 Relapse (ornidazole)." data-id="CD006085-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 5 Relapse (ornidazole).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alternative drug versus metronidazole, Outcome 6 Adverse events." data-id="CD006085-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Alternative drug versus metronidazole, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any antiamoebic drug versus placebo, Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Any antiamoebic drug versus placebo, Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any antiamoebic drug versus placebo, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Any antiamoebic drug versus placebo, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any antiamoebic drug versus placebo, Outcome 3 Adverse events." data-id="CD006085-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Any antiamoebic drug versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Combination regimen versus monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Combination regimen versus monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Combination regimen versus monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Combination regimen versus monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Combination regimen versus monotherapy, Outcome 3 Parasitological failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Combination regimen versus monotherapy, Outcome 3 Parasitological failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Combination regimen versus monotherapy, Outcome 4 Adverse events." data-id="CD006085-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Combination regimen versus monotherapy, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Single‐dose regimen versus longer regimen, Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Single‐dose regimen versus longer regimen, Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Single‐dose regimen versus longer regimen, Outcome 2 Clinical failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Single‐dose regimen versus longer regimen, Outcome 2 Clinical failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Single‐dose regimen versus longer regimen, Outcome 3 Parasitological failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Single‐dose regimen versus longer regimen, Outcome 3 Parasitological failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Single‐dose regimen versus longer regimen, Outcome 4 Parasitological failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Single‐dose regimen versus longer regimen, Outcome 4 Parasitological failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Single‐dose regimen versus longer regimen, Outcome 5 Adverse events." data-id="CD006085-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Single‐dose regimen versus longer regimen, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other antiamoebic drug comparisons, Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Other antiamoebic drug comparisons, Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other antiamoebic drug comparisons, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Other antiamoebic drug comparisons, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other antiamoebic drug comparisons, Outcome 3 Parasitological failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Other antiamoebic drug comparisons, Outcome 3 Parasitological failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other antiamoebic drug comparisons, Outcome 4 Adverse events." data-id="CD006085-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Other antiamoebic drug comparisons, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 1 Parasitological failure 15 to 60 days after end of treatment, by clinical category." data-id="CD006085-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 1 Parasitological failure 15 to 60 days after end of treatment, by clinical category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 2 Parasitological failure 15 to 60 days after end of treatment, by age group." data-id="CD006085-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 2 Parasitological failure 15 to 60 days after end of treatment, by age group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 3 Parasitological failure 15 to 60 days after end of treatment, single or mixed intestinal infection." data-id="CD006085-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 3 Parasitological failure 15 to 60 days after end of treatment, single or mixed intestinal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 4 Parasitological failure 15 to 60 days after end of treatment, by criteria." data-id="CD006085-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Subgroup analyses: alternative drug versus metronidazole, Outcome 4 Parasitological failure 15 to 60 days after end of treatment, by criteria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 1 Parasitological failure 1 to 14 days after end of treatment, by clinical category." data-id="CD006085-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 1 Parasitological failure 1 to 14 days after end of treatment, by clinical category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 2 Clinical failure 1 to 14 days after end of treatment, by age group." data-id="CD006085-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 2 Clinical failure 1 to 14 days after end of treatment, by age group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 3 Parasitological failure 1 to 14 days after end of treatment, by age group." data-id="CD006085-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 3 Parasitological failure 1 to 14 days after end of treatment, by age group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 4 Clinical failure 1 to 14 days after end of treatment, by diagnostic method." data-id="CD006085-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 4 Clinical failure 1 to 14 days after end of treatment, by diagnostic method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 5 Parasitological failure 1 to 14 days after end of treatment, by diagnostic method." data-id="CD006085-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analyses: any antiamoebic drug versus placebo, Outcome 5 Parasitological failure 1 to 14 days after end of treatment, by diagnostic method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analyses: combination regimen versus monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment, by intervention." data-id="CD006085-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analyses: combination regimen versus monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-008-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analyses: combination regimen versus monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by intervention." data-id="CD006085-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analyses: combination regimen versus monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analyses: combination regimen versus metronidazole, Outcome 1 Clinical failure: 1 to 14 days after end of treatment, by clinical diagnosis." data-id="CD006085-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analyses: combination regimen versus metronidazole, Outcome 1 Clinical failure: 1 to 14 days after end of treatment, by clinical diagnosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analyses: combination regimen versus metronidazole, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by clinical diagnosis." data-id="CD006085-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analyses: combination regimen versus metronidazole, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by clinical diagnosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analyses: any single‐dose regimen versus longer regimen, Outcome 1 Parasitological failure: 1 to 14 days after end of treatment, by intervention." data-id="CD006085-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analyses: any single‐dose regimen versus longer regimen, Outcome 1 Parasitological failure: 1 to 14 days after end of treatment, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose, Outcome 1 Clinical failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose, Outcome 1 Clinical failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose, Outcome 2 Parasitological failure: 15 to 60 days after end of treatment." data-id="CD006085-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose, Outcome 2 Parasitological failure: 15 to 60 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, Outcome 1 Clinical failure: 15 to 60 days after end of treatment, excluding Misra 1978." data-id="CD006085-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, Outcome 1 Clinical failure: 15 to 60 days after end of treatment, excluding Misra 1978. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, Outcome 2 Clinical failure: 15 to 60 days after end of treatment, excluding trials sponsored by pharmaceutical companies." data-id="CD006085-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, Outcome 2 Clinical failure: 15 to 60 days after end of treatment, excluding trials sponsored by pharmaceutical companies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995), Outcome 1 Clinical failure: 1 to 14 days after end of treatment." data-id="CD006085-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995), Outcome 1 Clinical failure: 1 to 14 days after end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006085-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/urn:x-wiley:14651858:media:CD006085:CD006085-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_t/tCD006085-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995), Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by intervention." data-id="CD006085-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995), Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/media/CDSR/CD006085/image_n/nCD006085-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006085-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Tinidazole compared with metronidazole as treatment for amoebic colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with amoebic colitis </p> <p><b>Settings:</b> low‐ and middle‐income countries </p> <p><b>Intervention:</b> tinidazole </p> <p><b>Comparison:</b> metronidazole </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Tinidazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> <p>(&lt; 1 to 7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.17</b> </p> <p>(0.02 to 1.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a‐d</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole may be more effective than metronidazole for reducing clinical failure</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 to 60 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> <p>(3 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> </p> <p>(0.15 to 0.51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (8 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e‐h</sup> </p> <p>due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole may be more effective than metronidazole for reducing clinical failure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Parasitological failure</b> </p> <p>Method: stool microscopy demonstrating <i>E histolytica</i> cysts or trophozoites </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> <p>(28 to 84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.58 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c,d,i</sup> </p> <p>due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparing tinidazole and metronidazole treatment, there may be little or no difference in number of parasitological failures </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 to 60 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> </p> <p>(4 to 23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> </p> <p>(0.25 to 1.64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (9 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,g,j</sup> </p> <p>due to imprecision, risk of bias, and inconsistency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether the number of parasitological failures differs comparing tinidazole or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Until 30 days after start of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> <p>(21 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.46 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (8 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>g,k‐m</sup> </p> <p>due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole is probably associated with fewer adverse events than metronidazole</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; <i>E histolytica</i> :<i>Entamoeba histolytica</i>; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 for serious risk of bias: the two trials that assessed outcomes 1 to 14 days after end of treatment were unclear regarding randomization, allocation concealment, and blinding. Both trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>b</sup>Heterogeneity could not be assessed because only one trial contributed data.<br/> <sup>c</sup>No serious indirectness: studies were conducted in countries endemic for amoebiasis: India (<a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>) and Kenya (<a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a>). Trials included participants with unspecified intestinal amoebiasis or amoebic colitis, and results could be applied to other populations for whom amoebic colitis is endemic and who have similar clinical presentation.<br/> <sup>d</sup>Downgraded by 1 for imprecision: total sample size and number of events are small. The 95% confidence interval around pooled estimates includes both no effect and appreciable benefit or appreciable harm for tinidazole.<br/> <sup>e</sup>Downgraded by 2 for very serious risk of bias: trials were at high risk of selection bias because of unclear randomization and allocation concealment and inadequate blinding of outcome assessors. In four trials (<a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a>; <a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a>; <a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a>; <a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>), treatment was extended to 10 days if there was persistence of clinical symptoms or presence of <i>E histolytica</i> in stools at the end of the planned treatment duration, but outcomes were analysed regardless of duration of treatment. It is also possible that <a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a> is a duplicate of the study <a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a>. All trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>f</sup>No serious inconsistency: there was no statistical heterogeneity (I<sup>2</sup> is 0% and the P value for heterogeneity is greater than 0.10). Effect sizes in these trials all seem to favour tinidazole.<br/> <sup>g</sup>No serious indirectness: eight trials were conducted in endemic areas (seven trials in India and one trial in Bangladesh), and one trial was conducted in an industrialized country (Sweden). All trials included patients with unspecified intestinal amoebiasis or amoebic colitis, and study results could be applied to other populations for whom amoebic colitis is endemic and who have similar clinical presentation.<br/> <sup>h</sup>No serious imprecision: these studies are adequately powered to detect 50% reductions in clinical and parasitological failure. The result is statistically significant.<br/> <sup>i</sup>No serious inconsistency: there was no statistical heterogeneity (I<sup>2</sup> is 10% and the P value for heterogeneity is greater than 0.10). Confidence intervals in trials overlap, and the point estimate indicates both benefit and harm for tinidazole.<br/> <sup>j</sup>Downgraded by 1 for inconsistency: statistical heterogeneity was high (I<sup>2</sup> is 64% and the P value for heterogeneity is less than 0.10), which could be explained by differences in populations. All studies indicate that tinidazole is comparable with metronidazole, except <a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a>, which favours metronidazole.<br/> <sup>k</sup>Downgraded by 1 for serious risk of bias: trials had inadequate or unclear blinding of outcome assessors for adverse events. Procedures for reporting adverse events and for monitoring laboratory test results were not standardized and were inadequately reported.<br/> <sup>l</sup>No serious inconsistency: statistical heterogeneity was not significant (I<sup>2</sup> is 48% and the P value for heterogeneity is 0.10), except for one trial (<a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a>); all trials consistently show lower risk of adverse events among those given tinidazole compared with those given metronidazole. Adverse effects reported were predominantly gastrointestinal, such as nausea, vomiting, anorexia, bitter or metallic taste, and abdominal discomfort.<br/> <sup>m</sup>No serious imprecision: studies are adequately powered to detect 50% difference in adverse events between the two groups. The result is statistically significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006085-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combination therapy compared with metronidazole alone as treatment for amoebic colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with amoebic colitis </p> <p><b>Settings:</b> low‐ and middle‐income countries </p> <p><b>Intervention:</b> combination therapy </p> <p><b>Comparison:</b> metronidazole alone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combination therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical failure 1 to 14 days after end of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> <p>(8 to 70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> </p> <p>(0.11 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a‐d</sup> </p> <p>due to risk of bias, inconsistency, and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether clinical failure differs between combination therapy or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure 1 to 14 days after end of treatment</b> </p> <p>Method: stool microscopy demonstrating <i>E histolytica</i> cysts or trophozoites </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> <p>(2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> </p> <p>(0.15 to 0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>720 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c‐e</sup> </p> <p>due to risk of bias and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy may result in fewer parasitological failures compared with metronidazole</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Adverse events were incompletely reported and could not be combined in a meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,f</sup> </p> <p>due to indirectness and risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether the number of adverse events differs with combination therapy or metronidazole treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; <i>E histolytica</i> :<i>Entamoeba histolytica</i>; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 for serious risk of bias: all three trials included for this outcome had unclear randomization and allocation concealment, and two trials had inadequate blinding. <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> was at high risk of selective reporting bias because of inadequate reporting of the method used for outcome evaluation and variable treatment duration ranging from 5 to 10 days. All trials used only stool microscopy to diagnose and assess parasitological outcomes, and misclassification of diagnosis and eradication of <i>E histolytica</i> in stools is possible.<br/> <sup>b</sup>Downgraded by 1 for inconsistency: heterogeneity was statistically significant (I<sup>2</sup> is 71% and the P value for heterogeneity is less than 0.05). Heterogeneity could be explained by differences in severity of illness and variable drug combinations used.<br/> <sup>c</sup>Downgraded by 1 for indirectness: trials were conducted in countries that are endemic for amoebiasis (India ‐ <a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a> and <a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> ‐ and South Africa ‐ <a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a>) but used various drug combinations. Studies using different combination of drugs would need to be studied. Some of these drugs are no longer marketed, and it is not known whether the results could be applied to other combinations.<br/> <sup>d</sup>No serious imprecision: these studies are adequately powered to detect 50% reductions in clinical and parasitological failure 15 to 60 days after end of treatment. The result is statistically significant.<br/> <sup>e</sup>No serious inconsistency: statistical heterogeneity was moderate with I<sup>2</sup> of 42% and P value for heterogeneity of 0.18). The CIs overlap, and the pooled estimate shows significant benefit favouring combination therapy.<br/> <sup>f</sup>Downgraded by 2 for very serious risk of bias: blinding was inadequate, and reporting of the frequency and type of adverse events in trials was incomplete. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006085-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Amoebicide classes and examples</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amoebicide</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Class</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Examples</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Luminal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arsenical compounds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbarsone, acetarsone or acetarsol, treparsol, diphetarsone, glycobiarsol or bismuth glycolylarsanilate, stovarsol, thioarsenite, thiocarbarsone, and arsthinol </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyquinoline derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chiniofon or quinoxyl, clioquinol or iodochlorhydroxyquin, and iodoquinol or diiodohydroxyquin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dichloroacetamide derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate or entamide furoate, clefamide, eticlordifene or ethylchlordiphene, etofamide or etophamide, and quinfamide </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzylamine derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teclozan, chlorbetamide or mantomide, and chlorphenoxamide or mebinol</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic amoebicides</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline, oxytetracycline, chlortetracycline, erythromycin, paromomycin, and fumagillin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Tissue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emetine and its derivatives</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emetine hydrochloride, emetine bismuth iodide, dehydroemetine dihydrochloride, and dehydroemetine resinate </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aminoquinoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloroquine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiazole derivative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niridazole</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitroimidazoles</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, tinidazole, ornidazole, secnidazole, and nimorazole</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nithrothiazole salicylamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitazoxanide</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Amoebicide classes and examples</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006085-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year completed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test used to measure parasitological outcome</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Various antiamoebic drugs versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0008" title="DonckasterR , AtiasA , FaiguenbaumJ , JarpaA , SapunarJ , CuelloE . Chronic intestinal amebiasis. Therapeutic trial of antibiotics, chemotherapeutics and placebos [Amibiasis intestinal cronica. Ensayo terapeutico con antibioticos, quimioterapicos y placebo]. Boletin Chileno de Parasitologia1964;19:46‐54. ">Donckaster 1964</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the University of Chile in Santiago, Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>346 adults and children with clinical symptoms of intestinal amoebiasis and stool specimens positive for cysts and/or trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0003"> <li> <p>Dimethychlortetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 15 mg/kg and adults 900 mg </p> </li> <li> <p>Oxytetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 25 mg/kg and adults 1500 mg </p> </li> <li> <p>Tetracycline: once daily on an empty stomach for 10 days at the following oral daily doses – children 25 mg/kg and adults 1500 mg </p> </li> <li> <p>Chlorphenoxamide: once daily after meals for 10 days at the following oral daily doses – children 125 mg for every 2 years of age and adults 1500 mg </p> </li> <li> <p>Chlorbetamide: once daily after meals for 10 days at the following oral daily doses – children 100 mg/kg and adults 4000 mg </p> </li> <li> <p>Racemic dehydroemetine: once daily after meals for 10 days at the following oral daily doses – children 5 mg for every 2 years of age and adults 40 mg </p> </li> <li> <p>Diiodohydroxyquinoline: once daily after meals for 21 days at the following oral daily doses – children 200 mg for every 2 years of age and adults 1800 mg </p> </li> <li> <p>Phenanthridinone: once daily after meals for 10 days at the following oral daily doses – children 25 mg for every 2 years of age and adults 300 mg </p> </li> <li> <p>Bismuth glycoarsanilate: once daily after meals for 10 days at the following oral daily doses – children 250 mg for every 2 years of age and adults 2000 mg </p> </li> <li> <p>Iodochlorhydroxyquinoline: once daily after meals for 21 days at the following oral daily doses – children 125 mg for every 2 years of age and adults 1000 mg </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (starch): once daily after meals for 10 days at the following oral daily doses – children 250 mg for every 2 years of age and adults 1500 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0004"> <li> <p>Parasitological failure: presence of cysts and/or trophozoites in stool examinations done 10 and 40 days after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants every 3 days during treatment and every 10 to 15 days after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using modified Telemann concentration technique (centrifugation with saline formol and ether) for cysts; polyvinyl alcohol with fixative of Schaudinn for the trophozoites </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0010" title="HugginsD . Double‐blind clinical trial with WIN 40.014 in the treatment of intestinal chronic amebiasis [Ensaio clinico duplo‐cego com o WIN 40.014 no tratamento da amebiase intestinal cronica]. Folha Medica1982;85 Suppl 1:869‐70. ">Huggins 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical Hospital of the Federal University of Pernambuco, Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 adults with chronic intestinal amoebiasis and stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0005"> <li> <p>Win 40.014 (quinfamide): 100 mg single oral dose</p> </li> <li> <p>Win 40.014 (quinfamide): 100 mg twice a day orally at 12‐hourly intervals for 1 day</p> </li> <li> <p>Win 40.014 (quinfamide): 100 mg thrice a day orally at 8‐hourly intervals for 1 day</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo: 300 mg daily dose orally, no information given on the frequency of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0006"> <li> <p>Parasitological cure: clearance of amoebae from stools on days 2 and 7 after treatment</p> </li> <li> <p>Clinical cure: disappearance of the 4 symptoms recorded at baseline (pain, colic, diarrhoea, and constipation) evaluated on days 2 and 7 after treatment </p> </li> <li> <p>Adverse events: only 2 symptoms (nausea and headache) solicited from participants; laboratory tests done before and after treatment but results not presented </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using Lugol's stain (Telemann‐Richter or Hoffman, Pons, and Janer methods) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Department of Hepatology, Gastroenterology, and Infectious Diseases of the Benha University Hospital, Governorate of Kalubia, Nile Delta, Egypt </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 adults and children with diarrhoea and stool specimens positive for cysts or trophozoites of <i>E histolytica</i> and/or <i>E dispar</i> alone or with concomitant <i>G intestinalis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: 500 mg twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo tablet (identical): twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0007"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from 2 stool specimens collected between days 7 and 10 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms, resolution of diarrhoea and haematochezia on day 7 after start of treatment </p> </li> <li> <p>Median duration of diarrhoea (days)</p> </li> <li> <p>Adverse events: clinical adverse events monitored by study personnel</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear, concentration technique, Ziehl‐Neelsen stain, and immunofluorescent assay (MeriFluor Meridian Diagnostics) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Benha University Hospital, Benha, Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 adults and children with diarrhoea; ≥ 1 enteric symptoms; <i>E histolytica</i> /<i>E dispar</i> trophozoites identified in stool and stool‐positive for <i>E histolytica</i> by antigen‐based ELISA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: for 3 days; adults aged ≥ 12 years, 500‐mg tablet twice daily; children 100 mg/5 mL suspension – 1 to 3 years received 5 mL twice daily, 4 to 11 years received 10 mL twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo: matching placebo tablet or suspension twice daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0008"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from 2 stool specimens collected between days 7 and 10 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms, resolution of diarrhoea and haematochezia on day 7 after start of treatment </p> </li> <li> <p>Adverse events: monitored by patient diary</p> </li> </ul> </p> <p><i>Not included in this review:</i> time from first dose to passage of last unformed stool (survival graph) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and concentration technique; <i>E histolytica</i> by antigen‐based ELISA </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tinidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0002" title="AwalARMA , AliS . Tinidazole in the treatment of symptomatic intestinal amoebiasis. Current Therapeutic Research1979;26(6):962‐6. ">Awal 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bangladesh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 adults and children with clinical signs and symptoms of intestinal amoebiasis and motile haematophagous trophozoites of <i>E histolytica</i> in fresh stool specimens and on sigmoidoscopy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0009"> <li> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </li> <li> <p>Tinidazole: 2 g single oral dose daily for 2 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single dose for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0010"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 from start of therapy </p> </li> <li> <p>Clinical cure: resolution of baseline symptoms of intestinal amoebiasis on day 30 from start of therapy </p> </li> <li> <p>Adverse events: voluntary reporting of side effects by participants; laboratory tests monitored before and after treatment including complete blood count, serum bilirubin, alkaline phosphatase, and liver transaminase (SGOT) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0006" title="ChungeCN , EstambaleBB , PambaHO , ChitayiPM , MunangaPN , Kang'etheS . Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. East African Medical Journal1989;66(11):724‐7. ">Chunge 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient departments of 3 district hospitals in Kiambo, Kilifi, and Machakos in Kenya </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 adults and children presenting with at least any 4 of the following symptoms of intestinal amoebiasis: abdominal pain, diarrhoea, constipation, mucoid stools, malaise, flatulence, nausea, fever, tenesmus, and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0011"> <li> <p>Tinidazole (Fasigyn): 2 g single oral dose daily for 3 days</p> </li> <li> <p>Tinidazole (Tynazole): 2 g single oral dose daily for 3 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0012"> <li> <p>Metronidazole (Flagyl): 400 mg thrice daily orally for 5 days</p> </li> <li> <p>Metronidazole (Metrozol): 400 mg thrice daily orally for 5 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0013"> <li> <p>Parasitological cure: absence of trophozoites or cysts from stool specimens on day 6 after start of treatment </p> </li> <li> <p>Clinical cure: absence of any 4 of the symptoms initially present at day 6 after start of treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0011" title="JoshiHD , ShahBM . A comparative study of tinidazole and metronidazole in treatment of amoebiasis. The Indian Practitioner1975;28:295‐302. ">Joshi 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahmedabad, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 or 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0014"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical response: complete or partial relief of symptoms and healing of ulcers on sigmoidoscopy, when carried out </p> </li> <li> <p>Adverse events: voluntary reporting by participants; laboratory tests monitored before and after treatment including haemogram, urinalysis, serum bilirubin, serum transaminases (SGOT, SGPT), alkaline phosphatase, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0015" title="MathurSN , ItigiA , RaoPD , Krishnaveni , RaiV . Evaluation of tinidazole in treatment of amoebiasis. Indian Medical Gazette1976;15:361‐4. ">Mathur 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults and adolescents with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days (for acute amoebic dysentery) or 800 mg thrice daily for 5 days (for other cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0015"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: relief of presenting clinical signs and symptoms and healing of ulcers on sigmoidoscopy, when carried out </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including haemogram, urinalysis, serum bilirubin, transaminases (SGOT, SGPT), alkaline phosphatase, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0016" title="MisraNP , LaiqSM . Comparative trial of tinidazole and metronidazole in intestinal amebiasis. Current Therapeutic Research1974;16(12):1255‐63. ">Misra 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical College Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults and children with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E. histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to relieve symptoms or clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days (for acute amoebic dysentery) or 800 mg thrice daily orally for 5 days (for chronic intestinal amoebiases if symptoms were of more than 15 days' duration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0016"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> on follow‐up stool examinations or ulcer scrapings on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before and after treatment including complete blood count and platelet count, urinalysis, electrocardiogram, blood urea, serum bilirubin, alkaline phosphatase, and liver transaminases (SGOT, SGPT) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or concentration method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0017" title="MisraNP , GuptaRC . A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. Journal of International Medical Research1977;5(6):434‐7. ">Misra 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0017"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools or ulcer scrapings on day 30 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including urinalysis, complete blood count, serum bilirubin, alkaline phosphatase, liver transaminases (SGOT, SGPT), blood urea, and electrocardiogram </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0018" title="MisraNP . A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis. Drugs1978;15 Suppl 1:19‐22. ">Misra 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0018"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools on day 30 after start of treatment </p> </li> <li> <p>Clinical cure: disappearance of presenting clinical symptoms and healing of ulcers on sigmoidoscopy on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory monitoring done before and after treatment including complete blood count, urinalysis, and blood chemistry </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique, sigmoidoscopy for colonic pathology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0026" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis ‐ a comparison between tinidazole and metronidazole. Annals of Tropical Medicine and Parasitology1984;78(5):505‐8. ">Pehrson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic in Stockholm, Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 adults with clinical symptoms of intestinal amoebiasis but no signs of invasion (e.g. no fever or acute dysentery) and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 600 mg twice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0019"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> trophozoites or cysts in any of the 3 stool specimens taken 1 month after end of treatment </p> </li> <li> <p>Adverse events: only adverse events severe enough to result in cessation of therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0036" title="SinghG , KumarS . Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Current Medical Research and Opinion1977;5(2):157‐60. ">Singh 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical outpatient department of the Government Medical College and Hospital, Patiala, India </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 500 mg tablets × 4 (2 g) single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400‐mg tablets × 5 (2 g) single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0020"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on follow‐up stool examinations on day 30 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of presenting clinical signs and symptoms on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants; laboratory tests monitored before and after treatment including complete blood count, urinalysis, serum bilirubin, alkaline phosphatase, transaminases, and blood urea </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear or formol‐ether concentration technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0039" title="SwamiB , LavakusuluD , DeviCS . Tinidazole and metronidazole in the treatment of intestinal amoebiasis. Current Medical Research and Opinion1977;5(2):152‐6. ">Swami 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visakhapatnam, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 2 g single dose daily for 3 days</p> <p>Treatment was extended if <i>E histolytica</i> persisted in the stool on the day following the last treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 g single dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0021"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on follow‐up stool examinations on day 30 after start of treatment </p> </li> <li> <p>Clinical response: relief of presenting clinical signs and symptoms on day 30 after start of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of adverse events by participants; laboratory tests monitored before and after treatment including blood counts, urinalysis, serum bilirubin, alkaline phosphatase, transaminases (SGOT, SGPT), and blood urea </p> </li> </ul> </p> <p><i>Not included in this review:</i> number of participants who required extension of treatment beyond 3 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ornidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0004" title="BoteroD . Double blind study with a new nitroimidazole derivative, Ro 7‐0207, versus metronidazole in symptomatic intestinal amebiasis. American Journal of Tropical Medicine and Hygiene1974;23(5):1000‐1. ">Botero 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Medellin, Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 adult males with clinical symptoms of intestinal amoebiasis confirmed by the presence of <i>E histolytica</i> in the stools </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole): 2 × 250‐mg capsules twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 × 250‐mg capsules twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0022"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools at end of treatment and at weekly intervals on follow‐up for at least 1 month </p> </li> <li> <p>Relapse: reappearance of <i>E histolytica</i> in the stools within 1 month after becoming negative at end of treatment </p> </li> <li> <p>Clinical response: disappearance of or improvement in clinical signs and symptoms on day 5, at end of treatment, and at weekly intervals during follow‐up for at least 1 month </p> </li> <li> <p>Adverse events: clinical adverse events monitored for all participants, but cardiovascular, neurological, and laboratory monitoring only for the first 20 participants (laboratory tests not specified) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and Ritchie formalin‐ether concentration methods </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinics in Jakarta, Indonesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 adults and children with bloody diarrhoea and stools positive for motile haematophagous trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole) given as follows: 2 to 6 years of age – 125 mg daily in 3 divided doses for 7 days; 7 to 12 years of age – 250 mg daily in 3 divided doses for 7 days; adults – 1500 mg daily in 3 divided doses for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole given as follows: 2 to 6 years of age – 125 mg daily in 3 divided doses for 7 days; 7 to 12 years of age – 250 mg daily in 3 divided doses for 7 days; adults – 1500 mg daily in 3 divided doses for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0023"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools at end of treatment and 1 month after end of treatment </p> </li> <li> <p>Clinical cure: disappearance of symptoms at end of treatment and at 1 month after end of treatment </p> </li> <li> <p>Relapse: reappearance of <i>E histolytica</i> in stools 1 month after end of treatment </p> </li> <li> <p>Time (range in days) from start of treatment to clearance of <i>E histolytica</i> in stool specimens </p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of bloody diarrhoea</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before and after end of treatment including complete blood counts, liver transaminase (SGPT), alkaline phosphatase, urinalysis, blood urea, and electrocardiogram </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and stained smears using eosin and iodine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Department of Child Health, Medical School University of Indonesia, Jakarta, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 children with bloody diarrhoea and stools positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 7‐0207 (ornidazole): 125‐mg capsule given as follows: up to 2 years of age – 62.5 mg, 2 to 6 years of age – 125 mg, and 6 to 12 years of age 250 mg daily, divided into 3 daily doses for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 125‐mg capsule given as follows: up to 2 years of age – 62.5 mg, 2 to 6 years of age – 125 mg, and 6 to 12 years of age 250 mg daily, divided into 3 daily doses for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0024"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools after 7 days of treatment </p> </li> <li> <p>Clinical response: disappearance of clinical symptoms after 7 days of treatment</p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of <i>E histolytica</i> from the stools </p> </li> <li> <p>Time (range in days) from start of treatment to disappearance of bloody diarrhoea</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment; laboratory tests monitored before, during, and after treatment including complete blood count, urinalysis, electrocardiogram, liver transaminases (SGPT), and alkaline phosphatase </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and eosin and Lugol's solution</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Military hospital in Erzurum, Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 adults with acute amoebic dysentery and stool specimens positive for <i>E histolytica</i> cysts and/or trophozoites </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 2 g single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 750 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0025"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools on days 14 and 21 </p> </li> <li> <p>Time (mean number of days) from start of treatment to resolution of clinical symptoms (abdominal pain, diarrhoea, bloody diarrhoea, abdominal distension, tenesmus, fever) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using 0.85% saline water, Lugol's solution, and trichrome stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Panidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0005" title="BoteroD , PerezA . Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole. Transactions of the Royal Society of Tropical Medicine and Hygiene1977;71(6):508‐11. ">Botero 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 adult males with clinical symptoms of intestinal amoebiasis and stools positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panidazole: 2 × 250‐mg tablets (500 mg), 4 times daily for 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 2 × 250‐mg tablets (500 mg), 4 times daily for 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0026"> <li> <p>Parasitological cure: eradication of parasites in any of the post‐treatment laboratory examinations </p> </li> <li> <p>Clinical response: improvement in or disappearance of symptoms during weekly follow‐up until 4 weeks after treatment </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment and on follow‐up; laboratory tests monitored before and after treatment including complete blood count, erythrocyte sedimentation rate, blood urea nitrogen, liver transaminases, urinalysis, and electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> number of stools passed in 24 hours on day 3 and day 6 of treatment, and on days 7 and 21 after treatment; clearance of <i>E histolytica</i> in 14 asymptomatic carriers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and Ritchie formalin‐ether concentration methods </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Satranidazole versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0041" title="TripathiBM , MisraNP , TiwariA . A double‐blind trial of GO 10213 and metronidazole in intestinal amoebiasis. Current Therapeutic Research1986;39(2):178‐82. ">Tripathi 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Bhopal, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults with symptoms of intestinal amoebiasis and stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GO 10213 (satranidazole): 150 mg thrice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0027"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> on stool examinations on follow‐up 28 days after start of treatment </p> </li> <li> <p>Clinical response: relief of presenting clinical signs and symptoms and healing of ulcers on sigmoidoscopy on follow‐up 28 days after start of treatment </p> </li> <li> <p>Adverse events: volunteered by participants; laboratory tests monitored before and after treatment including complete blood count, liver transaminases (SGOT, SGPT), serum bilirubin, blood urea, urinalysis, and electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> frequency of loose stools/d from start of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using formol‐ether concentration methods, sigmoidoscopy, colonic ulcer scrapings, and positive stool culture on NIH media </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Praziquantel versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0019" title="MohammedKA , StrakSK , JawadAM , Al‐SadoonIO , MahdiNK . Effectiveness of praziquantel in treatment of intestinal amoebiasis and giardiasis. Eastern Mediterranean Health Journal1998;4(1):161‐3. ">Mohammed 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients in Iraq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 adults with clinical symptoms of intestinal amoebiasis and stool specimens positive for vegetative trophozoite forms (acute amoebic dysentery) or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Praziquantel: 40 mg/kg body weight divided into 2 doses orally and taken 4 to 6 hours apart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 800 mg thrice daily orally for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD006085-list-0028"> <li> <p>Parasitological response: disappearance of <i>E histolytica</i> from stools 1 week after treatment </p> </li> <li> <p>Clinical response: disappearance of baseline clinical signs and symptoms at end of treatment </p> </li> <li> <p>Adverse events: voluntary reporting of clinical adverse events by participants only for praziquantel </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0031" title="RubidgeCJ , ScraggJN , PowellSJ . Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate. Archives of Disease in Childhood1970;45(240):196‐7. ">Rubidge 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Durban, South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 children with amoebic dysentery presenting with acute onset of diarrhoea with blood, mucus, and actively motile haematophagous trophozoites of <i>E histolytica</i> in stool specimens </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydroemetine, tetracycline, and diloxanide furoate: dehydroemetine (2 mg/kg body weight daily by subcutaneous injection for 10 days), tetracycline (50 mg/kg body weight daily orally for 7 days), and diloxanide furoate (25 mg/kg body weight daily orally for 10 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 50 mg per kg body weight orally for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0029"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> at end of treatment and on subsequent stool specimens during follow‐up until 28 days after start of treatment </p> </li> <li> <p>Clinical response: disappearance of symptoms at end of treatment and during follow‐up until 28 days after start of treatment </p> </li> <li> <p>Adverse events: only tolerance to drugs reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear and zinc sulphate flotation technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0001" title="AsraniCH , DamleSS , GhotgeVV , GokhaleAS , JalgaonkarM , Pai KakodePR , et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a Primary Care Physician Research Group Study. Current Therapeutic Research1995;56(7):678‐83. ">Asrani 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Various cities in India (not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961 male and non‐pregnant female patients &gt; 12 years of age with clinical symptoms of intestinal amoebiasis and/or presence of trophozoites or cysts of<i>E histolytica</i> in stool specimens </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole and diiodohydroxyquinoline: fixed‐drug combination of metronidazole (200 mg) plus diiodohydroxyquinoline (325 mg) (Qugyl by Sil Pharma, Bombay, India) given as 2 tablets thrice daily for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 400 mg thrice daily orally for 5 days</p> <p>Treatment period was extended to 10 days in both groups when 5 days' treatment was inadequate to clear the stools of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0030"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> from stool specimens at end of treatment </p> </li> <li> <p>Clinical cure: remission of clinical symptoms on days 5 and 10 after start of treatment</p> </li> <li> <p>Adverse events: clinical adverse events monitored by study personnel during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> average daily frequency of stools on admission and on day 5 and day 10 of treatment; overall clinical response (rated as "poor" if &lt; 25% relief and not tolerated, "fair" if 25% to 49% relief and not well tolerated, "poor" if 50% to 74% relief and well tolerated, or "excellent" if 75% to 100% relief and well tolerated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0027" title="PrasadR , JagotaSC , MathurPP , TanejaV . Drug trial of ‘Dependal' ‐ M suspension against metronidazole suspension in amoebiasis and giardiasis. Indian Medical Gazette1985;119(7):219‐23. ">Prasad 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paediatric outpatient department of S.N. Medical College, Agra, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 children with clinical symptoms of intestinal amoebiasis or giardiasis (diarrhoea, abdominal pain, dysentery, gastrocolic urgency, etc.) and whose stools were positive for amoebae or <i>Giardia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole plus furazolidone: fixed‐drug combination suspension of (per 5 mL) metronidazole 75 mg plus furazolidone 25 mg, given as 5 mL thrice daily for those 1 to 5 years of age and as 10 mL thrice daily for those 6 to 15 years of age for 5 or 10 days depending on severity of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 100 mg/5 mL suspension, given as 5 mL thrice daily for those 1 to 5 years of age and as 10 mL thrice daily for those 6 to 15 years of age for 5 or 10 days depending on severity of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0031"> <li> <p>Parasitological and clinical response: evaluated jointly on day 7 after start of therapy; overall outcome was reported as complete cure, partial cure, and no cure, but these terms were not defined </p> </li> <li> <p>Adverse events: clinical adverse events reported by participants during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> clinical and parasitological response in those with mixed amoebiasis and giardiasis infection; 12/63 from the metronidazole group and 15/101 from the fixed‐drug combination metronidazole plus furazolidone had mixed amoebiasis and giardiasis and were not included in this review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination versus aminosidine or etophamide or nimorazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0023" title="PambaHO , EstambaleBB , ChungeCN , DonnoL . Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya. European Journal of Clinical Pharmacology1990;39(4):353‐7. ">Pamba 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 district hospitals of Kiambo, Machakos, and Kilifi in Kenya, Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417 adults and children with clinical symptoms of intestinal amoebiasis with stool specimens positive for <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0032"> <li> <p>Combination of nimorazole and aminosidine (NA): same doses as above for 5 days</p> </li> <li> <p>Combination of nimorazole and etophamide (NE): same doses as above for 5 days</p> </li> <li> <p>Combination of etophamide and aminosidine (EA): same doses as above for 5 days</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0033"> <li> <p>Aminosidine (A): 500 mg twice daily orally for adults, 15 mg/kg body weight twice daily orally for children for 5 days </p> </li> <li> <p>Etophamide (E): 600 mg twice daily orally for adults, 15 mg/kg body weight twice daily orally for children for 5 days </p> </li> <li> <p>Nimorazole (N): 1 g twice daily orally for adults, 20 mg/kg body weight twice daily orally for children for 5 days </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0034"> <li> <p>Parasitological cure: disappearance of any form of <i>E histolytica</i> from stools or ulcer scrapings at end of treatment </p> </li> <li> <p>Recurrence (relapse): reappearance of <i>E histolytica</i> during follow‐up on days 15, 30, and 60 after initial disappearance; owing to incomplete data on follow‐up, results could not be included in the meta‐analysis </p> </li> <li> <p>Clinical cure: disappearance of all baseline symptoms at end of treatment</p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment</p> </li> </ul> </p> <p><i>Not included in this review:</i> cumulative daily clearance of <i>E histolytica</i> from stools during treatment, at end of treatment, and on days 15, 30, and 60 after start of treatment; evolution of mild and severe amoebic ulcers seen on rectosigmoidoscopy; and anatomical cure (healing of previous ulceration) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and a concentration method (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Quinfamide and mebendazole versus nitazoxanide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0007" title="Davila‐GutierrezC , VasquezC , Trujillo‐HernandezB , HuertaM . Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. American Journal of Tropical Medicine and Hygiene2002;66(3):251‐4. ">Davila 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 communities in Colima, Mexico</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 children enrolled with various helminthic and protozoal intestinal infections; 105/275 (38%) had <i>E histolytica</i> or <i>E dispar</i> infection (25 single infection and 80 mixed infection with other intestinal parasites) and were included in the review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide: 100 mg/5 mL single oral dose; mebendazole 100 mg/5 mL twice daily orally for 3 days was added to quinfamide when another parasite other than <i>E histolytica</i> /<i>E dispar</i> was observed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitazoxanide: 100 mg/5 mL twice daily orally for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0035"> <li> <p>Parasitological cure: eradication of <i>E histolytica/E dispar</i> in stool examination 14 days after treatment </p> </li> <li> <p>Adverse events: only tolerance to drugs reported</p> </li> </ul> </p> <p>Data for parasitological cure were presented separately for nitazoxanide versus quinfamide for single infections and for nitazoxanide versus quinfamide plus mebendazole for mixed infections, and were included in a separate meta‐analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy with direct smear or Kato‐Katz technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination tetracycline and clioquinol versus secnidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0038" title="SoedinK , Alfien SyukranOK , FadillahA , SidabutarP . Comparison between the efficacy of a single dose of secnidazole with a 5‐day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica1985;4(4):251‐4. ">Soedin 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient in the Padang Bulan Health Centre, Medan, Indonesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 children with clinical symptoms of acute intestinal amoebiasis with stool specimens positive for trophozoites or haematophagous forms of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline and clioquinol: tetracycline (750 mg) and clioquinol (1 g for 5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 2 g orally in a single dose</p> <p><i>Co‐intervention:</i> 2 patients in secnidazole group were given spasmolytics (unspecified) for stomach cramps </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0036"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stools examined on days 1 to 7, and on days 7, 14, and 21 after start of treatment </p> </li> <li> <p>Clinical response: disappearance of clinical symptoms on days 1 to 7, and on days 14, 21, and 28 after start of treatment </p> </li> <li> <p>Adverse events: clinical adverse events during follow‐up</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Combination tinidazole and diloxanide versus tinidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0025" title="PehrsonP , BengtssonE . Treatment of non‐invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate. Transactions of the Royal Society of Tropical Medicine and Hygiene1983;77(6):845‐6. ">Pehrson 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in Stockholm, Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 adults and children with clinical symptoms of intestinal amoebiasis but no signs of invasion (e.g. no fever or acute dysentery) and stool specimens positive for trophozoites or cysts of <i>E histolytic</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole plus diloxanide furoate: tinidazole 40 mg/kg body weight in a single oral dose daily for 5 days plus diloxanide furoate 20 mg/kg body weight divided into 3 daily doses for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 40 mg/kg body weight in a single oral dose daily for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0037"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from any of the 3 stool specimens evaluated 1 month after end of treatment </p> </li> <li> <p>Adverse events: only adverse events severe enough to result in cessation of therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear or formol‐ether concentration technique by Ridley and Hawgood </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole single dose versus tinidazole for 2 days</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0032" title="SallesJMC , BecharaC , TavaresAM , MartinsM , SobrinhoJG , Dietrich‐NetoF , et al. Comparative study of the efficacy and tolerability of secnidazole suspension (single dose) and tinidazole suspension (two days dosage) in the treatment of amebiasis in children. Brazilian Journal of Infectious Diseases1999;3(2):80‐8. ">Salles 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 different centres in Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 children with clinical symptoms of intestinal amoebiasis with stool specimens positive for <i>E histolytica</i> enrolled; 275/303 (90.7%) included in evaluation for clinical efficacy; 300/303 (99%) included in evaluation for parasitological efficacy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 1 mL/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 0.5 mL/kg body weight once daily orally for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0038"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stool specimens collected on days 7, 14, and 21 following treatment </p> </li> <li> <p>Clinical response: disappearance of all symptoms at end of the study (day 21)</p> </li> <li> <p>Adverse events: solicited from participants or their guardians during follow‐up visits</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and the Faust and Katz method and no history of intolerance to imidazole drugs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Ornidazole versus tinidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0024" title="PanggabeanA , SutjiptoA , AldyD , SutantoAH , SiregarH . Tinidazole versus ornidazole in amebic dysentery in children (a double blind trial). Paediatrica Indonesiana1980;20(11‐12):229‐35. ">Panggabean 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the sub‐department of Gastroenterology, Department of Child Health Medical School, General Hospital, Medan, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 children with amoebic dysentery presenting with bloody stools and motile haematophagous trophozoites of <i>E histolytica</i> in stools: 25/40 (62.5%) analysed 1 week after treatment, 17/40 (42.5%) analysed 2 weeks after treatment, 11/40 (27.5%) analysed 3 weeks after treatment, and 6/40 (15%) analysed 4 weeks after treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole: 50 mg/kg body weight in a single oral dose daily for 3 days</p> <p><i>Other interventions:</i> Children with concomitant intestinal helminthic infection were given single‐dose pyrantel pamoate 10 mg/kg; those with trichuriasis were given mebendazole 1 tablet twice daily for 3 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 50 mg/kg body weight in a single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0039"> <li> <p>Parasitological cure: disappearance of all forms of <i>E histolytica</i> on stool examinations done weekly until 4 weeks after completion of treatment </p> </li> <li> <p>Re‐infection: reappearance of <i>E histolytica</i> after the second month </p> </li> <li> <p>Clinical cure: disappearance of blood and mucus from stools at follow‐up examinations done weekly until 4 weeks after completion of treatment </p> </li> <li> <p>Adverse events: clinical adverse effects reported by participants during treatment</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and eosin 2% stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0037" title="SitepuN , LubisCP , SutantoAH , SiregarH . Minute treatment with tinidazole and ornidazole in children with amebic dysentery. Paediatrica Indonesiana1982;22(7‐8):132‐5. ">Sitepu 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Pediatric Gastroenterology Subdivision, Department of Child Health, School of Medicine, University of North Sumatra/Dr Pirngadi Hospital, Medan, Indonesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 children with amoebic dysentery presenting with bloody diarrhoea and motile haematophagous trophozoites of <i>E histolytica</i> in stools: 41/50 (82%) analysed on the third day or 2 days after treatment, 18/50 (36%) were analysed 1 week after treatment </p> <p><i>Losses to follow‐up:</i> 9/51 (18%) were lost to follow‐up by the third day or 2 days after treatment ‐ 7 participants in the tinidazole group and 2 in the ornidazole group; 32/50 (64%) were lost to follow‐up 1 week after treatment ‐ 18 in the tinidazole group and 14 in the ornidazole group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole: 50 mg/kg body weight in a single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tinidazole: 50 mg/kg body weight in a single oral dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0040"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stools on subsequent follow‐up visits on days 2 to 4 and 1 week after treatment </p> </li> <li> <p>Clinical response: disappearance of diarrhoea, and faeces no longer contained mucus or red blood cells on days 2 to 4 and 1 week after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and eosin 1% stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Secnidazole versus quinfamide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0022" title="PadillaN , DiazR , MunozM . Efficacy and safety of quinfamide versus secnidazole in the management of amoebic non‐dysenteric colitis in children. Clinical Drug Investigation2000;20(2):89‐93. ">Padilla 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 urban federal elementary schools in Celaya, Guanajuato, Mexico (Urban Federal Elementary schools ‘Carmen Serdan' and ‘Juan Jesus de los Reyes') </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239 children with clinical symptoms of non‐dysenteric amoebic colitis with at least 1 of 3 stool specimens positive for <i>E histolytica</i> cysts </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 30 mg/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide: 4.3 mg/kg body weight orally in a single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0041"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> cysts on days 5, 6, and 7 after administration of drugs </p> </li> <li> <p>Adverse events: Clinical adverse events were solicited by investigators through direct questioning for the presence of abdominal pain, nausea, vomiting, headache, diarrhoea, and unpleasant taste in the mouth </p> </li> </ul> </p> <p><i>Not included in this review:</i> acceptability of the test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear and the Faust concentration method</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ornidazole versus secnidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical Center Hospital, Ankara, Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 children with gastrointestinal symptoms and stool specimens positive for haematophagous trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ornidazole 15 mg/kg body weight given twice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secnidazole: 30 mg/kg body weight given as a single oral dose daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0042"> <li> <p>Parasitological cure: clearance of <i>E histolytica</i> cysts or trophozoites from stools 10 days after completion of treatment </p> </li> <li> <p>Clinical response: resolution of diarrhoea and abdominal discomfort</p> </li> <li> <p>Time (median and range in days) from start of treatment to resolution of clinical symptoms </p> </li> <li> <p>Adverse events: side effects; method for obtaining information and specific adverse events not reported </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Quinfamide versus teclozan</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0009" title="GuevaraL . Evaluation of the tolerance and efficiency of quinfamide, a new intraluminal amebicide, in man (one day treatment). Double blind study. Revista de Gastroenterologia de Mexico1980;45(2):93‐7. ">Guevara 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients were hospitalized for 1 day, then were followed up as outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 adults with non‐dysenteric amoebiasis with trophozoites of <i>E histolytica</i> in recently emitted faecal material and/or in recto‐colonic mucosal exudate; recto‐colonic lesions suggestive of amoebiasis present or not; and not presenting clinical manifestations of acute amoebic recto‐colitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quinfamide given at 3 doses in 1 day: 100 mg for 3 doses (300 mg), 200 mg for 3 doses (600 mg), 400 mg for 3 doses (1200 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teclozan at 3 doses in 1 day: 500 mg for 3 doses (1500 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0043"> <li> <p>Parasitological failure: persistence of trophozoites in rectal exudates by rectosigmoidoscopy 15 and 30 days after end of treatment and in fresh faecal material 8, 15, and 30 days after treatment </p> </li> <li> <p>Adverse events: Clinical and laboratory tests were monitored on the day after drug administration, then 8, 15, and 30 days after treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Chlorhexidine versus diiodohydroxyquinoline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0012" title="KapadiaRM , PathakHY , ApteSP . Chlorhydroxyquinoline and di‐iodohydroxyquinoline in amoebiasis: a comparative study. Journal of the Indian Medical Association1968;51(3):125‐7. ">Kapadia 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bombay, India (location not stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 patients with clinical symptoms of intestinal amoebiasis and stool specimens positive for trophozoites and/or cysts of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorhydroxquinoline: 500 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Di‐diiodohydroxyquinoline: 500 mg thrice daily orally for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0044"> <li> <p>Parasitological cure: eradication of <i>E histolytica</i> from stools at the end of the 10‐day treatment period </p> </li> <li> <p>Clinical cure: improvement in or disappearance of symptoms at the end of the 10‐day treatment period </p> </li> <li> <p>Adverse events: clinical adverse events and liver function test monitored before and after treatment including total bilirubin, serum albumin and globulin, and zinc sulphate </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>MK‐910 low dose versus high dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital in New Delhi, India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 patients (age unspecified) with acute amoebic dysentery and stool specimens positive for trophozoites of <i>E histolytica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Methyl‐2‐(4'fluorophenyl)‐5‐nitroimidazole (MK‐910) at low doses: 0.5 mg/kg body weight or 1.0 mg/kg body weight, given in 3 divided doses orally for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Methyl‐2‐(4'fluorophenyl)‐5‐nitroimidazole (MK‐910) at high doses: 2.0 mg/kg body weight or 3.0 mg/kg body weight, given in 3 divided doses orally for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0045"> <li> <p>Parasitological response: disappearance of <i>E histolytica</i> from stools on day 5 and day 10 of treatment, on both saline and iodine smear examination and on stool culture using NIH medium </p> </li> <li> <p>Clinical response: reduction in clinical signs and symptoms (tenesmus, diarrhoea, bloody stools) </p> </li> <li> <p>Time (range in hours) until disappearance of <i>E histolytica</i> cysts and trophozoites in stools </p> </li> <li> <p>Adverse events: monitored by study personnel during treatment; laboratory tests monitored before and on day 5 and day 11 of treatment including complete blood count, platelet count, urinalysis, blood urea, blood sugar, serum bilirubin, alkaline phosphatase, liver transaminases (SGOT, SGPT), thymol turbidity tests, and 12‐lead electrocardiogram </p> </li> </ul> </p> <p><i>Not included in this review:</i> disappearance of colonic ulcers on sigmoidoscopic examination on day 5 and at end of treatment on day 10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and iodine smears</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Fixed drug combination diloxanide‐tetracycline‐chloroquine versus fixed‐drug combination diloxanide‐tetracycline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0021" title="NnochiriE . Oral chemotherapy in amoebic dysentery ‐ potentiating effect of chloroquine on the action of diloxanide furoate. Journal of Tropical Medicine and Hygiene1967;70(9):224‐8. ">Nnochiri 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yaba Military Hospital in Lagos, Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 military personnel and their families given diagnosis of acute amoebic dysentery and stool specimens positive for <i>E histolytica:</i> 60 analysed at end of treatment, and 58 (96.8%) analysed 7 weeks after end of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate, tetracycline hydrochloride, and chloroquine phosphate (per capsule): diloxanide furoate (187.5 mg), tetracycline hydrochloride (125 mg), and chloroquine phosphate (50 mg) given in 3 dosage regimens of 2 capsules 4 times a day for 5 days, 2 capsules 4 times a day for 7 days, or 2 capsules 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diloxanide furoate and tetracycline hydrochloride (per capsule): diloxanide furoate (187.5 mg) and tetracycline hydrochloride (125 mg) given in 3 dosage regimens of 2 capsules 4 times a day for 5 days, 2 capsules 4 times a day for 7 days, or 2 capsules 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0046"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> cysts and trophozoites at end of treatment, then on follow‐up 7 weeks from completion of treatment; patients whose stools remained negative 7 weeks after treatment were followed up 3 and 6 months from completion of treatment </p> </li> <li> <p>Clinical response: recurrence of symptoms (reported only for those given 10 days' treatment: 16/34 in the diloxanide furoate‐tetracycline hydrochloride‐chloroquine phosphate group and 10/26 in the diloxanide furoate‐tetracycline hydrochloride group) </p> </li> <li> <p>Adverse events: clinical adverse events monitored during treatment and on follow‐up; laboratory tests monitored before and after treatment including urine cytology and presence of protein, blood examination for haemoglobin, total erythrocyte and leucocyte counts, and differential count </p> </li> </ul> </p> <p><i>Not included in this review:</i> results of stool examination 3, 6, and 12 months after treatment; clearance of <i>E histolytica</i> from stools of 36 asymptomatic cyst carriers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and iodine‐stained smears</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient in Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 children from 1 to 15 years of age who presented with <i>E histolytica</i> ‐<br/> associated diarrhoea defined as presence of compatible clinical presentations (acute diarrhoea, fever, and abdominal pain) and presence of <i>E histolytica</i> trophozoite engulfing red blood cells in diarrhoeal stool </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole: 30 to 50 mg/kg/d orally for 10 days (maximum: 500 to 750 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole plus <i>S boulardii</i> (Reflor, Sanofi‐Synthelabo, France): metronidazole 30 to 50 mg/kg/d orally (maximum: 500 to 750 mg) plus lyophilized <i>S boulardii</i> 250 mg (includes 5,000,000 living microorganisms) orally once a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0047"> <li> <p>Parasitological response: clearance of <i>E histolytica</i> from stool specimens collected 14 days after end of treatment </p> </li> <li> <p>Clinical response: disappearance of all symptoms (diarrhoea, bloody diarrhoea, vomiting, fever, abdominal pain) at the end of the study (day 10) </p> </li> <li> <p>Time (median and range in days) to resolution of diarrhoea, bloody diarrhoea, vomiting, fever, abdominal pain </p> </li> <li> <p>Adverse events: recorded during the active treatment period</p> </li> </ul> </p> <p><i>Not included in this review:</i> survival analysis graph of the number of stools per day during the 10‐day treatment period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline and trichrome stain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Metro‐iodoquinol versus metro‐iodoquinol + <i>Saccharomyces</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shahid Beheshti Educational and Therapeutic Center in Shiraz, Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 adults with amoebic dysentery presenting with mucous bloody diarrhoea, fever, and abdominal pain; stool specimens positive for haematophagous trophozoites of <i>E histolytica</i> in the laboratory </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, iodoquinol, and placebo: metronidazole 750 mg and iodoquinol 650 mg given thrice daily orally with placebo tablets for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole, iodoquinol, and <i>S boulardii</i> : 750 mg and iodoquinol 650 mg thrice daily given orally for 10 days plus lyophilized <i>S boulardii</i> 250 mg orally thrice daily given for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0048"> <li> <p>Parasitological failure: persistence of amoebic cysts at stool examination at 4 weeks after treatment </p> </li> <li> <p>Mean duration of diarrhoea, abdominal pain, fever, and headache from start of treatment to resolution of symptoms </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct faecal smear and flotation technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Herbal versus fixed‐drug combination metronidazole‐diloxanide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0035" title="SiddiquiMI , UsmanghaniK . Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolytica. Journal of Medicinal Plants Research2015;9(9):301‐9. ">Siddiqui 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient department of 2 centres in Pakistan (Shifa‐Ul‐Maluk Hospital, Gadap and Zahida Medical Centre, North Karachi) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 patients between the ages of 5 and 60 years with symptoms of amoebiasis (abdominal pain, blood in stool, or diarrhoea) and positive for <i>E histolytica</i> cyst or trophozoite: 153 analysed; 18/171 were not included in the analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal product (Endemali, Pakistan) available in 4‐g sachet containing <i>Boswellia glabra</i> 270.9 mg, <i>Kaolinum ponderosum</i> 255 mg, <i>Ocimum pilosum</i> 580 mg, <i>Pistacia terebinthus</i> 116.1 mg, <i>Plantago ispagula</i> 812.7 mg, and <i>Vateria indica</i> 232.2 mg sweetening agent q.s. Endemali was given 4 times a day for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of metronidazole 400 mg + diloxanide furoate 500 mg (Entamizole DS, Pakistan) in tablet form given 3 times a day for 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0049"> <li> <p>Parasitological response: no <i>E histolytica</i> cyst found in the stool 5 days after treatment was stopped </p> </li> <li> <p>Clinical response: absence (partial or complete) of symptoms after treatment was stopped</p> </li> <li> <p>Adverse events: Clinical adverse events were reported by participants after they received study drugs, but the method of reporting was not specified; no biochemical tests were monitored </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct smear, Lugol's iodine smear, zinc sulphate flotation preparation, or formalin‐ether sedimentation method </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Herbal product versus metronidazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0034" title="ShahSMA , UsmanghaniK , AkhtarN , AkramM , AsifHM , HasanMM . Clinical study on the efficacy of Amoebex (coded herbal drug) compared with metronidazole for the treatment of amoebic dysentery. Pakistan Journal of Pharmaceutical Sciences2016;29(6):2005‐14. ">Shah 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital, multi‐centre (Shifa‐ul‐mulk Memorial Hospital, Hamdard University Karachi, Hakeem, Pakistan) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 adult patients suffering from amoebiasis infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herbal drug Amoebex 400‐mg tablet 2 tablets after meal thrice daily, duration not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metronidazole 400 mg 2 tablets thrice daily for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD006085-list-0050"> <li> <p>Parasitological response: eradication of <i>E histolytica</i> from stool specimens at end of treatment </p> </li> <li> <p>Clinical response: disappearance of signs and symptoms of amoebiasis at the end of the study </p> </li> </ul> </p> <p><i>Not included in this review:</i> improvement in intensity of symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stool microscopy using direct saline smear</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><i>E dispar</i> : <i>Entamoeba dispar</i> ; <i>E histolytica</i> :<i>Entamoeba histolytica</i> ; ELISA: enzyme‐linked immunosorbent assay; <i>G intestinalis</i> : <i>Giardia intestinalis</i>; SGOT: aspartate aminotransferase; SGPT: alanine aminotransferase. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006085-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time‐to‐event in trials using various antiamoebic drugs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Time to resolution of diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 low dose (≤ 1 mg/kg/d</b> ) </p> <p>Range (h) = 24 to 72, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 high dose (≥ 2 mg/kg/d)</b> </p> <p>Range (h) = 24 to 48, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 1; n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 2, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol and</b> </p> <p><i><b>S boulardii</b> </i> </p> <p>Mean (h) = 12 ± 3.7 (SD), n = 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol and placeb</b>o </p> <p>Mean (h) = 48 ± 18.5 (SD), n = 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0029" title="RossignolJF , AyoubA , AyersMS . Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double‐blind, placebo‐controlled study of nitazoxanide. Journal of Infectious Diseases2001;184(3):381‐4. ">Rossignol 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitazoxanide</b> </p> <p>Median (d) = 3,</p> <p>n = 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>No median presented because 60% still had diarrhoea at end of follow‐up period, n = 31 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and range not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0030" title="RossignolJF , KabilSM , ElGoharyY , YounisAM . Nitazoxanide in the treatment of amoebiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(10):1025‐31. ">Rossignol 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitazoxanide</b> </p> <p>Mean or median and range not presented, n = 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>Mean or median and range not presented, n = 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented as survival analysis graph of time from first dose to passage of last unformed stools </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 4.5 (1 to 10), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 5 (1 to 10), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0040" title="ToppareMF , KitapciF , SensesDA , YalcinkayaF , Safa KayaI , DilmenU . Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Tropical Doctor1994;24(4):183‐4. ">Toppare 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Mean (d) = 2 to 3, range (d) = 1 to 5, n = 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 5, range (d) = 1 to 29, n = 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD of mean and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Time to resolution of bloody stools</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0003" title="BatraSK , AjmaniNK , ChuttaniHK . Evaluation of 1‐methyl‐2‐(4'‐fluorophenyl)‐5‐nitroimidazole. Journal of Tropical Medicine and Hygiene1972;75(2):40‐1. ">Batra 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 low dose, ≤ 1 mg/kg/d</b> </p> <p>Range = 48 to 72 hours, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MK‐910 high dose, ≥ 2 mg/kg/d</b> </p> <p>Range = 48 to 72, n = 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 1, n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 1, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (h) = 48 to 72, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (h) = 48 to 72, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 3 to 7, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 3 to 7, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 2 (1 to 5), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 2 (1 to 3), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Time to resolution of abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0013" title="KarabayO , GodekmerdenA . Comparison of therapeutic efficacies of the single dose secnidazole versus 10‐day metronidazole in acute amebiasis [Akut intestinal amebiyaz tedavisinde tek doz seknidazol ile 10 gunluk metronidazolun etkinliklerinin karsilastirilmasi]. Klimik Dergisi1999;12(2):82‐4. ">Karabay 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secnidazole</b> </p> <p>Mean (d) = 2, n = 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Mean (d) = 3, n = 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD not reported</p> <p>P &gt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0014" title="Mansour‐GhanaeiF , DehbashiN , YazdanparastK , ShafaghiA . Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World Journal of Gastroenterology2003;9(8):1832‐3. ">Mansour‐Ghanaei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol, and</b> </p> <p><i><b>S boulardii</b> </i> </p> <p>Mean (h) = 12 ± 3.2 (SD), n = 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole, iodoquinol, and placebo</b> </p> <p>Mean (h) = 24 ± 7.3 (SD), n = 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0033" title="Savas‐ErdeveS , GokayS , DallarY . Efficacy and safety of Saccharomyces boulardii in amebiasis‐associated diarrhea in children. Turkish Journal of Pediatrics2009;51(3):220‐4. ">Savas‐Erdeve 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole and <i>S boulardii</i> </b> </p> <p>Median (range, days) = 3 (1 to 10), n = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Median (range, days) = 2 (1 to 10), n = 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to disappearance of <i>E. histolytica</i> in stools </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0020" title="NaoemarSA , RukmonoB . Clinical trial of Ro 7‐0207, a nitroimidazole derivative, in amoebic dysentery. Southeast Asian Journal of Tropical Medicine and Public Health1973;4(3):417‐20. ">Naoemar 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 2 to 3, n = 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 2 to 3, n = 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006085-bbs2-0028" title="PudjiadiSH , Sunoto , Suharjono , KadriN . A new oral amoebicid (RO 7‐0207) in the treatment of intestinal amoebiasis. Paediatrica Indonesiana1973;13(4):113‐9. ">Pudjiadi 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ornidazole</b> </p> <p>Range (d) = 2 to 4, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metronidazole</b> </p> <p>Range (d) = 2 to 4, n = 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) and median not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><i>E histolytica</i> : <i>Entamoeba histolytica</i> ; <i>S boulardii</i> :<i>Saccharomyces boulardii</i>; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time‐to‐event in trials using various antiamoebic drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/full#CD006085-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alternative drug versus metronidazole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.11, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ornidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Praziquantel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.17, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.21, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Ornidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Panidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Satranidazole (GO 10213)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.40, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.85, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.58, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ornidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Praziquantel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.17, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Parasitological failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.25, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Ornidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Panidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.81, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Satranidazole (GO 10213)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relapse (ornidazole) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.74 [1.07, 20.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ornidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Satranidazole (GO 10213)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Panidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.87, 1.45]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alternative drug versus metronidazole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any antiamoebic drug versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.13, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Quinfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.21, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nitazoxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.06, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.22, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Quinfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.19, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nitazoxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.05, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 10 different drugs belonging to 6 drug classes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.26, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Quinfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.22, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nitazoxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.41, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 10 different drugs belonging to 6 drug classes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.97, 4.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any antiamoebic drug versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combination regimen versus monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 DHE, tetracycline, and diloxanide furoate vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.24, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Metronidazole and diiodohydroxyquinoline vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.13, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Metronidazole‐furazolidone vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.09, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Combinations vs nimorazole, aminosidine, and etofamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.07, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Tetracycline and clioquinol vs secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.5 [2.10, 34.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dehydroemetine and tetracycline and diloxanide furoate vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.24, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Metronidazole and diiodohydroxyquinoline vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.11, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Fixed‐drug combination metronidazole‐furazolidone vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.09, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Combinations vs nimorazole or aminosidine or etofamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.12, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Quinfamide and mebendazole vs nitazoxanide (mixed infections only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.85, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Tetracycline and clioquinol vs secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [2.91, 19.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 DHE, tetracycline, and diloxanide furoate vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combination regimen versus monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Single‐dose regimen versus longer regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Quinfamide: 1 dose vs 2 or 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.92, 9.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Secnidazole (1 dose) vs tetracycline and clioquinol (5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Secnidazole (1 dose) vs tinidazole (2 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.37, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Quinfamide (1 dose) vs nitazoxanide (3 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.37, 33.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Quinfamide: 1 dose vs 2 or 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.91, 4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Secnidazole (1 dose) vs metronidazole (10 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Secnidazole (1 dose) vs tetracycline and clioquinol (5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.05, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Parasitological failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Secnidazole (1 dose) vs tinidazole (2 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.43, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.19, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Quinfamide: 1 dose vs 2 or 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Secnidazole (1 dose) vs tinidazole (2 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.37, 1.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Single‐dose regimen versus longer regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other antiamoebic drug comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Ornidazole vs tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.07, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ornidazole vs secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.17, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Chlorhydroxyquinoline vs diiodohydroxyquinoline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.11, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 MK‐910 (low dose, ≤ 1 mg/kg/d vs high dose, ≥ 2 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Metronidazole and Saccharomyces boulardii vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Herbal product vs fixed dose combination metronidazole‐diloxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.69, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Herbal drug vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ornidazole vs tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [0.11, 60.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Ornidazole vs secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.39, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Chlorhydroxyquinoline vs diiodohydroxyquinoline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 MK‐910 (low dose, ≤ 1 mg/kg/d vs high dose, ≥ 2 mg/kg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.39, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Quinfamide vs secnidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.34, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Quinfamide vs nitazoxanide (Entamoeba infection only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.37, 33.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Metronidazole and Saccharomyces boulardii vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.20, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Two fixed‐drug combinations of diloxanide furoate and tetracycline with or without chloroquine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.31, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Herbal product vs fixed‐dose combination metronidazole‐diloxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.67, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Herbal drug vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Quinfamide vs teclozan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.08, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Metronidazole and iodoquinol plus Saccharomyces boulardii vs metronidazole and iodoquinol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Two fixed‐drug combinations of diloxanide furoate and tetracycline with or without chloroquine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ornidazole vs tinidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.12, 65.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Quinfamide vs teclozan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.41, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 MK‐910 low dose vs high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 98.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Herbal vs fixed‐drug combination metronidazole‐diloxanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.09, 0.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other antiamoebic drug comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analyses: alternative drug versus metronidazole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure 15 to 60 days after end of treatment, by clinical category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amoebic dysentery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.07, 8.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Non‐dysenteric amoebic colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.09, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amoebic colitis or intestinal amoebiasis, unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure 15 to 60 days after end of treatment, by age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults (age ≥ 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children (age &lt; 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Both adults and children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.34, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure 15 to 60 days after end of treatment, single or mixed intestinal infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amoebic infection only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Mixed intestinal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.10, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Parasitological failure 15 to 60 days after end of treatment, by criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.58, 2.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analyses: alternative drug versus metronidazole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analyses: any antiamoebic drug versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure 1 to 14 days after end of treatment, by clinical category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.22, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Non‐dysenteric amoebic colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.19, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amoebic colitis or intestinal amoebiasis, unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.17, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical failure 1 to 14 days after end of treatment, by age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.14, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults (age ≥ 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.16, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children (age &lt; 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure 1 to 14 days after end of treatment, by age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults (age ≥ 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.20, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children (age &lt; 15 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Both adults and children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.26, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical failure 1 to 14 days after end of treatment, by diagnostic method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.13, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Stool microscopy with staining or concentration technique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.23, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Antigen‐based ELISA test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Parasitological failure 1 to 14 days after end of treatment, by diagnostic method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.22, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Stool microscopy with staining or concentration technique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.29, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Antigen‐based ELISA test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analyses: any antiamoebic drug versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analyses: combination regimen versus monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Combination vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.11, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Combination vs alternative drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [0.20, 33.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Combination vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Combination vs alternative drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.41, 8.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analyses: combination regimen versus monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analyses: combination regimen versus metronidazole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment, by clinical diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.11, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intestinal amoebiasis, unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.12, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amoebic dysentery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.24, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment, by clinical diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intestinal amoebiasis, unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.13, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amoebic dysentery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.24, 4.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analyses: combination regimen versus metronidazole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analyses: any single‐dose regimen versus longer regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure: 1 to 14 days after end of treatment, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.11, 4.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Secnidazole single dose vs longer duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.06, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Quinfamide single dose vs longer duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.02, 4.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analyses: any single‐dose regimen versus longer regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 High‐dose tinidazole vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.13, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Low‐dose tinidazole vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.08, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 15 to 60 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.25, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐dose tinidazole vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.16, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐dose tinidazole vs metronidazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.44, 2.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment, based on tinidazole dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 15 to 60 days after end of treatment, excluding Misra 1978 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.16, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical failure: 15 to 60 days after end of treatment, excluding trials sponsored by pharmaceutical companies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.11, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis: tinidazole versus metronidazole 15 to 60 days after end of treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006085-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical failure: 1 to 14 days after end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure: 1 to 14 days after end of treatment, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analyses: combination regimen versus metronidazole alone, excluding pharmaceutical company‐sponsored study (Asrani 1995)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006085.pub3/references#CD006085-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006085.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006085-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006085-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006085-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD006085-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006085-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD006085-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006085-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006085\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006085\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006085\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006085\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006085\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006085.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006085.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006085.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006085.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006085.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729193371"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006085.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729193377"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006085.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed6e3adf3f55b',t:'MTc0MDcyOTE5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 